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Abstract 
Background: 
Patients with diarrhoea predominant irritable bowel syndrome (IBS-D) suffer 
from loose frequent stools with associated urgency and fear of incontinence. 
Relief from these symptoms is an important unmet need. The 5-HT3 receptor 
antagonist Alosetron has been shown to increase stool consistency, decrease 
urgency and reduce abdominal pain leading to a global increase in satisfaction 
with treatment [1]. Its use is restricted following an increased incidence of 
ischaemic colitis and this agent is not available in Europe.  
The serine proteases family of proteolytic enzymes have been identified as 
the source of increased faecal proteolytic activity in patients with IBS.  These 
enzymes may be mechanistically important via their action on the Protease 
activated receptor (PAR) -2, inducing increases in permeability and 
hypersensitivity.  
Aims: 
To assess the efficacy of the commonly prescribed 5-HT3 antagonist 
Ondansetron, in patients with IBS-D and to identify biomarkers that might 
allow us to predict response defining an Ondansetron responsive 
endophenotype of IBS. 
To structurally characterise faecal serine proteases and define the impact of 
treatment with Ondansetron. 
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Methods: 
120 patients meeting Rome III criteria for IBS-D entered a randomised, 
double-blind, placebo controlled, cross-over study of 5 weeks of Ondansetron 
4mg  versus placebo with dose titration allowed up to two tablets thrice daily 
in the first 3 weeks. Patients completed daily bowel symptom diaries 
documenting stool consistency using the Bristol Stool Form Score (BSFS). Gut 
transit and small bowel water content were measured in the last week of each 
treatment. The primary endpoint was average stool consistency in the last 2 
weeks of treatment. 
Faecal samples were obtained from 30 healthy volunteers (HV) and 79 IBS-D 
patients participating in a trial of Ondansetron versus placebo. Colonic transit 
was measured using radio-opaque markers. Faecal serine proteases (FSP) 
were purified from faecal extracts using Benzamidine-Sepharose affinity 
chromatography. SDS-PAGE profiled components were identified using 
trypsinolysis and tandem-mass-spectrometry. Functional protease activity in 
faecal extracts was measured using a colourimetric assay based upon the 
proteolysis of azo-casein 
 
Results: 
Ondansetron significantly improved stool consistency In the intention to treat 
analysis n= 101, with a 1.39 (95% CI1.20-1.58)point decrease on the Bristol 
stool form scale whilst taking Ondansetron compared to  a 0.51 (95% CI 0.32-
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0.72) point reduction whilst taking placebo p=<0.0001. Compared to placebo 
patients on Ondansetron experienced fewer days with urgency (p=0.01), 
lower urgency scores (P<0.001), reduced frequency of defecation (p=0.001) 
and less bloating (p=0. 25) although pain scores did not change significantly.  
Protein analysis identified the most abundant FSPs as being of human origin 
and likely pancreatic juice derived. Functional assays showed increased FSP 
and faecal amylase in IBS-D compared to HV. Those with higher amylase had 
significantly higher FSP and greater anxiety. FSP activity correlated negatively 
with whole gut transit in IBS-D (Spearman r=-0.32, p=0.005) and HV (r=-0.55, 
p=0.014), but was not affected by treatment with Ondansetron. 
 
Conclusions: 
Ondansetron is an effective and well tolerated treatment in patients with IBS-
D with a low number of side effects. It slows whole gut transit, but without a 
demonstrable difference in small bowel water content. Clinical rather than 
biochemical indicators predicted responsiveness to Ondansetron best. 
Patients with less severe symptoms are more likely to respond well to 
Ondansetron which should prove a useful addition to the current rather 
limited therapies available for this important group of patients.  
Previous reports that FSP activity is elevated in some patients with IBS-D has 
been confirmed. We have increased our understanding of this phenomenon 
by characterising the proteins responsible for the serine protease activity, 
showing that most of this activity is likely due to human pancreatic enzymes. 
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1 Introduction  
1.1 Irritable bowel syndrome          
The irritable bowel syndrome (IBS) is a substantial and difficult clinical 
problem characterised by abdominal pain, bloating, and disturbed defecation. 
It is also associated with other intestinal and extra intestinal complaints such 
as heartburn, dyspepsia headache, backache, chronic fatigue and 
genitourinary symptoms. Its prevalence is estimated to be between 14 and 
24% in women and 5-19% in men in a western population [2] and accounts for 
up to 40% of consultations in the gastroenterology outpatients. The direct and 
indirect costs of caring for this group of patients have been estimated to be as 
high as $30 billion dollars per year in the United States alone[3]. 
 IBS patients show a range of psychosocial and gastroenterological 
abnormalities and it is this heterogeneity of complaints, which are often 
variable with time within an individual patient, that presents clinicians and 
researchers with a challenge, first to define the pathological process (or more 
likely processes) at work, and ultimately provide safe and effective therapy for 
this group of patients whose symptoms can lead to a greatly impaired quality 
of life[4]. Understanding of disease mechanisms and therefore effective 
treatment discoveries are hampered by a lack of reproducible biomarkers. 
Attempts through the years to define the irritable bowel syndrome have been 
legion.  There are to date 5 sets of existing diagnostic criteria and it can be 
seen in Table 1.1 that the positive predictive value of each set of criteria when 
applied to unselected patients with lower gastrointestinal symptoms, varies 
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often with wide confidence intervals. These criteria are evaluated as to their 
ability to distinguish organic from non organic disease. 
There is evidence that the predictive value is altered depending on whether 
the criteria are applied to men or women[5] and also depending on the ethnic 
group that is being assessed[6].  
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Criteria 
or model 
Symptoms, signs, and laboratory investigations 
included in model 
Symptom 
duration 
required 
Method of defining 
IBS 
Positive 
likelihood 
ratio for a 
diagnosis of 
IBS 
Manning
[7] 
 
Abdominal pain relieved by defecation 
More frequent stools with onset of pain 
Looser stools with onset of pain  
Passage of mucus per rectum 
Feeling of incomplete emptying 
Patient-reported visible abdominal distension 
none 3 positive symptoms 2.9(95% CI 
0.93 -1.6)[8]  
 
Kruis[9] 
 
Symptoms: abdominal pain, flatulence , or bowel 
irregularity 
Description of pain as “burning, cutting, very 
strong, terrible,feeling of pressure, dull, boring, 
or not so bad” 
Alternating constipation and diarrhoea 
Signs: abnormal physical findings and/or history 
pathognomic for any diagnosis other than IBS 
Erythrocyte sedimentation rate >20mm/2h 
Leukocytosis >10 000 cells / microlitre 
Anaemia 
Impression by the physician that the patient’s 
history suggests blood in the stools 
>2 years Logistic regression 
model 
8.6 (95% CI 
2.9-26)[8]  
Rome I 
 
Altered stool frequency 
Altered stool form 
Altered stool passage 
Passage of mucus per rectum 
Bloating or distension 
≥ 3 months Adnominal pain or 
discomfort relieved 
with defecation or 
associated with a 
change in stool 
frequency or 
consistency, plus ≥2 
positive symptoms  
on at least 25% of 
occasions or days 
4.8 (95% CI 
3.6-6.5)[8]  
Rome 
II[10] 
Pain relieved with defecation 
Onset of pain associated with a change of 
frequency of stool 
Onset of pain associated with a change of form 
of stool 
≥12 weeks( 
need not 
be 
consecutive 
in the last 
year) 
abdominal 
discomfort that has 
≥2 positive 
symptoms   
 
Rome 
III[11]
1
 
Improvement with defecation  
Onset associated with a change of frequency of 
stool 
Onset associated with a change in form of stool  
Symptom 
onset ≥6 
months 
prior to 
diagnosis 
Recurrent 
abdominal pain or 
discomfort ≥3 days 
per month in the 
last 3months 
associated with ≥2 
positive symptoms 
 
Table 0-1 Diagnostic criteria and statistical models for the diagnosis of IBS 
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Our current symptom-based disease definitions are important in providing a 
diagnosis in a population in whom a positive diagnosis is often key to a 
meaningful therapeutic relationship with the clinical team. These criteria are 
also essential in facilitating accurate patient selection into research studies 
and provide a common language for clinicians and scientists. Despite the 
trend towards this approach many doctors feel uncertain and treat IBS as a 
diagnosis of exclusion, based largely on a fear of missing a progressive organic 
condition. This approach is expensive and often significantly increases 
patient’s anxiety. This concern persists despite studies in both primary and 
secondary care confirming that patients who meet symptom based criteria for 
IBS have a low pre-test probability for organic disease, with the exception of 
celiac disease, and current recommendations do not support the employment 
a battery of tests in these patients [12, 13].  
Symptom based criteria have several weaknesses, inclusion into trials of 
relatively heterogeneous groups lead to conflicting results from trial to trial, 
large numbers are needed to generate interpretable data and there is the risk 
of missing important positive findings in smaller subgroups or 
endophenotypes who are swamped by the “noise” generated by other 
subjects whose disease mechanisms are likely different.   An area of particular 
unmet need is the difficulty clinicians have in selecting patients with IBS who 
will respond to a given treatment. Multiple trials of unsuccessful therapy 
leaves patients dissatisfied[14], and even with clinically proven preparations 
numbers needed to treat are high, for example for Alosetron the number 
needed to treat  was still  7[15]. 
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It is clear that the introduction of a test which positively identifies even a 
small number of these individuals as having IBS via a biologically sound 
marker would be invaluable to patients, clinicians, scientists and the public 
purse alike. Furthermore being able to preselect patients most likely to 
respond to a particular treatment, via such a biomarker, would avoid 
prolonged trials of ineffective therapy leading to better outcomes and a 
better satisfied patient group.  
1.1.1 Epidemiology  
In order to better manage our patient population it is important to know who 
they are.  The classification systems described in the opening paragraphs are 
the tools by which we define incidence and prevalence.  The Manning criteria 
have traditionally given the highest estimates with values  between 9% using a 
cut off of ≥4 criteria and 20% using ≥ 2 criteria in North America[16]. With 
Rome II criteria the same group estimate a prevalence of 4.7% although 
others have found higher rates at 12.1%[17]. In the U.K. and Europe using  ≥2 
manning criteria estimates a prevalence of 21.6%[18] but again lower values 
of between 2.9-8.1% are reported using the Rome II criteria[19, 20]. Attempts 
have been made to define the prevalence of the different IBS subtypes. There 
is some agreement, with most studies finding the largest subgroup (46.7-63%) 
to be those complaining of an alternating type [17, 20].  In the US two studies 
have found the diarrhoea subtype to be most common (53.9-57.6%)[21, 22], 
and important differences in subtype prevalence may exist in the developing 
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world, with constipation being reported as occurring in 50.4% of subjects in a 
Pakistani study[23].  
Estimating the incidence of IBS in a given population is challenging. Due to the 
fluctuating nature of symptoms it is difficult to pick out those cases that are 
truly incident, from those that represent a flare of this relapsing and remitting 
condition. The criteria themselves have been shown in short term studies not 
to be stable with the proportion of subjects in each of the IBS subtypes 
staying the same, but individuals commonly transitioning between subtypes, 
particularly between mixed IBS (IBS-M) and constipated IBS (IBS-C)[24]. A UK 
study including nearly 4000 subjects has however estimated the incidence of 
new IBS to be between 1.5-2.8% a year, again depending on the criteria used 
[25].  
At least two-thirds of patients with IBS during the aforementioned UK follow 
up at study entry had persistent symptoms at 10 years[25], and an Icelandic 
group found that during a decade of follow up a similar number of patients 
developed IBS as those who lost IBS. Their conclusion was that rather than a 
true resolution of symptoms that their findings were consistent with a 
condition where a cluster of symptoms float in time between IBS categories, 
functional dyspepsia and heartburn. The prognosis of post infectious irritable 
bowel syndrome (PI-IBS) is somewhat better than unselected IBS but may take 
years to resolve[26].  
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1.1.2 Risk factors for the development of IBS 
The current view of IBS aetiology is that several factors interact during the life 
time of the patient to induce IBS. These include gender, early life experience, 
genetics, infection and personality traits such as anxiety and neuroticism. Of 
the risk factors studied the role of infection is one of the areas that we have 
the most data on. Post infectious or PI-IBS can be regarded as a natural 
experiment in which an insult in the form of an infective illness impacts on an 
individual with underlying genetic and psychosocial predispositions who then 
develops IBS.  Unlike other IBS patients, there is a clear onset in time and well 
defined patho-physiological changes.  Measuring both psychological as well as 
pathophysiological features has allowed us to weigh the importance of these 
different factors in the generation of IBS symptoms. 
Around 1 in 10 of patients with IBS [27] believes their IBS began with an 
infectious illness, and risk factors for developing PI-IBS include in order of 
importance:  
1. The duration of illness and severity, an illness lasting greater than three 
weeks confers a relative risk of 11.4 (95% confidence interval (CI), 2.2-58) 
compared to one lasting  less than 7 days[28].  
2. The toxicity of the infecting bacteria also plays a role illustrated by patients 
whose cultured C. jejuni supernatants demonstrated toxicity to an in vitro cell 
line. These patients had a relative risk of developing persistently deranged 
bowel habits of 12.8 (95% CI) 6.1-101) compared with those who had no toxin 
[29]. 
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3. Patients who smoke are more likely to develop PI-IBS with an OR of 4.8(1.5-
15.2)[30].  Whether this is a direct effect of nicotine or more likely smoking is 
a marker for adverse psychological factors is unclear. However smokers report 
more anxiety than non-smokers [31], which is also more common in IBS 
patients. 
4. The role of low grade immune activation in IBS has been established in 
animal and human studies Increased lymphocytes have been reported 
throughout the colon in unselected IBS with diarrhoea[32], and in the rectum 
in PI-IBS[33-35].  This has been associated with increased mRNA for 
interleukin (IL)-1β [36, 37].  After Campylobacter jejuni infection the 
persistence of inflammatory cells predicts the subsequent development of PI-
IBS, a 1-SD increase in enterochromaffin cell (EC) count was a associated with 
a mean 3.8-fold (95% CI, 1.3–7.5) increase in relative risk[35]. 
Mast cells are increased in animal models of infection and in the human 
terminal ileum after Shigella infection [37] and in rectal biopsies of PI-IBS 
patients [38]. They have also been reported  to be increased in the terminal 
ileum of unselected  IBS patients with diarrhoea[39]. PI- IBS may well involve 
inflammatory changes in the small intestine as well as the colon since small 
intestinal permeability is increased [29] , a change which could be mediated 
by increased ileal mast cells. 
Other markers of inflammation in IBS patients include higher cortisol and 
increased peripheral blood mononuclear cells cytokines including IL-6, IL-
8[40], tumour necrosis factor (TNF)-alpha, IL-1beta, IL-6, as well as increased 
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lipopolysaccaride -induced IL-6 levels when compared to healthy controls 
[41]. 
5. All subtypes of IBS are more frequent in females than males, with a male: 
female ratio of between 1.2 and 3.1 in North America and Europe [16, 42]. 
There is no evidence of any differences between the immune response of 
men and women to infection and rectal immunocyte numbers are not 
different[43], yet female gender is frequently reported risk factor for 
developing PI-IBS[34, 35]. This may in part be due to confounding with anxiety 
and depression which is commoner in women, since when this is controlled 
for in multivariate analysis female gender is no longer a risk factor [34, 35]. 
However female gender did remain a factor in multivariate analysis in one 
recent study where there was relative risk of 2.36 (1.23 – 3.98) for gender 
versus 1.82 (1.05 – 1.22) for anxiety [44].  
6. Subjects with IBS have higher levels of anxiety neuroticism and depression 
compared to subjects without IBS. This has also been demonstrated 
prospectively in patients without IBS where high levels of illness behaviour, 
anxiety, sleep problems and somatic symptoms predict the subsequent 
development of IBS [45].  This vulnerability to develop IBS may depend on 
early learning. Exposure in childhood to parenting styles which reinforce 
illness behaviour in early life is associated with the later development of 
functional bowel disorders[46].   The presence of hypochondriasis and 
neuroticism, which are thought to be enduring rather than acquired traits, 
increase the risk of PI-IBS, RR=2.0 (1.7-2.5)[47] while each standard deviation 
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increase in depression, increases the risk of PI-IBS 3.2 fold(1.8 – 8.2)[28]. 
Adverse life events in the 3 months preceding infection also increase the risk, 
RR= 2.0 (1.7 -2.4) [34].  Other psychological factors including perceived stress 
RR 1.10 (1.02-1.15) and negative illness beliefs RR 1.14 (1.03-1.27) have also 
been shown to increase the risk of developing PI-IBS [48]. Ongoing stress may 
initiate an inflammatory response in the human jejunum [49] and also 
increase the severity of inflammation in rats with 2,4,6-trinitrobenzene 
sulfonic acid  (TNBS) colitis[50].  
 A genetic predisposition to IBS has been proposed with work looking at 
candidate genes within the serotonin and inflammatory pathways amongst 
others. To date studies have been small and as yet the effects seen have not 
been shown to be reproducible. A single large twin pair study showed 
increased concordance for IBS in monozygotic compared to dizygotic twins 
(17.2% versus 8.4%) supporting a genetic component to IBS but also 
demonstrated that having a mother or father with IBS were independent 
predictors of IBS and stronger predictors than having a twin with IBS, 
suggesting that social learning has an equal or greater influence than genetic 
factors[51].   
Age >60 years may protect against the development of PI-IBS[28] while 
treatment with antibiotics may be associated with increased risk. Antibiotics 
have been shown to cause a transient alteration in the normal microbiota[52] 
and one possibility is that increased antibiotic use by patients with IBS results 
in an unstable flora. Patients given antibiotics are 4 times more likely to report 
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bowel symptoms 4 months after treatment initiation than a control 
population with no antibiotic use[53], and antibiotic use has been reported to 
be a risk factor for developing IBS per se  with an adjusted OR of 3.70 (1.80-
7.60)[54].  
1.1.3 Comorbidities and overlap with other functional GI 
disorders 
Patients with IBS are about twice as likely to be diagnosed with a variety of 
somatic disorders as other comparison groups[55]. These include fibromyalgia 
chronic fatigue syndrome, chronic pelvic pain, temporomandibular joint 
dysfunction and others such as back pain and premenstrual syndrome. The 
overlap with other functional gastrointestinal diseases is even greater with 
between 23 and 87% of IBS subjects studied reporting dyspepsia [56, 57].  
These disorders share many common aetiological mechanisms, such as 
visceral hypersensitivity, stress and anxiety and the psychological trait of 
somatisation, but attempts to define specific disease mechanisms, and thus 
targeted treatments, to account for the occurrence of these multiple 
symptoms in patients are as yet inadequate. 
The sheer number of these co morbid conditions and symptoms is an 
important factor in determining quality of life in our patients and   impacts 
significantly on health care costs with IBS patients   making twice as many 
health care visits in a year as age matched controls[58]. 
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1.1.4 Treatment 
Because the aetiology of IBS has not been firmly established there is no 
discrete target for pharmacological therapy. Therapies to date have been 
focused on symptom relief. Traditional first line therapy has been the use of 
fibre to regulate defecation, and antispasmodics to improve pain and 
diarrhoea.  The benefits of fibre however have been shown to be small and 
insoluble fibre can in some make the condition worse[59] . Other first line 
treatments include laxatives and anti diarrhoeal agents; Loperamide an opiod 
analogue reduces diarrhoea but has little effect on abdominal pain[60], but is 
preferable  to the use of codeine which has sedating and potentially addictive 
properties. There is a dearth of controlled evidence in IBS-C regarding the use 
of traditional laxatives; consensus opinion here is that the use of osmotic 
laxatives such as polyethylene glycol is preferred, with stimulant laxatives 
acting erratically with tachyphylaxis and a risk of dependency resulting in 
recommendations only for occasional use [61]. Encouragingly 2 new agents, 
Linaclotide, a novel intestinal secretagogue, which works by activating the 
guanylate cyclase C receptor on the luminal surface of the intestinal 
epithelium, and Lubiprostone which causes secretion of fluid and electrolytes 
in the small bowel through the activation of chloride channels, have been 
demonstrated to be efficacious in patients with both chronic functional 
constipation and with IBS-C [62-64].  
Tricyclic antidepressants are often used in the treatment of chronic pain and 
their use to modulate the pain experienced by patients with IBS is widely 
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accepted although evidence for efficacy as been conflicting with society 
guidelines being cautious in recommending their first line use[61]. A meta-
analysis including a total of 575 patients concluded the number need to treat 
was 4[65]. In practice the use of these drugs is often limited by their side 
effects which include somnolence and a troublesome dry mouth. Selective 
serotonin reuptake inhibitors (SSRI’s) lead to a significant improvement in 
health related quality of life but without significant changes in bowel 
symptoms or pain [61] .  
Rifaximin, a poorly absorbed antibiotic that is therefore present in high 
concentrations in the gastrointestinal lumen has been shown in two large 
randomised control trials to have benefit in patients with non-constipated IBS. 
Here the end point, adequate relief from IBS symptoms for at least 2 of the 
first 4 weeks following treatment was reached in 41% receiving active therapy 
compared to 32% on placebo, this was sustained for 10 weeks of follow 
up[66].  However only a minority respond with a number needed to treat of 
11.  Others have sought to modify the bacterial milieu of the colon by the use 
of probiotics. These by definition are live microorganisms that confer benefit 
to the host in this case by quantitative and qualitative changes in the colonic 
flora. Benefit has been shown in 5 randomised control trials in reducing 
bloating and flatulence but the variety of species strains and doses of 
probiotics used means it has thus far been difficult to come to any conclusion 
about the optimum strategy to use in IBS.  
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We know that psychological morbidity is important in IBS and an awareness of 
this should instruct the delivery of all treatments. Specific psychological 
approaches that have been explored include simple relaxation techniques, 
cognitive behavioural therapy (CBT), formal psychotherapy and hypnotherapy. 
Trial design and blinding is challenging in these therapies but evidence exists 
to suggest at least in expert hands there is benefit in assisting patients in 
coping with their symptoms and in the case of hypnotherapy delivering lasting 
improvements in the quality of life and psychological status[61].  
It is clear that new strategies are needed and a number of new mechanistic 
agents targeted at abnormalities thought to be important in the aetiology of 
IBS have come onto and are coming to market in recent years. Of these by far 
the largest group is the drugs designed to target the serotonin system, 
primarily at the 5-hyroxytryptamine (5-HT)4 and 5-HT3 receptors. I will discuss 
the drugs that have targeted the 5-HT3 receptor in more detail in section 
1.2.1.  
Prucalopride a 5-HT4 receptor agonist is highly selective and does not display 
the problems with ischaemic cardiovascular events associated with its 
predecessor Tegaserod and has been shown to improve symptoms in chronic 
constipation although not yet in patients with IBS and chronic constipation 
[67].  Alternative strategies aimed at other sites have met with varied success. 
Mesalazine has been shown to reduce total colonic immune cell numbers[68] 
and also to improve pain[69], but targeting the Corticotrophin release 
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hormone-1 receptor showed early promise without resulting in significant 
benefit clinically [70].   
1.2 5-HT3 antagonists  
The 5-HT3 receptor antagonist’s major clinical use has been in the inhibition of 
chemotherapy induced nausea and vomiting and for the prophylaxis of post 
operative nausea and vomiting. This class of drugs includes Ondansetron, one 
of the first to market, Tropisetron, Granisetron, Cilansetron, Alosetron and 
Ramosetron.  
1.2.1 Alosetron 
The appearance of Alosetron, which largely replaced Ondansetron in the early 
1990’s means that most evidence on the role of 5-HT3 antagonists in IBS 
relates to Alosetron and subsequently Cilansetron and Ramosetron.  
Alosetron and Cilansetron have been evaluated in several very large 
randomised clinical trials.  Ramosetron has been shown in 2 randomised 
control trials to be effective in improving global symptom severity and stool 
consistency[71, 72] A meta-analysis of Alosetron trials shows a consistent 
beneficial effect in females with diarrhoea predominant IBS (IBS-D)[73]. Most 
of the studies lack enough males to make any significant observations but a 
single study has shown efficacy using the same dose found to be effective in 
women [74].  The most consistent benefits are an increase in stool 
consistency, a decrease in urgency and a reduction in abdominal pain leading 
to a global increase in satisfaction with treatment.  In spite of all the clinical 
evidence of benefit, the mechanism of action in individual patients was never 
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clearly identified and the number needed to treat was 7.  Genetic factors may 
be important since a previous somewhat underpowered study has shown that 
the presence of the LL serotonin transporter (SERT) promoter polymorphism 
was associated with a greater effect of Alosetron in slowing colonic transit 
when compared to heterozygote patients with the LS polymorphism [75]. 
A cloud fell over the use of 5-HT3 antagonists with the finding of an increased 
incidence of ischaemic colitis in patients on treatment. This ischaemic colitis 
associated with the use of Alosetron is as yet without a clearly demonstrated 
biological mechanism. 5-HT3 receptors, although not present on the blood 
vessel wall itself are expressed on sensory endings, and it is hypothesised that 
blockade of these that potentially inhibits the reflex mechanisms regulating 
gut blood flow. However a study in anesthetized rats showed that Alosetron 
did not interfere with splanchnic vascular control mechanisms during 
occlusion and reactive hyperaemia [76]. This finding has been added with a 
series of studies that show although there is a small reduction in mesenteric 
blood flow in rats given intravenous Alosetron, this reduction failed to modify 
blood flow or intra-luminal pressure in the colon. This appeared to be a class 
effect, at least in the rat, with similar findings with the injection of 
Cilansetron. This study went on to show that short term oral administration of 
Alosetron did not affect the haemodynamics of the superior mesenteric artery 
and that fasting had no additional effect on the actions of Alosetron on blood 
flow [77]. An alternative, and more likely, explanation is that it is the increase 
in incidence of constipation, itself shown to be associated with a reduction in 
colonic blood flow[78], that predisposes patients to this complication. It 
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should be noted that most cases of ischaemic colitis were mild and self 
limiting once treatment was ceased. An important potential contributory 
factor to the problems experienced with constipation was the use in these 
trials of a fixed dose in all comers.  
1.2.2 Ondansetron 
Early studies of 5-HT3 antagonists did use Ondansetron and showed slowing of 
colonic transit in healthy volunteers. Here  mean colonic transit time as 
measured by radio-opaque markers  was 27.8 hrs whilst taking placebo vs. 
39.1 hours on Ondansetron, and this effect was seen to be greatest in the left 
colon and rectosigmoid[79]. Ondansetron was also shown to improve stool 
consistency in patients with IBS-D in a small pilot study[80], to  inhibit the 
ascending colon response to feeding[81], and increase rectal compliance[82].  
In the early 1990’s Ondansetron was shown to have a beneficial effect on 
both functional dyspepsia and IBS-D though the study was probably 
underpowered.  Although it didn’t alter abdominal pain it did reduce bowel 
frequency and improve stool consistency in 50 patients with IBS-D[83].  The 
effect of Ondansetron on stool consistency is important since it alleviates 
urgency, one of the most debilitating features of IBS. 
1.2.3 Ondansetron pharmacokinetics, safety and 
rationale for use 
Following oral administration, Ondansetron is passively and completely 
absorbed from the gastrointestinal tract and undergoes first pass metabolism. 
Peak plasma concentrations of about 30ng/ml are attained approximately 1.5 
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hours after an 8mg dose. Bioavailability, following oral administration, is 
slightly enhanced by the presence of food but unaffected by antacids. Studies 
in healthy elderly volunteers have shown slight, but clinically insignificant, 
age-related increases in both oral bioavailability (65%) and half-life (five 
hours) of Ondansetron. Gender differences have been shown in the 
disposition of Ondansetron, with females having a greater rate and extent of 
absorption following an oral dose and reduced systemic clearance and volume 
of distribution (adjusted for weight). Ondansetron has now been used very 
extensively in sick patients for nearly 20 years and has in contrast to Alosetron 
never been associated with ischemic colitis. There is early evidence of its 
efficacy in patients with IBS-D and its safety track record makes it an attractive 
potential treatment in our patient group.  
1.3 Biomarkers in Irritable bowel syndrome  
In medicine a biomarker can be used as an indicator of a particular disease 
state and to predict and monitor response to treatment. An ideal biomarker 
according to the FDA is one which is specifically associated with a disease 
state and can differentiate between conditions with similar physiological 
conditions. It would be desirable if this could be measured in blood urine or 
stool, removing the need for painful or invasive testing and if the test itself 
should rapid, accurate, simple, cheap and readily available with a measurable 
and standard baseline as a reference point.  
There already are some candidates in IBS but they are far from ideal. 
Differences in permeability, motility, visceral hypersensitivity, and evidence of 
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mucosal inflammation have been proposed and will be discussed in the 
following sections, but all lack some or many of the characteristics of an ideal 
marker with many of them being arduous to perform and invasive in nature.   
Another approach is to use existing markers and software to design panels of 
tests which can be used to differentiate IBS from organic disease [84]. The 
hunt is however still on for ideal one stop tests that will allow the definition of 
disease mechanisms which will in turn lead to drug discovery and a safe and 
effective treatment for the patient in the clinic or primary care.  In the context 
of this thesis I will be exploring the ability of biomarkers in the serotonin 
system to predict response to treatment acting at the 5-HT3 receptor, as well 
as emerging potential markers in the stool as well as the tried and tested 
measures of transit and the novel field of magnetic resonance imaging (MRI). 
1.3.1 Motility and transit 
Abnormalities in gut motility have been described in IBS with the use of 
invasive manometric techniques. Intubation of the small bowel has revealed 
prolonged periods of small bowel contractions and giant contractions in the 
distal terminal ileum in patients with IBS. The same study found that cramping 
abdominal pain was associated with  propulsive ileal motility and jejunal 
bursts were also sometimes associated with abdominal symptoms[85]. 
Despite this association the impracticality of these measurement techniques 
precludes their use in routine practice. The advent of the new wireless 
motility capsule has recently overcome many of these methodological 
challenges. This capsule measures pressure, temperature and pH and at 
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present is best validated as a test for transit. Although it does measure 
pressure, the clinical utility of the pressure data yielded by this technique has 
not been clearly established[86].  
In contrast to manometry the methods available to measure the time it takes 
for food or other materials to pass through the gastrointestinal (GI) tract are 
highly patient acceptable. These measures of gut transit include the use of 
radio-opaque markers and scintigraphy. The most simple of all is the marker 
method validated by Metcalf et al[87]. Here the subject swallows 20 markers 
at 9 am on each of three consecutive days with a plain abdominal radiograph 
on day 4, the transit time is calculated as 1.2 x number of markers present. 
Validation was performed against multiple daily abdominal films and the 
faecal output of markers. This simple method provides a good estimate of 
mean colonic transit in subjects whose transit is <72 hours and is quick and 
cheap to perform. The technique can be modified in subjects with retention of 
all sixty markers at day 4 by the addition of a further film on day 7.  
There is evidence of accelerated transit in IBS-D patients compared to normal 
values. In a study of 72 IBS patients and 25 healthy controls total gut transit 
was accelerated compared to healthy controls and those with IBS-C, no 
differences between IBS-C patients and controls were seen[88]. A 
combination of markers and the hydrogen breath test to examine small and 
large bowel transit in IBS patients demonstrated that small bowel transit 
times were significantly shorter in patients who complained predominantly of 
diarrhoea, and significantly longer in patients who complained predominantly 
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of constipation, compared with controls [60]. However these are not 
consistent findings with other authors finding no differences in transit times 
between groups and transit times falling within the normal range which do 
not appear to correlate well with bowel symptoms in IBS[89]. 
Colonic transit is significantly associated with changes in stool form 
accounting for 19-27% of the variance [90], and changes in transit in response 
to drug treatment appear to correlate consistently with stool form and to a 
lesser extent stool frequency [91]. It would seem transit is a suitable marker 
for the assessment of a drug whose aim is to affect bowel habit but there is no 
evidence to suggest transit is a marker for overall IBS severity. 
1.3.2 Visceral hypersensitivity 
Visceral hypersensitivity was the first feature of IBS to be seriously considered 
as a biomarker. This phenomenon of an enhanced perceptual response to a 
standardised stimulus is measured in a variety of standardised ways; most 
commonly by the use of a computerised barostat that delivers controlled 
balloon distension either in the colon or the rectum or by the application of 
heat or a chemical stimulus. A number of peripheral mechanisms such as 
mucosal immune activation and mast cell degranulation, as well as changes in 
central pain processing are potentially responsible for these findings.  As a 
group, patients with IBS show lower average thresholds for pain or discomfort 
than healthy controls, and 20-60% are hypersensitive at baseline[89]. Pain and 
bloating scores do correlate with measures of visceral hypersensitivity but 
there is at best only a moderate correlation with IBS symptoms or response to 
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treatment[92]. There is considerable variability across patients, between 
different research groups,  and there is an appreciable overlap with the 
healthy volunteer population[89]. In addition the data obtained are in the 
laboratory rather than a real life environment where a number of cognitive 
and emotional variables (both positive and negative) will influence this 
subjective measure. These factors as well as the considerable time and effort 
needed to standardise the procedure limits the use of this technique outside 
expert centres. 
1.3.3 Mucosal inflammation 
Mucosal immune activation is a cornerstone concept in the aetiology of IBS 
and shows some promise as a biomarker. Immune cells have been shown to 
interact with sensory and motor systems indicating a potential role in 
symptom generation. The use of measures of inflammation as a biomarker is 
limited by several factors. There is considerable overlap between healthy 
subjects and those with IBS[35], and the most commonly used method of 
quantitative histology are time consuming and subject to error, some of these 
difficulties can be overcome with automated analysis[38], but there is as yet 
no standard method that can be easily applied to routine clinical samples.  
1.3.4 Other emerging biomarkers  
A small number of studies suggest that genetic polymorphisms might predict 
drug responsiveness. Proposed polymorphisms include those found in genes 
coding drug metabolism enzymes and also the serotonin transporters 
gene[82]. However these studies are rather small and the results require 
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replication in larger series before they can be considered potential biomarkers 
of drug responsiveness. New advances in microbiological techniques are 
revealing hitherto unknown complexities in the GI tract flora of patients one 
consistent feature of the many studies in this area being a decrease in overall 
diversity and the number of aerobic bacteria with an increase in aerobes 
including Proteobacteria [93]. These may well in the future prove useful 
biomarkers for studies of treatments likely to alter the flora such as probiotics 
and antibiotics. The discovery of increased proteolytic activity in the stool of 
patients with IBS-D [94] has led to the consideration of this activity as a 
potential biomarker that may be altered by treatment, this will be further 
discussed in the section 1.5.  
1.4 Serotonin and the irritable bowel syndrome 
For the purpose of understanding the use of the serotonin system to provide 
biomarkers in IBS I will first describe the role of serotonin and in particular the 
5-HT3 receptor, the target of our therapy, in normal gut physiology. Secondly I 
will describe the abnormalities of 5-HT signalling found in the periphery (i.e. 
serum) and thirdly those abnormalities of the serotonin system that are not 
accessible by simple venepuncture, primarily those seen in the gut mucosa. 
This is pertinent as it is clear our ideal biomarker would be one easily accessed 
and venepuncture is easy quick and acceptable to most patients. 
1.4.1 Serotonin and its role in the GI tract in health 
Serotonin or 5-Hydroxytryptamine is a biogenic amine synthesised from the 
essential amino acid tryptophan. Tryptophan is hydroxylated by the enzyme 
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tryptophan hydroxylase to 5-hydroxytryptophan. This is then decarboxylated 
to 5-hydroxytryptamine by the action of L-amino acid decarboxylase. 
Complete dietary deficiency of tryptophan will  reduce serotonin synthesis 
within 24 hours but by contrast an increase in intake will not increase 
synthesis as it is present in normal diet in excess[95].  Serotonin is 
metabolised 5-HIAA and excreted by the kidneys via glomerular filtration and 
active secretion into the proximal tubules. 
5-HT is present throughout the gastrointestinal tract , in the enterochromaffin 
cells and the enteric nervous system and makes up 80% of the total body 5-
HT[95]. Its primary role is as a mucosal signalling molecule activating 
receptors on neurons, smooth muscle cells and epithelial cells within the gut 
regulating peristalsis secretion and sensation[96].  
Serotonin signalling is terminated by its uptake via the serotonin transporter 
(SERT) expressed on the epithelial cells of the gut. SERT is a highly regulated 
protein that can be influenced by genetic or epigenetic factors. The SERT gene 
is located on chromosome 17: it spans 37.8 kb and is composed of 14 exons 
that encode a 630 amino acid protein. It is associated with a 5-HT transporter 
length polymorphic region (5-HTTLPR) which has a long L and short S variant. 
This is located 1.2kb upstream of the transcription start site in exon 1 and the 
length of the polymorphism potentially influences the level of transcription 
with least SERT expression in the SS type and most in the LL. 
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The actions of serotonin depend on the interaction of 5-HT with its receptor 
subclasses which are 7 in number. Receptor subclasses 5-HT1A and P, 5-HT2, 5-
HT3, 5HT-4 and 5HT-7 are found in the gut. 
1.4.2 5-HT3 receptor  
The 5-HT3 receptor is phylogenetically older than the other serotonin 
receptors and, rather than being a G-protein coupled unit, is a ligand-gated 
cation channel belonging to the nicotine/gamma-amino-butyrate (GABA) 
receptor super-family. It is a pentamer consisting of five monomers which 
form a centrally permeable cylindrical body that is easily penetrated by small 
cations. There are five monomer subtypes (A-E) and the 5-HT3 receptor exists 
as a variety of homo or hetero dimers with differing biophysical and 
pharmacological properties, the functional relevance of these differences is 
not yet clarified[97].  
5-HT3 receptors are located on mononuclear cells, lymphocytes, and intestinal 
enterochromaffin cells as well as peripheral and central neurons. In the 
periphery they are found on pre and post ganglionic autonomic neurons and 
within the myenteric and submucosal plexus. Within the central nervous 
system (CNS) 5-HT3 receptors are much less prevalent than other subtypes but 
are found in the areas responsible for the integration of the vomiting reflex, 
pain processing, the reward system and anxiety control (area postrema, 
nucleus tractus solitarii, nucleus dorsalis, nervi vagi, nucleus caudatus, nucleus 
accumbens, amygdale, hippocampus, entorhinal cortex, cingulated cortex and 
dorsal horn ganglia)[98], and their location at nerve endings suggests a role in 
 48
the regulation of neurotransmitter release. CNS effects of 5-HT3 blockade have 
been found to be anxiolytic [99]  and have a role in reducing alcohol intake in 
early onset alcoholism[100]. 
Activation of 5-HT3 receptors can be immunomodulatory, for example via the 
induction of T cell proliferation via the protein kinase C-dependent 
phospholipase D pathway [101]. These immunoregulatory pathways may have 
a net anti-inflammatory effect with Tropisetron being shown to have an 
inhibitory effect on the secretion of TNF alpha and interleukin 1beta in 
rheumatological patients.  Topical Tropisetron showed clinical macroscopic 
and microscopic improvements in acetic acid induced experimental colitis in 
rats  similar to that seen with dexamethasone [102]. Other studies have 
shown Tropisetron to exert its effects through non 5-HT3 pathways, inhibiting 
T cell proliferation via a calcineurin inhibiting function and inhibiting the 
signalling pathway leading to NF kappa b activation [103]. Ondansetron may 
have less potent effects with partial inhibition of T cell proliferation and may 
therefore not have these other non 5-HT3 mediated immune effects [103]. 
Important in our patient group is the effect 5-HT3 antagonism has on 
neurogenic inflammation and noiciception in the periphery where it can  
inhibit the stimulated release of substance P, neurokinin A and calcitonin gene 
related peptide from primary afferents[104]. it is this substance P related pain 
modulation that is thought to be the mechanism by which 5-HT3 receptor 
antagonists are effective in fibromyalgia in other pain syndromes such as 
migraine[105] and chronic neuropathic pain[106]. Benefit in fibromyalgia is 
also gained from a reduction in fatigue which has been demonstrated in other 
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non painful conditions such as the fatigue associated with chronic hepatitis C 
virus infection [107]. Taken together the evidence points to usefulness of a 5-
HT3 blockade in conditions linked to inflammatory stimuli and altered pain 
perception in the context of chronic pain, making this an attractive target for 
IBS therapy.  
1.4.3 Biomarkers within the serotonin system  
1.4.3.1Platelet free plasma 5HT 
Free platelet poor plasma serotonin represents the serotonin that is newly 
released by gut enterochromaffin (EC) cells not yet taken up into platelets via 
the SERT transporter. Conversely platelet serotonin content represents 
changes in serotonin over time. Studying plasma serotonin requires the 
careful collection of blood via a large bore needle without the use of a 
tourniquet in order to minimise platelet activation and serotonin release. In 
this way increases in postprandial serotonin in IBS patients have been shown. 
It is hypothesised that serotonin release (greatest postprandially) leads to the 
increase in symptoms that is often observed in patients after eating. A small 
pilot study found no differences in fasting 5-HT in IBS patients, but higher 
post-prandial 5-HT concentrations with a longer duration of 5-HT peak than 
healthy volunteers[108]. These findings have been confirmed in larger study 
which also showed IBS-D patients to have higher fasting 5-HT than healthy 
control and patients with IBS-C, with increased area under the curve (AUC) 
postprandially in IBS-D compared to healthy volunteers but no increase 
compared to fasting in the IBS-C group [109]. This increase in postprandial 5-
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HT has also been shown in PI-IBS[110]  and demonstrated to weakly correlate 
with postprandial symptoms[111].  
1.4.3.2Plasma 5-Hydroxyindoleacetic acid (5-HIAA) 
Using platelet poor plasma to measure 5-HIAA has been less frequently 
studied. In patients with IBS-C a decrease in fasting 5-HIAA was observed but 
there was a preserved 5-HIAA:5-HT ratio suggesting normal breakdown of a 
reduced amount of serotonin in these patients. In the same study IBS-D 
subjects were found to have normal 5-HIAA but a decreased 5-HIAA: 5-HT 
ratio after feeding [109]. This points to the capacity for serotonin breakdown 
failing to match the amount of released serotonin indicating a disorder of 
metabolism and/or reuptake rather than synthesis and/or release of 5-HT. 
Importantly plasma 5-HIAA represents the relative activity of the enzyme 
monoamine oxidase not only in the platelets but also in other tissues such as 
the liver and lungs and as such should only be regarded as a surrogate marker 
of 5-HT turnover. 
1.4.3.3Plasma tryptophan 
A potentially understudied component of the serotonin system is the 
contribution another metabolic pathway of dietary tryptophan, the kyneurine 
pathway might have in IBS patients.  A study in 10 male patients looking at 
metabolites of tryptophan via this pathway found increased levels of L-
kyneurine and an increased ratio of L-kyneurine to tryptophan. Coupled with 
an increase in neoptrin whose production also relies on the enzyme 
indolamine 2,3-dioxygenase authors conclude that there may be an induction 
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of this enzyme potentially via an inflammatory mechanism  [112]. More 
recently other have found higher free serum tryptophan in patients but an 
inhibition of the kynurenine pathway[113], these conflicting results and the 
small numbers of subjects point to the need for further studies before the role 
of this pathway can be evaluated as a biomarker. 
1.4.3.4SERT polymorphisms 
DNA extraction and analysis is relatively easy and cheap and it is feasible to 
look for polymorphisms in large populations to better understand disease 
mechanisms and increasingly importantly to predict response to treatment. In 
IBS SERT polymorphisms have been proposed as possible candidates 
underlying a genetic predisposition to develop the condition. Evidence that 
SERT function is important includes the finding that blockade of SERT with a 
selective serotonin reuptake inhibitor leads to an increase in gut 
contractility[114] and the intriguing observation that SERT knockout mice 
have alternating diarrhoea and constipation[115].  The hypothesis being that 
deficient reuptake of serotonin leads to a supra-physiological level of 
serotonin and so the generation of symptoms. SERT polymorphisms have also 
have been linked to response to Alosetron. Here in patients who were 
genotyped for 5-HTTLPR those with an LL polymorphism had greater response 
to alosetron treatment as assessed by increase in colonic transit time was 
better in those with LL polymorphisms. The proposed mechanism being 
enhanced efficacy of alosetron in an environment with less available 
serotonin [75].  
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 Many studies have looked at the incidence of the 5-HTTLPR polymorphisms in 
groups of patients with IBS and the results are conflicting. In a meta-analysis 
of 1034 patients in comparison with 1377 controls it was concluded that 5-
HTTLPR genotypes are not risk factors for IBS[116] . This is despite some 
studies finding evidence of association when examining patients by their 
subtype. Consistent with the hypothesis that a reduction in SERT function 
leads to a greater availability of serotonin and enhanced bowel activity, 2 
studies have found an association between those with IBS-D and the SS 
genotype [117, 118] and in keeping with idea that IBS is a disorder of the gut 
brain axis patients with an SS genotype and IBS are reported to have a higher 
lifetime history of depression [119]. More promisingly the correlation 
between SERT polymorphisms and a therapeutic response to drugs acting on 
the serotonin system has been demonstrated [75]. I will discuss the regulation 
of gut mucosal SERT expression and its role in IBS in the section looking at 
changes detectable using biopsy sampling. 
1.4.3.5SERT binding kinetics  
Serotonin transport across the human blood platelet membrane through SERT 
has been widely used as a cellular model of neuronal 5-HT reuptake, however 
attempts to link platelet SERT function to different psychological states have 
had mixed success despite common molecular and physiological features. In 
the case of bowel SERT function the circulating platelets pass directly through 
the mucosal environment and therefore platelet SERT function may be more 
closely linked to the function of the mucosal SERT by being exposed to the 
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same environment. In a Study of 12 female patients taking 1mg bd of 
Alosetron the activity of platelet SERT receptors was assessed. Here the 
maximal binding capacity of the ligand and its receptor (Bmax), represents an 
estimate of the total number of binding sites expressed on the cell membrane 
and the dissociation constant Kd represents the affinity the drug has for its 
receptor. The patients with IBS had a lower Bmax than healthy volunteers 
coupled with a higher Kd representing a lower expression of SERT and a lower 
affinity for the ligand at its binding site. This did not change after Alosetron 
treatment. This combination of findings would create in the patient a situation 
where decreased uptake of serotonin leads to the presence of an over 
physiological concentration of serotonin in the gut and so symptoms, this is 
supported by the correlation of low density SERT on platelet membranes with 
more severe symptoms [120]. A second study using IBS-D patients found an 
increase in Paroxetine binding compared to controls. This was inversely 
correlated with platelet 5-HT uptake and associated with decreased mucosal 
SERT mRNA. The authors hypothesise that in the presence of reduced SERT 
the number of binding sites for Paroxetine increase as part of a potential 
compensatory mechanism[121]. Despite this discrepancy the ability to 
perform this assay on stored samples and the intriguing nature of results so 
far suggest platelet SERT could be a convenient biomarker for increased 
serotonin availability and warrants further investigation. 
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1.4.3.6SERT mRNA expression  
Reduced SERT expression has been demonstrated in the rectal biopsies of 
patients with ulcerative colitis IBS-D and IBS-C. This finding was accompanied 
by reduced tryptophan hydroxylase levels and reduced 5-HT content [122]. 
The finding of reduced SERT in conditions with mucosal damage and 
pronounced inflammation has been replicated in patients with celiac disease, 
but more importantly has also been seen in patients with IBS-D and subtle low 
grade inflammation[121] . In this study the reduction in SERT correlated with 
intraepithelial lymphocyte (IEL) numbers even in the range considered normal 
by conventional histopathology. 
These findings have not been demonstrated in all studies [123]  and may 
simply represent the patient heterogeneity which is so difficult to overcome. 
In addition interpreting the functional significance of altered mRNA levels is 
complex. SERT function relies on its apical position on the cell membrane, 
phosphorylation by Protein Kinase C leads to internalisation and reduction in 
5-HT uptake in SERT expressing cell lines. Therefore measures of 
phosphorylated SERT may give a better clue to the levels of functional 
transporter in the mucosa.  
1.4.3.7Enterochromaffin cells 
EC cells are serotonin-containing enteroendocrine cells that are distributed 
through the length of the gut,  greatest in number in the duodenum and 
rectum[124]. These cells are orientated with their base in contact with the 
basement membrane and their apex, covered by microvilli, extending out into 
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the lumen where they can sense and transduce luminal stimuli. Activation 
leads to the release of pre-stored serotonin from dense apical and basal 
granules and can be via mechanical, neural or chemical means. These cells are 
increased in number in inflammation and infection and it is hypothesised that 
their prolonged presence after the resolution of an infectious stimulus leads 
to PI-IBS.  Increased numbers of these cells have been found in PI-IBS [29, 35, 
125] and in a mouse model of post infectious bowel dysfunction infection with 
Trichinella spiralis where these changes were accompanied by reduced SERT 
expression via a T cell dependent mechanism [126]. EC cell hyperplasia is seen 
in patients with inflammatory bowel disease (IBD) and may be a contributing 
mechanism of visceral hypersensitivity and symptoms in IBS[127]. 
More recently the EC hyperplasia has been shown to be controlled by T 
lymphocytes, which activate IL-13 receptors found on EC cells [128]. T. spiralis 
infection leads to long lasting motor and sensory dysfunction [129] associated 
with increased EC numbers and reduced SERT expression [126]. The same 
model shows long term increases mucosal 5-HT content and spontaneous 
release and also increased afferent nerve response to distension which can be 
inhibited by the 5-HT3 receptor antagonist, Ondansetron [130].   
1.4.3.8Mucosal 5HT content 
Changes in mucosal 5-HT content of biopsies have been demonstrated in 
patients with C-IBS with elevated 5-HT concentrations when compared with 
IBS-D and controls[131]. A tendency towards increased 5-HT content in IBS-C 
patients has also been found by members of our own department [110]. This 
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is in contrast to the finding by others that mucosal 5-HT content is reduced in 
IBS-C, IBS-D and ulcerative colitis (UC) [122]. Opiate induced constipation has 
not been shown to alter mucosal 5-HT content or mucosal SERT suggesting 
these findings are primary as opposed to being secondary to altered motility 
[132].  
1.4.3.9Mucosal 5HT release 
A better understanding of the role of serotonin might therefore be gained by 
looking at mucosal release and turnover as the vast majority of serotonin in 
the gut is stored away in the EC cell and is only active during the time 
between release and reuptake. Mucosal 5-HT turnover as assessed by 
mucosal 5-HIAA/5-HT ratio has been shown to be decreased in both IBS-C and 
PI-IBS patients. IBS-C patients who release less 5-HT and hence generate less 
of the 5-HIAA metabolite might be predicted to have a  reduced 5-HIAA/5-HT. 
hover in PI-IBS there is increased 5-HT release so in this case reduced 5-
HIAA/5-HT ratio suggests a defect in SERT or monoamine oxidase as 
previously discussed [110]. In a small study that looked at basal and 
stimulated 5-HT release from biopsy of patients with IBS-D, IBS-C and UC 
controls no group differences were seen[131] but the trauma of biopsy may 
make this a poor model for studying 5-HT release. 
1.4.3.10 Summary of abnormalities in the serotonin system 
The overriding picture is of an altered serotonin system but with multiple 
potential mechanisms, including increased release, reduced uptake, 
differences in receptor number and sensitivity at peripheral, mucosal and 
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central sites. In addition none of the parameters discussed have thus far 
displayed characteristics of a good biomarker, with to date no data on 
reproducibility reliability, sensitivity and specificity. 
1.5 Serine proteases  
The serine proteases family of proteolytic enzymes have been identified as 
the source of increased faecal proteolytic activity in patients.  These enzymes 
may be mechanistically important via their action on the Protease activated 
receptor (PAR) -2, inducing increases in permeability and hypersensitivity.  
Proteolytic enzymes make up 2% of the human genome and almost a third of 
these proteases can be classed as serine proteases, so called because the 
active site contains a nucleophillic serine residue.  Classification is into 12 
clans according to catalytic mechanism and 40 families on the basis of 
common ancestry.  They are widely distributed in nature and are found in all 
cellular life including viruses. The chymotrypsin like clan is the largest and best 
studied  of these, and members play a critical role  in digestion (chymotrypsin, 
trypsin and pancreatic elastase), haemostasis, apoptosis, reproduction and 
the immune response (tryptase, neutrophil elastase, complement factor B,C 
and D, cathepsin G)[133].  
The largest pool of serine proteases in the intestinal tract of an animal model 
is derived from the pancreas under physiological conditions[134]. Trypsin and 
elastase enter the colon in much greater concentration than that found in 
stool, with the proteolytic activity of human ileal effluent being in the order of 
20 times that found in the faeces[135]. Protease inhibition studies with 
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washed faecal bacteria have shown that they produce serine-, cysteine-, and 
metallo-proteinases, and that these bacteria have low levels of trypsin and 
chymotrypsin like activity when whole. This activity greatly increases when 
the bacteria are lysed. It is clear that the proteolytic activity of the colonic 
flora [136] and the colonic transit time regulate the delivery of these to the 
rectum.  
Mast cells are another potential sources of serine proteases in the gut. 
Tryptase makes up to 25% of the total cellular proteins and is expressed by 
almost all subsets of human mast cells. There is some controversy as to the 
true in vivo potency of tryptase as a PAR activator with the consensus being 
that the activation is considerably less than that produced by trypsin and that 
the action of tryptase is likely to important when it is present in high 
concentrations during inflammation and mast cell activation[133]. 
1.5.1 Protease activated receptors (PARs) 
PARs are G-protein coupled membrane bound receptors that are activated in 
a unique way. The same general mechanism activates all types and consists of 
an extracellular free amino acid terminus which is cleaved by a protease; this 
exposes a new terminus which then binds to the second of remaining 
extracellular loops of the receptor resulting in the initiation of the signal. 
There is no known function of the amino-terminal fragment that is cleaved 
during this process. 
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Figure 1-1 Showing A, proteolytic cleavage of the extracellular free amino acid terminus, 
and B, binding of the new terminus to the remaining extracellular loops of the receptor. 
[137] 
PARs exist in 4 forms, and are distributed throughout the body with many 
important roles processes as diverse as coagulation and pain signalling; I will 
focus here however on their role and distribution in the GI tract.  PAR-1, the 
first of this family to be cloned and identified, is present in the endothelial 
cells of the lamina propria of the small intestine, intestinal epithelial cells, 
smooth muscle cells and the neurones of the enteric nervous system.  PAR-2 
is present throughout the GI tract but is found in lesser concentrations in the 
stomach. Its presence has been localised to enterocytes, smooth muscle cells, 
mesenteric afferent nerves and the neurons of the myenteric and submucosal 
plexuses, as well as vascular smooth muscle, endothelial cells and also 
neutrophils mast cells and lymphocytes.  PAR-3 is expressed in the stomach 
and small intestine and PAR-4 is highly expressed in the pancreas, small bowel 
and colon[137]. 
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Activation of PAR-1 and PAR-2 stimulates chloride ion secretion from the 
intestinal mucosa, an important physiological response to inflammation and 
infection allowing diarrhoea to assist in clearing the noxious agent.  In 
addition the presence of PARs in the myenteric plexus suggests a role in the 
control of motility, and the net effect of their activation in vivo appears to 
stimulate intestinal transit. PAR-2 also has a role in regulating pancreatic, 
gastric, and salivary secretion, with tissue specific pro and antisecretory 
effects. Under conditions of inflammation, during which proteases are 
generated and released, it appears that intraluminal administration of the 
selective PAR2 activating peptide (PAR-2-AP) SLIGRL-NH2 provokes 
inflammation in a wild type mouse but not its PAR-2 deficient counterpart 
[138] . The induction of this inflammation is in part via a neurogenic 
mechanism involving release of peptides from sensory nerves since this is 
suppressed by sensory nerve ablation [139].  Activation of PAR-2 by mast cell 
tryptase [140], trypsin or the agonist SLIGRL increases colonic paracellular 
permeability [141]. 
Multiple proteases can activate a PAR and the ability of a protease to activate 
a PAR depends on its secreted concentration, the presence or absence of co 
factors, and the relative abundance of specific inhibitory proteins. This is 
illustrated by the pancreatic trypsins whose activity depends on the release of 
zymogen trypsinogen, the presence of enteropeptidase which activates 
trypsinogen and the existence of a large array of endogenous trypsin 
inhibitors. Much less is known about the regulation of extra pancreatic 
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trypsins which are known to be present in endothelial and epithelial cells as 
well as the nervous system[137].  
1.5.2 Serine proteases and IBS 
Evidence for the role and action of these serine proteases in IBS has grown 
rapidly with initial animal studies showing that trypsin and tryptase are 
capable of activating colonic PAR-2 receptors in mice and that this activation 
results in inflammation and increased paracellular permeability [138]. 
Activation of PAR-2 receptors by injection of a sub inflammatory dose of 
agonist into the paw of both rats and mice results in visceral hyperalgesia, an 
important feature of IBS in patients [142]. Supernatants from IBS patient 
biopsies have increased proteolytic activity compared to controls and these 
supernatants when injected into the colons of mice causes hypersensitivity 
again via a PAR-2 dependent mechanism [143]. Bueno and colleagues have 
found increased levels of serine protease activity in the stool supernatant of 
patients with IBS-D and hypothesised that the source of these enzymes may 
be bacterial or from mucosal mast cells [94]. In this study there was no 
increase in pancreatic elastase in the IBS-D patients and coupled with the 
finding of no increase in activity in infectious diarrhoea they conclude that fast 
transit and delivery of pancreatic enzymes to the colon is not an important 
source of this activity. However this argument may be erroneous. Elastase 
may be atypical in not being rapidly degraded by colonic bacteria and so its 
levels may not change with accelerated transit. Furthermore the absence of 
increase in infectious diarrhoea may reflect the fact that subjects suffering 
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acute gastroenteritis often do not eat and hence may not secrete as much 
pancreatic enzymes. The source of increased faecal serine protease (FSP) 
activity is an important next question in establishing its role as a biomarker 
and a target for new treatments. 
1.6 Gastrointestinal Imaging in irritable bowel 
syndrome  
IBS patients have a disorder of gut function and not structure; conventional GI 
imaging is directed at the diagnosis of structural and mucosal alterations and 
employs a range of endoscopic and radiological techniques. Most if not all 
patients presenting with symptoms consistent with IBS will undergo at least 
one of these investigations whilst on their diagnostic pathway, most usually 
with the aim of excluding organic disease. This has the effect of exposing the 
patient to radiation and the small but important risk of perforation and 
bleeding at endoscopy as well as resulting in anxiety and uncertainty. These 
tests have been demonstrated to have a very low diagnostic yield,  for 
example in 2 large multinational studies colonic evaluations, including barium 
enema, computerised tomography (CT) or endoscopy were normal in 98% of 
screened patients[144], and perhaps should not be performed with such 
regularity. 
 
Less risky evaluation such as ultrasound may be helpful in selected cases but 
has not been shown to add valuable information in the majority of subjects. A 
study of 125 IBS patients diagnosed via symptom-based criteria concluded 
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that abdominal ultrasound was not necessary and may actually be 
counterproductive because the identification of irrelevant anatomic 
abnormalities could conceivably lead to unnecessary patient concern and 
additional, more invasive tests or procedures such as cholecystectomy[145]. 
 
The use of transit measurement via transit markers, scintigraphy, and wireless 
capsules has already been discussed and these techniques have a clear role in 
assessing gut function. Other more conventional and commonly available 
imaging modalities have demonstrated potential new disease mechanisms. 
Accarino et al have produced elegant work looking at abdominal gas volumes 
and distribution using CT scanning. They found that in contrast to patients 
with dysmotility total abdominal volume did not increase during bloating 
episodes in patients with IBS, rather that abdominal protrusion was mediated 
via alteration of posture and diaphragmatic descent [146] .  However CT gives 
a large radiation dose and this research technique should be avoided in IBS 
patients in routine clinical practice. 
1.6.1 MRI imaging in functional GI disorders 
In the early days of MRI it was difficult to image the GI tract. With long 
acquisition times, resolution was poor, and artefact common. New advances 
in MRI imaging methods have now made it possible to detect mural and 
transmural disease and these techniques are also ideally placed to assess 
abnormalities of gut function. A good example of the use of functional 
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imaging is MRI defecography, used clinically in the understanding of 
evacuatory disorders.  
The images are acquired via signal arising from the endogenous hydrogen 
protons, this means that the image contrast depends on the physicochemical 
environment of the organ of interest, fine tuning of the MRI sequences allows 
highlight of areas of interest for example the distribution of free water within 
the bowel itself. This has the potential to remove the need for unpleasant 
purging or the use of additional contrast medias making the test on the whole 
very patient acceptable. The avoidance of radiation facilitates multiple 
examinations during interventions such as eating a test meal or receiving a 
treatment in an otherwise undisturbed system.  There are of course some 
limitations to this emerging technique. The software to assess GI motility and 
other functional parameters has yet to be fully automated and is time 
consuming, MRI scanning time remains costly and some patients will not find 
the enclosed environment acceptable. 
To date several novel insights using MRI have been made.  Measuring 
distribution of freely mobile small bowel water using a validated 
technique[147], in patients with IBS-D compared to controls has resulted into 
several new insights. Patients have a reduction in total fasting small bowel 
water content (SBWC), median 42 ml compared to 100-150 ml which was 
associated with faster transit and a hypertonic “spaghetti” bowel. This would 
be predicted to deliver an increased amount of water to the colon and soften 
the stool. The scores of the first day’s stool showed a significant negative 
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correlation with the AUC for SBWC, a low value of which indirectly confirmed 
the suggested increased delivery of water to the ascending colon [148]. 
 
As well as giving insights into gut function in a disease state this technique has 
been successfully employed to investigate the effects of drugs on gut 
function. Measurement of intraluminal cross-sectional diameter changes in 
selected loops of bowel distended with oral contrast in healthy volunteers has 
allowed the inhibitory properties of hyoscine butlybromide[149] and 
glucagon[150] to be demonstrated. In another example using the same 
technique a reduction in net gut water, either by stimulation of absorption or 
inhibition of secretion with loperamide was demonstrated where previous 
invasive intubation methods had concluded Lopermide acts solely via change 
in intestinal transit [151]. In a double blind randomised placebo control trial of 
Ondansetron in healthy volunteers fasting small bowel water was significantly 
increased in the Ondansetron arm when compared to placebo. Ondansetron 
is known to inhibit colonic motility[79] and the migrating motor complex 
(MMC)  in rodents[152], and a second arm of this study was able, again using 
MRI, to demonstrate a reduction in antroduodenal motility[153].  
 
1.7 Clinical trial design in IBS 
There is no structural abnormality that defines IBS, and given the 
heterogeneity of symptoms experienced by patients and the absence of a 
reliable biomarker, optimal endpoints for clinical trials have been difficult to 
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establish. Therefore most usually response to treatment is assessed by 
improvement in symptoms. This is a subjective outcome and there are several 
factors including the large placebo response seen in this group[154] that need 
to be considered in the design of a trial to ensure the most meaningful result 
is obtained.  The use of patient reported outcomes (PRO) has been until now 
the most common method of collecting endpoint data. These endpoints 
should be validated and identify relief from important symptoms based on 
their pathophysiological mechanisms in patients with IBS.  Several 
recommendations have been made and an understanding of these has 
informed the study design that will be outlined in full in chapter 3 [155]. With 
this in mind we have designed a trial that uses PROs enhanced by a 
mechanistically appropriate set of proven (transit) and potential biomarkers in 
the serotonin system. In order to make this as clinically applicable as possible 
and patient acceptable we will also explore the new field of MRI Imaging as a 
possible biomarker of responsiveness to treatment. 
1.8 Aims of the thesis 
This thesis aims to identify biomarkers that allow us to predict response to 
our therapeutic intervention and to define an Ondansetron responsive 
endophenotype of IBS.  
I will test the following hypotheses: 
1. The 5-HT3 receptor antagonist Ondansetron is a well tolerated and 
effective treatment in patients with IBS-D. 
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2. Ondansetron acts to increase small bowel water and slow colonic 
transit. 
3. Response to Ondansetron will be more effective in those with 
abnormally increased mucosal serotonin availability at baseline. 
4. Faecal serine protease activity will be reduced by treatment with 
Ondansetron as a result of increased colonic transit. 
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2 Ondansetron in patients with diarrhoea 
predominant Irritable bowel syndrome 
“identifying the responder”: Study design 
2.1 Study configuration  
This was a 2 centre (Nottingham Digestive Disease Centre and Biomedical 
Research unit in conjunction with the department of Neurogastroenterology 
at the Wythenshawe Hospital, Manchester), randomised placebo controlled 
cross-over study of Ondansetron 4-8mg TDS with dose titration in IBS-D 
patients. The trial was conducted according to the principles of good clinical 
practice (GCP), ethical approval was granted by the Nottingham Research 
Ethics Committee 2 (REC). The trial was registered on clinicaltrials.gov and 
received the necessary approval from the Medicines and Healthcare 
Regulatory authority (MHRA). Funding was provided by the National Institute 
for Health Research.  A summary of the study design can be seen in figure 2.1 
 
Figure 2-1 Summary of the study design for the trial Ondansetron in patients with diarrhoea 
predominant Irritable bowel syndrome “identifying the responder”. 
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2.1.1 Power calculation 
Change in stool consistency from baseline in the final 2 weeks of treatment 
was the primary end point of the study.  Previous studies in Nottingham show 
a mean (SD) stool consistency of 3.8 (1.1), n=28 with a normal distribution.  
Using the sampsi command in Stata, 111 subjects were required for a one-
sample t-test with 90% power to detect a shift of 0.4 points on the stool 
consistency scale at a 1% two-sided significance. 0.4 was chosen as the 
difference obtained by Camilleri using alosetron in IBS-D[156].  Since the 
standard deviation is estimated from a small sample (itself prone to sampling 
variation) the sample size was multiplied by a correction factor of 1.111[157] 
to give a final sample size estimate of 123 evaluable subjects. An 18% drop 
out was assumed giving a final number of recruits of 150. This was a 
deliberately conservative calculation since the magnitude of effect was 
believed to  likely be larger as this study used the Bristol Stool Form Score 
which runs from 1-7 while Camilleri used a scale running from 1-4.  
2.1.2 Patient recruitment, inclusion and exclusion 
criteria 
Participants were recruited from IBS clinics at the Queens Medical Centre 
Nottingham and the Wythenshawe Hospital Manchester, and from Professor 
Spiller’s list of patients who have previously taken part in research studies. 
Adverts were placed in the clinical areas of the Queens’s Medical centre. 
Patients were also recruited from general practice via collaboration with the 
Trent Primary Care Research Network. All patients who expressed an interest 
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in taking part were sent a detailed information sheet, this contained the 
contact information of the study team and every effort was made to answer 
any questions regarding the trial before and during the first screening visit. 
Inclusion and exclusion criteria are listed in Table 2.2 and 2.3. Since many 
patients were on SSRIs or tricyclic antidepressants these were not excluded 
provided they had been on medication at least 3 months and that the dose 
remained unaltered throughout the study. 
 
 
Inclusion criteria 
IBS-D patients meeting the Rome III criteria. 
Male or female aged 18-75 years 
Women of child bearing potential (who have a negative pregnancy test) must 
agree to use    methods of medically acceptable forms of contraception during 
the study, (e.g. implants, injectables, combined oral contraceptives, sexual 
abstinence or vasectomised partners) 
Patients who were able to give informed consent. 
Table 2-1 Ondansetron in patients with diarrhoea predominant Irritable bowel syndrome 
“identifying the responder” inclusion criteria. 
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Exclusion criteria 
Women who were pregnant or breastfeeding 
Patients that, in the opinion of the investigator, were considered unsuitable. 
Patients who have had abdominal surgery which may cause bowel symptoms 
similar to IBS ( appendicectomy and cholecystectomy were not an exclusion) 
Patient unable to stop anti-diarrhoeal drugs 
Patients  who were currently participating in another clinical trial or who had 
been in a trial in the previous three months 
Table 2-2 Ondansetron in patients with diarrhoea predominant Irritable bowel syndrome 
“identifying the responder” exclusion criteria. 
2.1.3 Randomisation and blinding 
The randomisation was  based on a computer generated pseudo-random code 
using random permuted blocks of randomly varying size, created by the 
Nottingham Clinical Trials Support Unit (CTSU) in accordance with their 
standard operating procedure (SOP) and held on a secure server. The research 
team obtained a randomisation reference number for each participant by 
means of a remote, internet-based randomisation system developed and 
maintained by the Nottingham CTSU. The sequence and decode of treatment 
allocations was concealed until all interventions had been assigned and 
recruitment, data collected, and all other trial-related assessments was 
complete.   
2.2 Drug preparation and dosing  
Each participant received five weeks of placebo and five weeks of 
Ondansetron. The investigational medicinal product (IMP) was produced by 
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over encapsulation in a gelatin capsule of either a 4mg Ondansetron tablet 
(Pliva, Zagreb, Croatia) or placebo. The placebo formulation matched that of 
the Ondansetron in appearance and composition, except for the active drug. 
This was done by Bilcare (Crickhowel ,Powys, UK). The pharmacy at NUH then 
packaged, labelled and QP released (carried out by the designated person) 
blinded treatment packs. These packs were labelled with a single panel label 
according to clinical trial regulations. Subject name, randomisation number, 
storage conditions and date of dispensing were added to the label at the time 
of dispensing.  
 
The Ondansetron dose was titrated, and as such varied from 4mgs alternate 
days to 8mgs tds.  Patients were instructed to commence treatment with 1 
capsule once a day. Depending on the response, patients were asked to 
increase the dose to a maximum of 8mg tds. If stool consistency increased to 
hard (stool form 1 or 2), or if bowel frequency dropped below 1 per day the 
dose was reduced to a minimum of one tablet taken every 2 days.  Patients 
were encouraged to ring in to discuss dose adjustment. Dose adjustment was 
completed within the first 3 weeks.  During the final 2 weeks patients 
completed the stool diary on a steady dose of drug.  Following each treatment 
period patients underwent   a washout period of between 2 and 3 weeks.   
Patients were allowed to take Loperamide 2mgs BD as rescue medication in 
the event of uncontrolled diarrhoea.  They were asked to discontinue this for 
the final two weeks since stool consistency in this period was the primary end 
point of the study.   
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2.3 Visit schedule 
2.3.1 Visit 1 -Screening  
At this visit the inclusion and exclusion criteria were checked and if the 
patient was eligible to enter informed was consent taken, followed by: 
1) A physical examination, including a pregnancy test for women of child-
bearing potential. 
2) Taking of blood samples for: 
i) Routine screening test (Haemoglobin (Hb), tissue transglutaminase (tTG) 
antibodies, Calcium, Gamma-glutamyltransferase (γGT), alanine 
aminotransferase (ALT), Alkaline phosphatase (ALP), Albumin and C- 
reactive protein (CRP)) if these were not done within the last 3 months.  
       ii) Collection of DNA for analysis of genetic polymorphisms of SERT.   
iii) Fasting whole blood assessment of biomarkers of serotonin 
metabolism including the maximum binding (Bmax) of H3-labelled 
paroxetine binding to platelet membranes and H3-5-HT uptake together 
with plasma to be assayed for 5-HIAA  
3) Flexible sigmoidoscopy with mucosal biopsies to exclude microscopic colitis 
(if not done in preceding 2 years). 
4) Nottingham only: Flexible sigmoidoscopy and 8 rectal biopsies. 2 for routine 
histology and immunostaining for 5-HT containing cells, 2 for assessment of 5-
HT release and 2 for preservation in RNA Later for RNA extraction and 
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assessment for mRNA of inflammatory cytokines, 2 for snap freezing for 
subsequent protein assays  
We also performed a psychometric assessment at this visit using the following 
questionnaires: Hospital Anxiety and Depression Scales (HAD)[158], Personal 
Health Questionnaire (PHQ15) [159], Perceived Stress Questionnaire [160] 
and IBS quality of life (IBS QOL) [161] score. Patients were then asked to 
complete a one week stool diary using the Bristol Stool Form Score. The IBS 
symptom severity score (IBS SSS) which provides and overall assessment of 
symptoms and has been shown to be sensitive and responsive to treatment 
effects was also performed at this baseline visit (all study questionnaires are 
contained in appendix 1). 
2.3.2 Visit 2 - Enrolment and Randomisation – (end of 
Week 1):  
All sites: The stool diaries were examined to confirm loose stools >25% and 
hard stools <25% allowing classification of Rome III IBS.  The results of the 
blood tests were reviewed to ensure no other diseases were present.  The 
patients were then randomised using the previously described web based 
randomisation and allocated treatment. At this visit a stool sample collected 
that day was stored at -80˚C for later serine protease analysis as well as future 
microbiological analysis using the DNA based HITChip. Patients were then 
given the first 1x 100 capsules consisting of 4mg tablets of Ondansetron or 
placebo.  
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2.3.3 Visit 3 (end of Week 4): 
All sites: Patients returned to the hospital after completing 3 weeks of stool 
diary recording on treatment for a diary check. Patients were reminded to 
make no further dose adjustments and to no longer use rescue Loperamide in 
the final 2 weeks of the treatment period. They were also given 3 containers 
each containing 24 radio-opaque pellets one to be taken on each of the last 
three days of week 6.  
2.3.4 Visit 4 (end of Week 6):  
All Sites: On the day of the visit the colonic transit of the radio-opaque pellets 
were assessed by plain abdominal X-ray. A second IBS-SSS was completed, 
blood samples were taken for safety assessment (FBC & Liver function tests), 
and stool sample for serine protease activity and future microbiological 
assessment. Patients then stopped all study medication for the wash out 
period. Any un-used study medication was collected. The wash-out period 
was usually 2 weeks during which the patient continued to complete a stool 
diary. It some patients the washout was extended usually to allow them to 
meet work or family commitments during study period two. 
Nottingham only: A fasting MRI scan was carried out to assess small bowel 
and colonic water content.  
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2.3.5 Visit 5 (end of Week 8):  
All Sites: After confirming that the patient’s bowel habit had returned to 
baseline a new supply of 1x 100 capsules of study medication and new stool 
diaries were issued.  
2.3.6 Visit 6 (end of Week 11):  
All sites: Patients returned to the hospital after completing 3 weeks of stool 
diary recording for a second diary check. Patients were again reminded to 
make no further dose adjustments and to no longer use rescue Loperamide in 
the final 2 weeks of the treatment period. During this visit the patients were 
as previously given 3 capsules each containing 20 radio-opaque pellets to be 
taken on each of the last 3 days of week 6. 
2.3.7 Visit 7 Study end (end of Week 13):  
All Sites: as visit 4, in addition subjects were asked to express their preference 
for the first or second treatment and state whether they would like to 
continue to receive it. They were also reminded to mail in their final stool 
diaries in order to demonstrate the wearing off of any drug effect. 
Nottingham only: A fasting MRI scan was carried out to assess small and large 
bowel water content. 
2.4 Healthy volunteers 
21 age and sex matched healthy volunteers were recruited to provide normal 
values for comparison with our patient group. 
 77
2.4.1 Recruitment 
Participants were recruited via ethically approved adverts placed in the non-
clinical areas of the Queens’s Medical centre. All participants who expressed 
an interest in taking part were sent a detailed information sheet, this 
contained the contact information of the study team and every effort was 
made to answer any questions regarding the trial before and during the first 
screening visit. Inclusion and exclusion criteria are listed in Table 2.3 and 2.4.  
 
Inclusion criteria 
Healthy Volunteer 
Male or female aged 18-75 years  
 
Volunteers who are able to give informed consent 
Table 2-3 Inclusion criteria for healthy volunteers. 
 
Exclusion criteria 
IBS 
 
Women who are pregnant or breastfeeding 
 
Volunteers that, in the opinion of the investigator, are considered unsuitable 
 
Volunteers  who have had abdominal surgery (Please note, appendicectomy and 
cholecystectomy is not an exclusion) 
 
Concomitant use of drugs that affect stool consistency (e.g. opiate analgesia) 
 
Volunteers currently participating in another clinical trial or who have been in a 
trial in the previous three months 
 
Table 2-4 Exclusion criteria for healthy volunteers. 
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2.4.2 Visit schedule  
Visit 1: After signing a consent form healthy volunteers had: 
1) A physical examination, including a pregnancy test for women of child-
bearing potential. 
2) Taking of blood samples for: 
i) Routine screening test (Hb, tTG antibodies, Calcium, γGT, ALT, ALP, 
Albumin and CRP) if these were not done within the last 3 months.  
       ii) Collection of DNA for analysis of genetic polymorphisms of SERT.   
iii) Fasting whole blood assessment of biomarkers of serotonin 
metabolism including the maximum binding (Bmax) of H3-labelled 
paroxetine binding to platelet membranes and H3-5HT uptake together 
with plasma to be assayed for 5-HIAA  
3) Flexible sigmoidoscopy and 8 rectal biopsies. 2 for routine histology and 
immunostaining for 5HT containing cells, 2 for assessment of 5HT release and 
2 for preservation in RNA Later for RNA extraction and assessment for mRNA 
of inflammatory cytokines, 2 for snap freezing for subsequent protein assays  
We also performed a psychometric assessment at this visit using the following 
questionnaires: HAD, PHQ15, Perceived Stress Questionnaire. Volunteers 
were then asked to complete a one week stool diary using the Bristol Stool 
Form Score. 
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Volunteers were also given capsules each containing 24 radio-opaque pellets 
one to be taken on each of the last three days before visit 2. 
Visit 2: The colonic transit of the radio-opaque pellets were assessed by plain 
abdominal X-ray and a fasting MRI scan was carried out to assess small and 
large  bowel water. 
2.5 Case Report Forms (CRFs) 
Each participant was assigned a study identity code number at randomisation, 
for use on CRFs other study documents and the electronic database. The 
documents and database also used patient initials and date of birth 
(dd/mm/yy). CRFs were held securely in accordance with regulations. The 
investigator made a separate confidential record of the participant’s name, 
date of birth, local hospital number or NHS number, and Participant Study 
Number (the Study Recruitment Log), to permit identification of all 
participants enrolled in the study, in case additional follow-up was required. 
Computer held data including the study database was held securely and 
password protected. All data was stored on a secure dedicated web server. 
2.6 Stopping rules and discontinuation 
Participants were able to withdraw from the study at any point. Patients 
reporting rectal bleeding were asked to stop their treatment and attend for a 
flexible sigmoidoscopy to diagnose the cause. If the bleeding was due to 
minor haemorrhoidal bleeding they were allowed to continue treatment if 
they wished to. Other adverse events were assessed by the supervising doctor 
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who decided whether they should be allowed to continue in the trial.  
Participants were made aware (via the information sheet and consent form) 
that should they withdraw the data collected up to their withdrawal could not 
be erased and would still be used in the final analysis. 
2.7 Adverse events 
All adverse events were assessed for seriousness, expectedness and causality, 
definitions of an Adverse Event (AE), Serious Adverse Event (SAE) and 
Suspected Unexpected Serious Adverse Reactions (SUSARs) are contained in 
appendix 2. 
Reporting of adverse events 
Participants were asked to contact the study site immediately in the event of 
any serious adverse event. All adverse events were recorded and closely 
monitored until resolution, stabilisation, or until it had been shown that the 
study medication or treatment was not the cause.  
In concordance with Good Clinical Practice all SAEs would have been recorded 
and reported to the MHRA and REC as part of the annual reports. SUSARs 
would be reported within the statutory timeframes to the MHRA and REC. The 
Chief investigator was responsible for all adverse event reporting. There were 
no SAEs or SUSARs during this study. 
2.8 Compliance 
Patients kept a daily diary of drug ingestion, which was checked at each visit. 
Non-compliant participants were noted and encouraged to be compliant. 
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Unused pills were returned for counting. Ingestion of more than 75% of 
prescribed doses was considered compliant as assessed from the diary and 
count of returned tablets at each visit. Analysis per protocol excluded non-
compliant individuals. 
2.9 Primary and secondary endpoints Statistics 
including handling of missing data  
Analysis was performed by myself with the assistance of the statistician once 
the treatment codes had been broken. Data was entered into an Excel spread 
sheet and then imported into SPSS and Graph Pad Prism which were used for 
analysis. 
The distribution of each parameter analysed was assessed for normality using 
the Shapiro-Wilks test. 
Every effort was made to avoid missing data.  However, data omitted from 
diary cards will be imputed by taking an average of the day before and the day 
after(
2.9.1 Definition of populations analysed 
Full Analysis set: All randomised participants, who take at least one dose of 
study medication and for whom at least one post-baseline assessment of the 
primary endpoint is available.  
Per protocol set: All participants in the Full Analysis set who are deemed to 
have no major protocol violations that could interfere with the objectives of 
the study. 
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Primary Outcome Measure =Difference in average stool consistency in the last 
2 weeks of treatment of Ondansetron versus placebo.  
Secondary Outcome Measures ( all in last 2 weeks) 
1) Change from baseline in stool frequency  
2) Change from baseline in number of days with pain urgency and 
bloating  
3) Change from baseline in IBSSSS 
4) Proportion of patients preferring ondansetron versus placebo 
5) Proportion wanting to continue with ondansetron versus placebo 
6) Percentage satisfactory relief 
These results are described in detail in chapter 4, Patient reported outcomes.  
Chapter 5 describes the secondary outcome measures of difference between 
ondansetron and placebo periods with respect to: 
1) Colon transit   
2) Fasting SBWC 
3) Fasting ACWC 
 
Chapter 6 contains the secondary outcome measures pertaining to laboratory 
outcomes. 
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Chapter 7 contains the results of experiments to define the origin of faecal 
serine proteases and the effect of Ondansetron on faecal serine protease 
activity, 
 
2.9.2 Statistical methods 
Values were assessed for normality using the Shapiro-Wilks statistic and 
results are expressed as mean (95%, confidence interval, CI) for normally 
distributed data or median (interquartile range, IQR) if not normally 
distributed.  
The paired or unpaired students t test was used for paired or unpaired  
parametric data, and the Wilcoxon matched pairs or Mann-Whitney U for 
non-parametric data. 
Difference in responder status  between those with ss , sl and ll version of the 
SERT DNA polymorphism was assessed using Chi Squared test for trend.  
Correlation of outcome variables was  perfomed using either Pearson 
correlation coefficient or the nonparametric Spearman Rank Order correlation 
coefficient. Logistic regression was used to assess the relative value of these 
different measures in predicting response to Ondansetron. 
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3 Materials and Methods  
Here all the imaging and laboratory methods utilised in this thesis will be 
outlined in order starting with imaging, followed by analysis of blood samples, 
methods for analysing biopsies and finally stool analysis.  
3.1  Magnetic resonance imaging 
MRI was previously acronymed NMR or nuclear magnetic resonance 
reminding us that the physics behind the images is concerned with the 
nucleus. In the context of clinical MRI this is related to the nucleus of the 
hydrogen atom (also called the water proton) that is so abundant in the body. 
A detailed understanding of the physics behind the formation of a MRI image 
is beyond the scope of this thesis. This section summarises briefly the 
theory[162] with the only aim of introducing and describing the main MRI 
parameters measured during this work. 
The intrinsic nature of the NMR phenomenon requires a complex quantum 
mechanical description. In such a framework, the water protons have a 
magnetic moment arising from their spin angular momentum. This is a 
physical property meaning, in simple words, that each water hydrogen 
nucleus can be thought of as a little magnetic compass. Normally these 
magnetic moments in a sample will be randomly orientated. When the water 
protons in a sample are exposed to a main static magnetic field then their 
energy levels split into two separate values, one corresponding to the 
magnetic moments (compasses) aligning along the direction of the external 
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magnetic field (parallel) and one corresponding to aligning opposite to the 
direction of the external magnetic field (anti parallel). 
The parallel alignment requires less energy and is therefore slightly favoured. 
This creates a net sample magnetisation parallel to the applied field. It can be 
shown that the time evolution of this magnetisation in the main external 
magnetic field can be written as a clockwise rotation about the direction of 
the external magnetic field with a given angular frequency. This rotational 
frequency is called the Larmor frequency. In this equilibrium state no signal 
arising from this magnetisation is detected using a receiver coil. 
In order to get information from the proton spins they need to be excited. 
This is done with a short burst of radiofrequency, termed a radiofrequency (or 
RF) pulse.  This excitation is only possible if the pulse is delivered at the given 
Larmor frequency.  
Starting again with the information that the water protons have a magnetic 
moment which can be thought of as a little magnetic compass, when this is 
placed in a large external static magnetic field the magnetic moment will 
experience a torque causing it to spin about the direction of the main 
magnetic field in a gyroscopic fashion (see Figure 2.1) with a given precession 
frequency called the Larmor frequency. The Larmor frequency depends on the 
properties of the nucleus involved and the strength of the magnetic field.  
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Figure 3-1 Precession of a magnetic moment   about the static field B0  at a constant angle 
θ. In this reference frame the resulting magnetisation M is all along the main magnetic field 
B0 (longitudinal) whilst the component of M in the perpendicular (transverse) xy plane is 
zero.  
In analogy of what was described before, in this equilibrium state no signal 
arising from this magnetisation M is detected using a receiver coil. The 
application of a RF pulse delivered at the given Larmor frequency will tip the 
magnetisation away from the z axis creating two components, one along the z 
axis (longitudinal magentisation) and one perpendicular to it in the xy plane 
(transverse magnetisation).After excitation these two separate components 
will then return (relax) to equilibrium with two intrinsically different 
mechanisms called relaxation times T1 and T2 as described below. 
3.1.1 T1 longitudinal (spin-lattice) relaxation 
The longitudinal component of the magnetisation will return to thermal 
equilibrium by interacting with the surrounding lattice which functions as a 
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thermal reservoir. This is a first-order process characterised by a time 
constant T1 which is called the spin-lattice relaxation time or longitudinal 
relaxation time. Therefore T1 is the constant which describes the time 
required for the longitudinal component of the magnetisation to return to 
63% of its original value.  The rate at which energy can be transferred 
depends amongst other mechanisms on the size and rotation and 
translational motion characteristics of the molecules and therefore how easily 
they can move within this lattice. So large molecules usually move too slowly 
to transfer energy quickly and the best transfer of energy occurs at medium 
correlation times. T1 is therefore generally shorter in solutions than in solids. 
However in pure liquids small molecules move fast and their motion is too 
rapid to permit efficient energy transfer so a pure liquid will also have a 
relatively long T1. In addition T1 will also be affected by macromolecules such 
as proteins with hydrophilic bonding sites, as well as bound water the 
hydrophilic sites also slow the motion of free water in the near vicinity 
allowing it to transfer energy more efficiently and so shortening the T1. 
3.1.2 T2 transverse (spin-spin) relaxation 
The component of the magnetisation that is in the transverse, xy plane decays 
away after excitation but in this case the decay is due to random and 
irreversible loss of coherence between the ensemble of spins. This does not 
require transfer of energy to the lattice as it is just a dephasing process until 
each proton is spinning randomly and they are completely out of phase. In the 
liquid phase and with some assumptions this can be regarded again as a first-
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order process characterised by a time constant T2 which is called the spin-spin 
relaxation time or transverse relaxation time. Therefore T2 is the constant 
which describes the time for the transverse magnetisation to fall 63% of its 
original value. This spin-spin relaxation is also affected by physical state and 
molecular size. Solids and large molecules have a short T2; by contrast T2 is 
long in free water. Like T1, T2 is also affected by the presence of 
macromolecules, here they increase the efficiency of spin-spin interactions 
and shorten T2. Some T1 and T2 values for human tissue are given in table 
2.1[162] to illustrate how this can be exploited. 
Tissue T1 at 1.5 Tesla in 
milliseconds 
T2 at 1.5 Tesla in 
milliseconds 
Skeletal muscle 870 47 
Liver  490 43 
Kidney  650 58 
Spleen  780 62 
Fat  260 84 
Gray matter 920 101 
White mater 790 92 
Cerebrospinal fluid >4000 >2000 
Lung  830 79 
Table 3-1 Table showing the T1 value in ms of Tesla. 
3.1.3 MRI imaging 
The theory summarised so far shows that one can excite the water protons in 
a sample and that the decay characteristics of the signal contain rich 
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information about the physicochemical and motional environment of the 
protons. The use of specially designed RF pulses that selectively excite only a 
portion of the sample in conjunction with linear magnetic gradients that 
superimpose to the protons a predictable spatial variation in the Larmor 
frequency allow sampling and reconstruction of two-dimensional planar 
images. 
For an image to have diagnostic utility there must be contrast between the 
MR signal of different tissue types. The intensity of the signal is a function of 
T1 and T2 and also proton density, chemical shift and motion. The relative 
contribution of each parameter is controlled by adjusting the RF pulses, 
applied gradients and timing of the data acquisition. These parameters are set 
in the imaging sequence and the sequences used in this study will be 
described in the following methods. 
 
3.1.4 Equipment 
MRI scanning was performed on the state-of-the-art, research dedicated 1.5T 
Philips Achieva Scanner sited at the University of Nottingham 
3.1.5 Image sequences 
Each subject was positioned supine in the scanner with a body coil wrapped 
around the abdomen. Firstly, a coarse scout scan was taken to locate the 
position of the abdominal organs and plan the position of the image planes 
followed by a calibration scan allowing automatic setup of the scanner specific 
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to the subject at that time point. The subjects spent approximately 20 
minutes inside the magnet at each visit. 
  
Small bowel water content (SBWC) was assessed with a single shot, fast spin 
echo sequence (similar to that used for magnetic resonance 
cholangiopancreatography (MRCP), (effective echo time(TE)=320 
milliseconds)to acquire in a single breath-hold, 24 coronal images with in-
plane resolution interpolated to 0.78 mm X 0.78 mm and a slice thickness of 7 
mm, with no gap between slices (acquired voxel size = 1.56 X 2.83 X 
7mm3).This sequence yields high-intensity signals from areas with liquid fluid 
and little signal from body tissues.  
Secondly, a dual-gradient echo (dual-echo fast field echo [FFE], TE1 = 2.3 
milliseconds, TE2 = 4.6, repetition time =158 milliseconds) imaging sequence 
was used to visualize anatomy acquiring 24 coronal plane and 45 transverse 
images with in-plane resolution of 1.76mm X  1.76 mm and a slice thickness of 
7 mm, with no gap between slices. Each image set was acquired on an 
expiration breath hold, the duration of which varied between 13 and 24 
seconds. 
T1 in the ascending colon (AC) was measured using a single slice balanced 
Turbo Field Echo (bTFE) with a preparatory 180 deg inversion pulse applied 
before acquiring the imaging data.  Data were acquired from 8 different 
inversion times (TI) (time between inversion pulse and imaging pulses) ranging 
from 25 - 4925 ms.  T2 in the AC was measured using a single slice bTFE with a 
preparatory spin echo pulse (90deg-TE/2-180deg-TE/2--90deg) applied before 
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acquiring the imaging data.  Data were acquired from 10 different echo times 
(TE) ranging from 20-637 ms. For both sequences there was a 15 second gap 
between each acquisition to allow the system to return to equilibrium.  
3.1.6 Image processing  
3.1.6.1 Small bowel water content (SBWC) 
Image analysis was performed using the software Intestine Analyse 6 written 
in IDL by Dr Caroline Hoad at the Sir Peter Mansfield Magnetic Resonance 
Research Centre (SPMMRC) (Research Systems Inc., Boulder,Colorado, USA).  
This method of estimating SBWC assumes that in the MRCP images any pixel 
in the peritoneal cavity with signal intensity above a given threshold is filled 
with ‘free’ water. This threshold is used in order to normalize for intra- and 
inter-subject variations in signal due to scanner instabilities, subject 
repositioning and coil loading. The signal from cerebral spinal fluid is used  to 
calculate the threshold as it covers multiple slices, is near the centre of the 
field of view and it is known to have a very accurately regulated and hence 
constant composition. The use of this threshold has been validated against 
the infusion of known volumes of water[147]. 
The volume of free mobile water in the small bowel was then calculated by 
integrating the volume of all image pixels with signal greater than the 
threshold, after manually excluding regions containing the colon, kidneys, 
gallbladder, bladder and visible blood vessels.  An example of the images used 
for this calculation can be seen in figure 3.2. 
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Figure 3-2 showing a slice of the MRCP series loaded into the Intestine Analyse 6 
programme; here free water has been defined as all areas above the threshold 4500. The 
gall bladder, biliary tree and transverse colon have been excluded and the total SBWC of 
this slice can be seen in the top left window. 
3.1.6.2 Ascending colon water content 
Free ascending colon water was measured as for small bowel water, by 
manually excluding the signal from the small bowel, kidneys, gallbladder and 
visible blood vessels as before. 
3.2 Whole gut transit  
The method of assessing whole gut transit was adapted from that published 
by Metcalf et al[87]. Subjects took 20 silicon markers impregnated with 13.5% 
barium (Altimex, Nottingham, UK) at 9am each morning for three consecutive 
days. A plain abdominal film was then taken on the morning of day 4. In the 
absence of clear outlines of the bowel, markers located to the right of the 
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vertebral spinous processes above the pelvic brim on the right were allocated 
as right colon. Markers to the left of the vertebral spinous processes and 
above an imaginary line from the fifth lumbar vertebrae to the anterior 
superior iliac spine were assigned to the left colon. Markers in between these 
two lines were assigned to the rectosigmoid and rectum. However, if bowel 
outlines clearly showed a pelvic caecum, a transverse colon, or a large sigmoid 
loop above the fifth lumbar vertebrae, markers were judged to be' in the 
anatomic segment based on the gaseous outlines


Figure 3-3 Showing a plain abdominal film dived into 3 sections, R= right colon, L =left colon 
and RS= rectosigmoid. 
3.3 Bloods for routine clinical testing  
Blood was colected into 1x 4.0ml ethylenediaminetetraacetic acid (EDTA) K2E 
Vacutainer tube (Becton Dickinson Ltd, Oxford, UK) and 1x 6.0ml SSTII 
vacutainer tube (Becton Dickinson Ltd, Oxford, UK) Analysis of liver function 
tests (LFT), CRP  calcium and albumin were performed by the Department of 
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Clinical Chemistry, University Hospital, Nottingham using a Vitros 5.1 analyser 
(Johnson and Johnson Ltd, UK). Analysis of the  full blood count (FBC) was 
done by the Deparment of Haematology, Nottingham University Hospitals. 
tTG was done by the Deparment of Immunology, Nottingham University 
Hospitals  by automated ELISA on a DS2 analyser (Dynex Ltd Worthing, UK). 
3.4 Platelet paroxetine binding 
3.4.1 Blood sampling  
All samples were taken via a 17g butterfly needle without the use of a 
torniquet with the patient in a seated positon. This method minimises platlet 
activation and thus the release of serotonin enabling a single venepuncture 
episode  to provide blood suitable for all of the assays. Blood  for platelet 
paroxetine binding was collected into 5x  6.0 ml EDTA K2E Vacutainer tubes 
(Becton Dickinson Ltd) and platelt plugs prepared within 2 hours of collection 
3.4.2 Preparation of platelet rich plasma 
Platelets were isolated by differential centrifugation. Briefly, anti-coagulated 
blood was centrifuged at 200g at 20 °C for 15 minutes to remove residual red 
and white blood cells. The supernatant platelet rich plasma (PRP) was 
centrifuged at 4500g at 20°C for 20 minutes and subsequently platelets were 
pelleted. The platelet pellet was frozen at -80oC until analysis. 
3.4.3 Radio-immune assay  
This assay was performed by Gulzar Singh (GS). 
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Preparation of reagents 
1. 50mM Tris Buffer pH7.4 
1 day before beginning the assay 6.10g of Tris, 7.02g NaCl and 380mg 
KCL were weighed out and added to 1l of double deionised water . The 
Ph was adjusted to 7.4 with hydrochloric acid. This was stored at 4˚C.  
2. [3H]Paroxetine  
A 10nM solution was prepared using a commercial stock solution 
(Perkin-Elmer, Waltham, Massachussetts, US) specific activity 24.4 
Ci/mmol, 902.8 GBq/mmol in Tris buffer. Immediately before use this 
was diluted again with Tris buffer to give a 1nM working solution. 
3. Fluoxetine hydrochloride 
Fluoxetine hydrochoride (Sigma-Aldrich) 10nM/l was diluted using 
double deionised water to give concentrations of 200, 100, 50, 20, 10 
and 1 um/l when added to the total reaction volume. 
The platelet pellets were disolved in 500ul of ice cold Tris and pippetted out 
into an eppendorph, the original container of the pelllet was washed with a 
further 400ul of Tris to ensure no platelets remained adhered to the 
eppendorph. The eppendorph was then placed on ice. The platelets were 
homogenised with a sonicator  (soniprep 150,MSE: Wolf Laboritories, 
Pocklington, York , England) at an amplitude of 10µm (2 strokes of 10 
seconds) and then placed on ice for 30 minutes. This was done to ensure the 
platelet mebranes came out of solution before the sample was centriuged at 
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3000 G for 10 minutes at 4oC. The supernatant was then discarded and 2 
further cycles of washing were performed with the pellet being dissolved by 
sonication in a further 1ml of cold Tris for 20 seconds, rested on ice and 
centrifuged as previously. This was done to remove any endogenous 5-HT. 
The assay was performed in triplicate in the prescence (non-specific binding) 
and absence (total binding) of fluoxetine. Reagents were added to LP4 tubes 
(Sarstedt, Numbrecht, Germany) as detailed in the following table. 
 
 Total binding  Non-specific binding 
3H paroxetine –1nM 100µl 100µl 
Tris buffer 1700µl 1600µl 
fluoxetine - 100µl 
Platelet membrane 
suspension 
50µl 50µl 
Table 3-2 Paroxetine binding assay reagents. 
The reaction was incubated at room temperature for 1 hour. During the 
incubation a Brandel harvester (Brandel, Gaithersburg, US.) was prepared by 
washing  3 times with ice cold Tris. The reaction was then halted by the 
addtion of ice cold Tris, followed by immediate filtration under vaccum using 
the Brandel Harvester and ice cold Tris buffer as a washing solution.The circles 
of filter paper that had absorbed the 3H paroxetine were pricked out and  
placed in 7mL plastic Scintillation vials, with a PV3push in cap (Meridian, 
Epson Surrey, UK), containing 3mls of Emulsifier Scintillation Plus(Perkin-
Elmer, Waltham, Massachussetts, US).These were incubated overnight and 
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counted on a Wallac B counter (Perkin-Elmer, Waltham, Massachussetts, US) 
to determine radioactivity. 
 
3.4.4 Calculation SERT binding kinetics 
Radioactive counts were averaged for total and nonspecific binding. Specific 
binding was then determined by subtracting nonspecific binding from total 
binding averages.  Values were calculated using Prism 5.0 (Graph Pad 
Software) and the Scatchard transformation method.  The technique is based 
on the assumption that 1) the drug interacts reversibly with a single molecular 
site on its receptor and that 2) the formation of the drug receptor complex 
obeys the law of mass action. Under these circumstances the relationship 
between the drug concentration and receptor occupancy at the equilibrium is 
described by the equation: )*	*
where B is the amount 
of drug bound to receptors, Bmax the amount of drug required to saturate a 
population of receptors and a measure of the number of receptors present in 
the sample, F is the free drug concentration and Kd is the disassociation 
constant, a measure of the strength of ligand binding. In this plot, the X-axis is 
specific binding and the Y-axis is specific binding divided by free radioligand 
concentration. Here the Bmax is the X intercept and Kd is the negative 
reciprocal of the slope. An example plot is seen in figure 3.4. 
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Figure 3-4 An example Scatchard plot here the X axis is specific binding (usually labeled 
"bound") and the Y axis is the ratio of specific binding to concentration of free radioligand 
(usually labeled "bound/free"). Bmax is the X intercept; Kd is the negative reciprocal of the 
slope 
 
3.5  Serum plasma 5-HIAA analysis 
3.5.1 Blood sampling and preparation 
10 mls of blood was collected from subjects as in section 3.4.1. Samples were 
collected directly into prechilled 5ml plastic syringes containing 0.5ml of 
citrate-dipyridamole-adenosine-theophyline (CTAD) platelet stabalising 
solution that had been aspirated from 4.5ml Diatube H vacutainer tubes 
(Becton-Dickinson Ltd). Blood was drawn into the syringe to give a total 
volume of 4.5ml. Care was takent to ensure rapid smooth blood flow while 
avoiding turbulence again to minimise platelet activation. The blood-
anticoagulent mixture was placed immediately into the chilled empty 
vacutainer the lid replaced and the sample placed on ice.  
Platlet poor plasma for the analysis of 5-HIAA was produced in a single step by 
centrifuging the vacutainer tubes at 3500xG for 25 minutes at 4oC within 5 
minutes of being taken. Plasma was removed using a plastic pipette and 
stored until analysis at -80oC. 
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3.5.2 High performance liquid chromatography (HPLC)  
HPLC is a technique that separates small molecules on the basis of size, 
polarity, solubility or adsorption characteristics and is considered the method 
of choice for analysing biogenic amines. The analysis of serotonin in this study 
was performed using reversed phase ion-pair HPLC with electrochemical 
detection. In reversed phase HPLC a non-polar solvent chemically bonded to a 
pourous support matrix packed into a chromatographic coloumn forms a 
“stationary phase” while a polar solvent pumped through the coloumn at high 
pressure forms a “mobile phase”. Molecules passing through the column 
interact with the stationary phase through non-polar interactions so that 
hydrophobic molecules elute more slowly from the coloumn. By adding an 
ion-pairing agent such as sodium octyl sulphate (a negatively charged 
molecule with a hydrophobic side chain) to the mobile phase the elution of 
serotonin which is positively charged at experimental pH can be selectively 
retarded. Electrochemical detectors are highly sensitive and specific and 
measure the change in current or potential as sample molecules pass 
between 2 electrodes within a flow cell. One electrode works as a reference 
cell while the other is held at a voltage high enough to cause oxidation so the 
current generated by electron transfer is directly proportional to the 
concentration of the electrocactive substance. 
Quantification of plasma 5-HIAA was carried out as follows by GS. Plasma 
samples were sonicated in 0.2M perchloric acid for 30 seconds containing 
0.1% sodium metabisulfite, and centrifuged at 15 000 g for 15 min at 4°C. 
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Detection and subsequent quantification of 5-HT in the supernatant involved 
the use of reverse-phase, ion-pair high-performance liquid chromatography 
(HPLC) coupled with electrochemical detection. Briefly, the method employed 
a TARGA (75×2.1 mm internal diameter; Higgins Analytical CA).A solvent 
delivery pump (L-7110, Merck Hitachi,Poole,U.K) was used to circulate mobile 
phase (0.15 M sodium dihydrogen orthophosphate, 1 mM EDTA, 1.0 mM 1-
octane sulphonic acid sodium salt,14% methanol, (adjusted to pH 4.7 with o-
phosphoric acid, filtered and degassed). Samples were injected onto the 
column via a Perkin Elmer autosampler series 200(Bucks, U.K) with a cooling 
tray set at 4°C. An electrochemical detector (Antec Leyden, Netherlands).The 
flow rate was 0.15 mL/min and the glassy carbon working electrode potential 
was set + 0.70 V with reference to a saturated KCl-filled Ag/AgCl reference 
electrode. The current produced was monitored by ‘System Gold’ software on 
an IBM PC, with automated data collection (Analogue Interface Module 406). 
3.6 Genotyping for SERT promoter polymorphisms 
3.6.1 Blood sampling 
Blood was collected as in section 3.4.1 into a 4.0ml EDTA K2E Vacutainer tube 
(Becton Dickinson Ltd) and stored at – 80oC until analysis. 
3.6.2 Genotyping 
DNA was extracted from 200 ml of each blood sample using the QIAamp DNA 
Blood Mini Kit (Qiagen Cat. No. 51106) and then genotyped by KBiosciences 
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(Hoddesdon, UK) using Taqman methodology for allelic discrimination. All 
genotyping was performed blinded to clinical status by Caroline Swan. 
3.7 Serine protease activity 
3.7.1 Stool sample collection 
Stool samples were collected by the patient at home into 3 separate  pots 
(Sterilin, Newport, UK) on the morning of the visit, no patient travelled for >30 
miles to reach the hospital and the expectation was that samples were usually 
no >2 hours old on recipt in the department. The samples were immediately 
frozen at -80C˚. 
3.7.2 Stool supernatant preparation 
Tris buffer was prepared and frozen in 50ml aliquots at -80oC. 500mls of 
20nM Tris required the addition of 3.02g of trizma base , 0.1855g of 
potassium chloride and 3.505g of sodium chloride to double deionised water. 
The PH was adjusted to 8.2 with the use of hydrochloric acid. 
1g of stool was homogenized in 5ml of Tris buffer pH8.2. The resulting 
supernatant was centrifuged at 3500G at 4˚c for 20 minutes to remove any 
insoluble fibrous material. The remaining supenatant was aspirated with a 
plastic pipette and frozen at -80˚C in 0.5ml aliquots. 
3.7.3 Serine protease assay 
The assay was performed by Gulzar Singh. 
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Preparation of reagents 
1. Trypsin standard 
1mg of trypsin 10,000u/mg (Sigma Aldrich, UK) was dissolved in 10mls 
of double deionised water and frozen at -80˚C 
2. 2% azocaesin 
1g of azocaesin (Sigma Aldrich) was dissolved completely in 50mls of 
double deionised water. The solution was stored at 4oC and used 
within 24 hours of preparation. 
3. Tris buffer 
Tris buffer was prepared as for stool supernatant extraction, and used 
once defrosted within 24 hours. 
4. 10% Trichloracetic acid (TCA) 
10g of TCA were dissolved in 100ml of double deionised water and 
stored in a locked chest at room temperature. 
5. Stool supernatant 
0.5ml of stool supernant was defrosted and filtered using a 0.2micron 
filter (Nalgene, Rochester, US) immediately before use in the assay. 
All assays were performed in triplicate in a 96 well plate (Sigma Aldrich, UK). 
First 0.1ml of Tris was added to each  microplate well. 0.1mls of 1% trypsin 
standard was added to wells 1A and 1H, this was diluted 2-fold serially using a 
 103 
multichannel pipette to column 12 and the residual 0.1ml discarded to waste. 
0.1ml of a positive control stool supernatant with a known value for serine 
protease activity was added to wells B1 B5 and B9. 0.1ml  of Tris was added to 
wells G1-12 as a blank control. Finally 0.1ml of test stool supernatant were 
added to rows C1, 5 and 9, D1, 5 and 9, E1, 5 and 9, and F1, 5 and 9. This 
allowed 4 patient samples to be tested in triplicate per plate. 2-fold serial 
dilution of  rows B to H 1-4, 5-8 and 9-12 respectively was performed and the 
residual 0.1ml discarded to waste. 0.1mL of 2% azo-casein was added to each 
well, and mixed briefly by tapping by hand. Wells were sealed using adhesive 
film-seals and transferred to a 37oC incubator for 30 minutes. The film seal 
was then removed and 0.1mL 10% TCA was added to each well. Microplates 
were resealed and centrifuged for 10 minutes at >2k RCF. Finally the seal was 
again removed and using the multi-channel pipette 0.2 ml of supernatant was 
transferred to the corresponding wells of a second analytical microplate. The 
absorbance was read at 440nm on a plate reader and the plate reader 
software used to determine the unknown relative protease levels against 
Trypsin calibration values. The values for stool supernatant serine protease 
activity were expressed as units of trypsin/mg of protein. The protein content 
of the stool supernatant was assayed using the Bradford method[163]. 
 
3.8 Faecal elastase  
Faecal elastase was assayed by GS using a commercial ELISA kit (ScheBo 
Biotech AG, Giessen Germany). Briefly the method comprises of: an initial 
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binding step where pancreatic elastase in the sample binds to a specific 
monoclonal antibody on a pre-coated plate. A further incubation with a 
complex of monoclonal anti-elastase 1-Biotin and Peroxidase –streptavidin 
allows binding to the bound pancreatic elastase. The peroxidise oxidises 2, 2’-
Azino-bis-(3-ethylybenzothiazolin-6-sulfonic acid) diammonium salt (ABTS) 
which turns dark green. The concentration of oxidised ABTS is determined 
photometrically. 
 
 
Preparation of reagents 
1. 100mls of wash buffer was diluted in 400ms of double deionised water 
and stored at 4-8oC until required. 
Specimen preparation 
Stool samples were prepared using the E1 Quick-PrepTM dosing device. These 
devices contain ready to use extraction buffer and a comb which captures a 
fixed dose of sample, it can be seen in figure 3.5.  

Figure 3-5 The E1 Quick-Prep
TM
 dosing device 
 105 
1. The yellow dosing tip was removed and inserted into the stool sample 
to a depth of 1cm ensuring all notches of the comb like tip were filled 
with stool. 
2. The dosing tip was reinserted into the tube through the blue cone and 
turned clockwise to close. 
3. The tube was vortexed to mix and incubated at room temperature for 
10 minutes. 
4. A further vortex was performed after incubation to ensure no stool 
was left on the dosing tip. 
5. After the particles had settled the blue cone and dosing tip were 
removed and 10µl of stool sample extract were diluted to a 
concentration of 1:70 using 700µl of wash buffer. 
 
Test procedure 
1. All tests were carried out in duplicate. 
2. 50µl of diluted stool extract or provided standard (15, 50, 150 and 
500µg/g) were added to individual wells of the pre-coated plate. 
3. The plate was incubated at room temperature for 30 minutes. 
4. The contents of the plate were decanted and each of the wells of the 
plate washed 3 times with 250µl of wash buffer. Any remaining fluid 
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was removed by inverting the plate and tapping onto a clean paper 
towel. 
5. 50µl of anti-E1-biotin and peroxidise-streptoviridin complex was added 
to each well. 
6. The plate was incubated in the dark at room temperature for 15 
minutes. 
7. The contents of the plate were decanted and the wells washed as in 
step 4. 
8. 100µl of substrate solution was added to each well. 
9. The plate was incubated as in step 6. 
10.The substrate reaction was stopped by adding 100µl of stop solution 
to each well. 
11.The absorption at 405nm was read on a plate reader, between 5 and 
30 minutes after adding the stop solution, using 492nm as a reference,  
and the pancreatic elastase concentration calculated from a 
calibration curve constructed using the provided standards. 
 
3.9 Faecal amylase 
Faecal amylase was assayed by GS using a commercial ELISA kit 
(Immunodiagnostik AG,Bensheim, Germany). Briefly the method comprises 
of: an initial step where there was binding of pancreatic amylase in stool 
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supernatant in to a specific mouse monoclonal antibody on a coated plate.  
This is followed by a washing step to remove any excess before incubation 
with a monoclonal anti pancreatic amylase antibody. A further wash removes 
all unbound substances before the chromogenic substrate 
tetramethylbenzidine is added. An acidic stop solution halts the reaction and 
there is a colour change from blue to yellow. The intensity of the yellow 
colour is directly proportional to the concentration of pancreatic amylase in 
the sample. The concentration in the patient samples is calculated from a 
standard curve that is obtained using standards supplied by the manufacturer. 
Preparation of regents 
1. The ELISA wash buffer was diluted to a 1:10 concentration with 
deionised water 
2. Both the standards and the control were reconstituted with 250µl of 
deionised water. The vials were allowed to stand for 10minutes before 
being gently inverted to mix and ensure complete reconstitution. 
3. 10µl of the anti-pancreatic amylase monoclonal antibody was diluted 
with 10mls of wash buffer and stored at 2-4oC until required. 
Specimen preparation 
1. 100mg of stool was weighed and diluted in 5ml of wash buffer. 
2. The sample was then centrifuged at 3000G for 10 minutes. 
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3. 1ml of sample supernatant was then placed in an eppendorf and 
centrifuged at 13,000G for a further 5 minutes. 
4. 25µl of the final supernatant was then diluted to a concentration of 
1:40 with a further 975µl of the wash buffer. 
Test procedure 
1. All tests were carried out in duplicate 
2. Each well of the pre-coated microtiter plate was washed 5 times with 
250µl of wash buffer 
3. 100µl of each of the standard solutions (0; 440; 1750; 7000; 28000 
mU/l) and the prepared patient stool supernatants were added to 
individual wells of the pre-coated plate. 
4. The plate was incubated for 1 hour at room temperature whilst 
shaking on a horizontal mixer. 
5. The contents of the plate were then decanted and the wells washed 5 
times with 250µl of wash buffer. 
6. 100µl of tetramethylbenzidine was then added to each well of the pre-
coated plate  
7. The plate was incubated at room temperature for a further 10 
minutes. 
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8. The reaction was stopped by the addition of 50 µl of a sulphuric acid 
containing stop solution to each well. 
9. The absorption at 450nm was read on a plate reader, using 650nm as a 
reference, and the pancreatic amylase concentration calculated from a 
calibration curve constructed using the provided standards. 
10.The concentration of pancreatic amylase per sample was calculated as 
in the follow example: 
Example sample weight: 80 mg (1ml Stool = 1g) = 0,08 ml 
Dilution step 1: 5ml / 0,08ml = 62,5 
Dilution step 2: 40 
Dilution factor: 62,5 x 40 = 2500x the value obtained using the 
calibration curve. 
3.10Mast cell tryptase  
A fluorescence reporter assay system (PHADIA-CAP, Phadia Ltd, Uppsala, 
Sweden) was used to specifically quantitate mast cell tryptase. The assay was 
demonstrated to give undetectable readings when samples were spiked with 
pancreatic Trypsin. This assay was performed by the Department of 
Immunology, University Hospital, Nottingham. 
3.11Serine protease identification 
All of the following analyses were performed by Dr David Tooth. 
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3.11.1 Affinity chromatographic purification of 
serine     proteases 
Faecal serine proteases were purified by passing faecal extracts at 1mL/min 
through a Benzamidine-sepharose column (1mL, HiTrap, GE Healthcare, 
Amersham, UK) which specifically retains serine proteases. Samples were 
loaded and washed (10 column-volumes) in 50mM Tris, pH 7.4, 0.5M sodium 
chloride buffer and retained components were eluted by the step-wise 
adjustment to 50mM Glycine pH 3.0 buffer. Stool extracts were buffer-
exchanged to wash-buffer, prior to loading using gel-permeation (PD-10, GE-
Healthcare, Amersham, UK), according to the vendor protocol. 
Chromatography was profiled by monitoring protein absorbance at 280nm 
and components in flow- through and eluate fractions were collected for 
subsequent characterisation.  
3.11.2 Protein electrophoresis  
SDS-Polyacrylamide gels (SDS-PAGE, Bis-Tris using MES buffer, Invitrogen, 
Paisley, UK,) were electrophoresed under thiol-reducing conditions, according 
to vendor guidelines. Protein components were visualised by chemical 
staining using colloidal Coomassie Brilliant Blue G-250 according to vendor 
guidelines. 
3.11.3 Identification of Protein components  
Protein components in gel bands were excised, reduced using dithiothreitol, 
alkylated using iodoacetamide and proteolysed using Porcine Trypsin in 0.2M 
ammonium bicarbonate pH8.0. All protocols were standard procedures 
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essentially according to Hellman et al [164].Proteolytic peptides were 
extracted captured and desalted to a chromatographic trap (Dionex C18, 0.3 x 
5mm) and subjected to micro-capillary-high-pressure-liquid-chromatography 
with Tandem-mass-spectrometry (nano-LC-MS/MS) using a hybrid 
quadrupole-time-of-flight (Waters Q-TOF2) instrument equipped with a nano-
electrospray ion-source in positive-ion mode and calibrated against synthetic 
peptides and product ions. Data-dependent product-ion spectra were 
acquired ‘on-the-fly’ during test-experiments. The MASCOT server 
(www.matrixscience.com) was used to interrogate genome databases using 
precursor- and product-ion data and reports were returned together with 
(MOWSE) probability scores. 
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4 Results: Patient reported outcomes. 
4.1  Study populations 
Of the 125 patients that were recruited from both sites, 71 were enrolled in 
Nottingham and 54 in Manchester, along with 20 age and sex matched 
controls from the Nottingham site only.  Patients recruited in Manchester 
were significantly more depressed (4.5 (2-8) vs.  5.5 (3-10) p= 0.04) and had an 
increased IBS-SSS (281.8 ± 10.06 vs. 342.2 ± 9.75 p=<0.001) with the mean 
value in Nottingham being classified as moderate and in Manchester severe. 
This was coupled with a lower quality of life (488.0 ± 18.41 vs. 446.0 ± 14.23 
p=0.0006) than those recruited in Nottingham. Although the Manchester 
recruits had significantly higher pain, bloating and urgency scores they did not 
experience symptoms on more days per week, these findings are summarised 
in table 4.1. The mean age of patients recruited was not significantly different 
between sites and the number of men in the study was 37 or 29% of the total 
study population. 
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 IBS-D 
Nottingham 
IBS-D 
Manchester 
P= IBS-D total 
Number 71 54  125 
Age 39.75 ± 1.50 42.7 ± 1.57 0.18 41.02 ± 1.10 
Sex (Male/Female) 23/48 13/41  36/89 
Anxiety (<7) 9.37 ± 0.59 10.7 ± 0.53 0.39 9.7 ± 0.41 
Depression ( <7) 4.5 (2-8) 5.5 (3-10) 0.04 5 (2.75-9) 
PHQ-15 (0-30) 11.79 ± 0.52 12.8 ± 0.52 0.18 12.22 ± 0.38 
PSSS (0-40) 17.44 ± 0.95 19.43 ± 0.10 0.16 18.31 ± 0.69 
IBS-SSS (0-500) 281.8 ± 10.06 342.2 ± 9.75 <0.001* 308.1 ± 7.56 
IBS-QOL 488.0 ± 18.41 391.5 ± 20.19 0.0006 446.0 ±14.23 
Stool Form (1-7) 5.29 ± 0.08 5.46 ± 0.11 0.18 5.24 ± 0.06 
Stool Frequency 2.93 (2.1-4.18) 2.57 (1.85-3.64) 0.22 2.7 (1.86-4) 
Pain (0-3) 1.21 ± 0.09 1.61 ± 0.11 0.005* 1.37 ± 0.07 
Days with pain/week 5.5 (3-7) 6.5 (4.75-7) 0.06 6 (4-7) 
Urgency (0-3) 1.54 ± 0.08 1.82 ± 0.09 0.03* 1.66 ± 0.06 
Days with 
urgency/week 
6 (5-7) 7 (5-7) 0.67 7(5-7) 
Bloating (0-3) 1.2 ± 0.10 1.56 ± 0.12 0.02* 1.35 ± 0.08 
Days with 
bloating/week 
6 (3-7) 6 (5-7) 0.22 6 (3-7) 
Table 4-1 Characteristics of patients: Data shown as mean (SEM) or median (IQR). Where 
stool form and frequency as well as pain, urgency and bloating are all weekly averages. 
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4.2 Study drop outs and adverse events 
4.2.1 Drop outs 
Of the 125 patients recruited, 5 did not complete the screening phase. 1 
patient received a diagnosis of microscopic colitis at screening biopsy and was 
therefore ineligible. 3 patients did not wish to take part after their initial 
screening visit, all expressed concerns about time needed to attend study 
visits. 1 patient developed swine flu during the screening period and 
subsequently was excluded. 
During the study there were 6 dropouts whilst taking Ondansetron, 5 in the 
first treatment period. 2 patients were lost to follow up, all were contacted by 
phone and post but failed to attend subsequent study visits. The GP was 
informed of their withdrawal. 2 patients discontinued secondary to 
constipation; both responded to dose reduction but did not wish to continue. 
1 patient discontinued secondary to a previously diagnosed back problem that 
prevented them from easily attending study visits.  
The same number of patients dropped out whilst taking placebo. In the first 
treatment arm, 1 patient had difficulty travelling, 1 patient simply wanted to 
discontinue and a third withdrew due to back pain. In the second treatment 
period 2 patients withdrew due to lack of efficacy and diarrhoea and 1 
secondary to worsening abdominal pain.  
This is summarised in figure 4.1. 
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Figure 4-1 Consort diagram: showing exclusions and drop outs from the study Ondansetron 
in patients with diarrhoea predominant Irritable bowel syndrome “identifying the 
responder”. 
4.2.2 Adverse events  
There were 28 adverse events, 1 in the screening period, 10 whilst taking 
placebo and 17 whilst taking Ondansetron. 3 patients withdrew from the trial 
secondary to adverse events in the Ondansetron arm and 3 withdrew in the 
placebo arm. There were no serious adverse events. The adverse events are 
summarised in table 4.2.  
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Treatment  Adverse event  Severity  Action  
Ondansetron  Abdominal pain Mild  None  
Ondansetron  Abdominal pain Severe  None  
Ondansetron Abnormal liver function tests Mild  Other  
Ondansetron Back pain Moderate  Withdrawn  
Ondansetron Constipation  Mild  Dose reduction 
Ondansetron Constipation Mild  Dose reduction 
Ondansetron Constipation Mild  Dose reduction 
Ondansetron Constipation Moderate  Withdrawn  
Ondansetron Constipation Moderate  Dose reduction  
Ondansetron Constipation Moderate  Dose reduction  
Ondansetron Constipation Moderate  Withdrawn  
Ondansetron Constipation Severe  Dose reduction  and over the counter laxatives  
Ondansetron Headache Mild  None  
Ondansetron Headache  Mild  None  
Ondansetron Rectal bleeding Mild  None  
Ondansetron Rectal bleeding Mild  Flexible sigmoidoscopy 
Ondansetron  Rectal pain Moderate  Simple analgesia  
Placebo Chest pain  Moderate  Cardiology review  
Placebo Elbow pain  Moderate  Simple analgesia  
Placebo Back pain Severe   Withdrawn  
Placebo Headache  Mild  None  
Placebo Headache  Severe  Simple analgesia  
Placebo Diarrhoea  Severe  Withdrawn  
Placebo Abdominal pain Moderate  Withdrawn  
Placebo  Rectal bleeding Mild  Flexible sigmoidoscopy  
Placebo  Rectal bleeding  Mild  Flexible sigmoidoscopy  
Placebo  Testicular lump Mild  Urology review  
Table 4-2 Adverse events during the study Ondansetron in patients with diarrhoea 
predominant Irritable bowel syndrome “identifying the responder” 
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There were 8 instances of constipation in the Ondansetron arm and none in 
the placebo arm of the study. The incidence of constipation is likely to be 
directly attributable to Ondansetron, all but 1 of the patients responded to 
dose reduction alone. 2 patients however did not wish to continue taking part 
in the trial.  The single patient who took laxatives purchased an over the 
counter remedy before contacting the study team. 2 patients experienced 
exacerbations of their abdominal pain whilst taking Ondansetron and 1 whilst 
taking placebo, these symptoms are likely due to exacerbation of the patient’s 
irritable bowel syndrome and no specific treatment was required. The patient 
in the placebo arm did not wish to continue and was withdrawn.  I patient had 
abnormal liver function tests at the end of the Ondansetron arm of treatment, 
after referral to hepatology and appropriate investigation a diagnosis of 
Epstein Barr virus infection was made, during follow up liver function returned 
to normal. 4 patients reported rectal bleeding during the trial, 2 whilst taking 
Ondansetron and 2 whilst taking placebo. All but one had a flexible 
sigmoidoscopy the next available working day, the 4th patient refused. All 
bleeding was diagnosed as local blood loss from the anal canal. 2 patients in 
each arm reported headache, 1 whilst on placebo was classed as severe and 
required the prescription of simple analgesia. The chest pain, back pain and 
elbow pain reported were all exacerbations of previously diagnosed disorders 
and the testicular lump was found to be not clinically significant. 
Despite the significant difference in number of patients experiencing 
constipation with Ondansetron compared to placebo there was no significant 
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difference in overall number of adverse events between the placebo and 
Ondansetron arms, Fisher’s exact test p=0.2. 
13 patients were excluded from the per protocol analysis. During the 2 year 
course of the study 3 patients under follow up by the medical team in 
Nottingham received another diagnosis: 1 chronic pancreatitis, 1 bile salt 
malabsorption, 1 diarrhoeal illness responding to steroids, it is interesting to 
note none of these patients responded to Ondansetron. 
3 patients provided insufficient diary data to be included in the analysis.  
There were 8 protocol violations, 5 patients took loperamide during 
endpoints, 3 during both placebo and Ondansetron and 2 during the 
Ondansetron arm.  2 patients were included at the Manchester site with a 
high CRP at entry. 1 patient had documented poor compliance. Compliance 
was monitored by asking to patient at study visits and by a final pill count of 
all returned medicines. 
4.3 Baseline diaries  
A wealth of information is contained in the baseline diaries of 119 patients 
with IBS-D (1 patient did not adequately complete the baseline diary) and 20 
healthy controls. The study is powered on change in mean daily stool form but 
the diaries provide an opportunity to investigate other abnormalities in stool 
form and pattern as well as pain, bloating, and urgency to better understand 
the symptoms our patients experience on a weekly basis. 
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4.3.1 Stool form.  
The average weekly Bristol stool form (BSF) of patients and healthy volunteers 
was normally distributed (Shapiro-wilks) using a t test as expected patients at 
baseline had a significantly greater mean weekly BSF than the healthy 
volunteers 3.5 (±0.16) vs. 5.4 (±0.06), p=0.0001. This is represented in Fig 4.2. 
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Figure 4-2 Baseline weekly average stool form in patients and healthy volunteers, with the 
mean weekly stool form being 3.5 (±0.16) in healthy volunteers vs. 5.4 (±0.06) in patients, 
p=0.0001. 
4.3.2 Stool form variability. 
The unpredictability of symptoms in IBS-D has been suggested to be a major 
cause of distress in patients, and this intra-individual variability is not 
captured by a weekly mean BSF score. Indeed Basseri et al have used a visual 
analogue measure of variability between constipation and diarrhoea to 
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predict the incidence and severity of IBS-C[165].  In order to understand the 
unpredictability and variability reported I have examined the stool diaries of 
patients and healthy volunteers to determine the minimum and maximum 
weekly BSF, the difference between these two values is termed the stool form 
variability.  
Somewhat surprisingly there was no difference in weekly stool form variability 
between patients and healthy volunteers, median variability being 3 (2-3.8) 
points on the BSF scale vs. 3(2-5) p= 0.3. Similarly there is no association 
between stool form variability and quality of life r2=<0.0004, IBSSS r2= 0.004, 
pain r2 =0.007, urgency r2 =0.01, or bloating r
2 =0.02. 
Stool form variability at best weakly  correlates with mean stool form , with 
some with the greatest mean stool form score on the Bristol Stool Form Scale, 
i.e. loosest stool on average having the least variability in form over 7 days (r2 
=0.05 p=0.005). There is also a similarly weak correlation between stool 
frequency and stool form variability (r2 0.04 p=0.02) with some of those with 
very high frequency having higher stool form variability. 
In order to determine whether stool form variability was related to any of the 
psychological and somatic measurements collected I divided patients and 
volunteers into those with low stool form variability (0-3 points on the BSF 
scale) and high stool form variability (4-6 points on the BSF scale).  There were 
no differences in psychological distress, 13.88 (±0.98) vs. 14.77 (±0.91) points 
p=0.5, or somatisation as measured by the PHQ12, 7.66 (±0.48) vs. 6.0 (±0.43) 
points p=0.1 between these groups. 
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4.3.3 Number of days with stool form >5.  
It is the incidence of very loose stool and subsequent urgency and threat of 
incontinence that is the driver to many patients consultation[166], this is 
intended to be captured in the measure of number of days per week with 
stool form 6 and 7 proposed as a measure of stool form response to a 
treatment by the FDA. 
At baseline patients had many more days with stool form >5 than healthy 
volunteers 5.5 (4-7), compared to 0 (0-0.75) p=<0.0001. The number of days 
with stool form >5 in patients correlated positively with psychological distress, 
the sum of the anxiety and depression components of the HADS score, with 
an r2 of 0.05 p= <0.01. There was also a correlation with, IBSQOL r2 = 0.1 
p=0.0009 and IBSSS r2= 0.04 p=0.02, making this a simple single measure of 
severity. Those with more days a week with stool form >5 had more urgency 
r2 0.01 p=<0.001 but not pain, bloating or a higher PHQ12. 
4.3.4 Stool frequency. 
Baseline stool frequency was non-normally distributed (Shapiro-Wilks). As 
expected patients had a greater average daily stool frequency than healthy 
volunteers 2.7 (1.9-4) vs. 1.1 (1-1.4) p=<0.00001, Mann Whitney-U.  This 
difference was surprisingly small reflecting the fact that episodes of diarrhoea 
do not occur every day 
 122 
*	 
-	
.























	





	

$

"$
"
 
Figure 4-3 Baseline weekly average stool frequency in patients and healthy volunteers, with 
the mean weekly stool in patients 2.7 (1.9-4) vs. 1.1 (1-1.4) in healthy volunteers 
p=<0.00001. 
4.3.5 Early morning rush (EMR)  
A commonly recognised clinical phenotype and a major source of 
unpredictable symptoms and high stool frequency is that of the “early 
morning rush”. Here the patient complains of multiple and frequent bowel 
motions (BM) soon after waking. To investigate the effect of Ondansetron on 
this commonly reported symptom I have defined a morning rush as 2 or more 
BM in less than 1 hour occurring after midnight and before 12 midday. Using 
this definition 60% of patients had at least one day with a morning rush in the 
baseline week compared to 10% of healthy volunteers.  Patients and 
volunteers were further stratified into 3 groups. Those with 1-3 episodes of 
EMR a week were classified as normal morning rush (NMR), this group 
included all of the healthy volunteers. Those with 3-4 days a week with EMR 
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were termed moderate morning rush (MMR) and those with 5-7 days a week 
were classified as severe morning rush (SMR). 
16 % of patients had MMR and 15 % of patients had SMR. Those with SMR 
had greater psychological distress (anxiety + depression component of the 
HADS score) than those with NMR, 19.11 (± 1.8) vs. 13.48 (±0.8) p=0.021, this 
can be seen in figure 4.4. This group also have more somatic symptoms as 
measured by the PHQ-12, 9.2 (± 0.9) vs. 6.5 (± 0.4) p=0.02. 
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Figure 4-4EMR and psychological distress with SMR had greater psychological distress 
(anxiety + depression component of the HADS score) than those with NMR, 19.11 (± 1.8) vs. 
13.48 (±0.8) p=0.021. 
The SMR group had greater mean daily stool frequency than those with NMR 
and MMR 5.6 (3.5-8.2) vs. 2.14 (1.7-3.0) and 3.7 (2.7-4.4) p=<0.0001. The SMR 
group was also found to have a higher IBSSS 366 (± 18.4) vs. 296.6 (± 9.4) and 
295.9 (±17.2) p= 0.005, and this was accompanied by a lower IBSQOL 334.3 
(±21.1) vs. 467.3 (± 17.9) and 467.3 (± 33.4) p=0.004. Whole gut transit (in 
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hours) whilst taking placebo, or at baseline in the case of the healthy 
volunteers, was significantly faster in the SMR group with transit times of  7h 
(5.5-15) vs. 19h (10-39) in the NMR and 16h (8.5-24.5) in the MMR groups, 
p=0.03, See Fig 4.5. 
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Figure 4-5 EMR and whole gut transit (in hours). Placebo, or  baseline transit in the case of 
the healthy volunteers, was significantly faster in the SMR group with transit times of  7h 
(5.5-15) vs. 19h (10-39) in the NMR and 16h (8.5-24.5) in the MMR groups, p=0.03. 
4.3.6 Days with pain, urgency and bloating  
As expected in accordance with the entry criteria patients had significantly 
more days with pain, bloating and urgency per week than healthy volunteers, 
see table 4.3. 
 Healthy volunteers Patients P value 
Pain score (0-3) 0 (0-0) 6 (4-7) <0.0001 
Urgency score (0-3) 0.5(0-1) 7(5-7) <0.0001 
Bloating score (0-3) 0(0-2) 6 (3-7) <0.0001 
Table 4-3 Days with pain, urgency and bloating inpatients and healthy volunteers. 
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4.3.7 Anxiety depression and somatisation  
Values for anxiety depression and somatisation at baseline were significantly 
higher in the patient population than in healthy volunteers this is summarised 
in table 4.4  
 Healthy volunteers Patients P value 
Anxiety  normal <7 5.2 (± 0.6) 9.7 (± 0.4) <0.0001 
Depression normal <7 1.5 (1-2.3) 5 (2.5-9) <0.0001 
PHQ12 (0-24) 2.3 (±0.4) 7.7 (±0.3) <0.0001 
Table 4-4 Baseline anxiety depression and somatisation in patients and healthy volunteers. 
4.4 Primary endpoint 
The primary endpoint was the change in stool form from baseline. Change in stool 
form from baseline was not normally distributed. In the intention to treat analysis n= 
101, there was a 1.39 (95% CI1.20-1.58)point decrease on the Bristol stool form scale 
whilst taking Ondansetron compared to  a 0.51 (95% CI 0.32-0.72) point reduction 
whilst taking placebo p=<0.0001, Wilcoxon matched pairs. In the per protocol 
analysis n=95 there was a 1.47 (95% CI 1.27-1.26) point decrease on the Bristol stool 
form scale whilst taking Ondansetron, compared to 0.51 (95% CI 0.30-0.71) points 
whilst taking placebo p=<0.0001, Wilcoxon matched pairs signed rank test. The 
intention to treat data is represented graphically in Fig 4.6. 
 126 
7	
		4			5

	
	


	




8#
$
#
+
(
*














4
"
8,
5
 
Figure 4-6 Primary endpoint, the change in stool form from baseline with Ondansetron 
compared to placebo (intention to treat) n= 101, Showing a 1.39 (95% CI1.20-1.58)point 
decrease on the Bristol stool form scale whilst taking Ondansetron compared to  a 0.51 
(95% CI 0.32-0.72) point reduction whilst taking placebo p=<0.0001, Wilcoxon matched 
pairs signed rank test. 
4.5 Secondary endpoints 
Secondary endpoints are presented as intention to treat only, and are 
summarised in table 4.5. 
4.5.1 Stool frequency 
Change in stool frequency from baseline was non-normally distributed 
(Shapiro-Wilks). There was a significant reduction in mean stool frequency 
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compared to baseline of 0.86 (IQ 0.24-1.7) stools per day whilst taking 
Ondansetron compared to 0.44 (IQ 0-1.13) whilst taking placebo p=0.001, 
Wilcoxon matched pairs signed rank test.  
4.5.2 Days with pain urgency and bloating 
There was a reduction in the number of days per week patients report 
urgency of any severity with Ondansetron of 1.5 (IQ 0-4) days, compared to 
0.5 (IQ 0-2) days with placebo p= 0.01. Average weekly scores for the severity 
of urgency (0-3), where 0 is no urgency, 1 is mild urgency, 2 is moderate 
urgency and 3 is severe urgency) were also reduced when taking Ondansetron 
by 0.62 (95% CI 0.48-0.77) compared to 0.34 (95% CI 0.21-0.47) whilst taking 
placebo p =<0.0001. 
There was no significant change in the number of days per week patients 
reported pain of any severity with Ondansetron with a median reduction from 
baseline of 0.25 (IQ 0.0-1.5) days, compared to 0.0 (IQ 0.0- 1.5) with placebo 
p=0.37. Average weekly scores for the severity of pain (0-3, where 0 is no 
pain, 1 is mild pain, 2 is moderate pain and 3 is severe pain) were also not 
significantly improved from baseline when taking Ondansetron,   0.25 (95% CI 
0.12-0.37) compared to 0.17 (95% CI 0.06-0.29) points whilst taking placebo, p 
= 0.12. 
Additionally there was no significant change in the number of days per week 
patients report bloating of any severity with a median reduction whilst taking 
Ondansetron of 0.25 (IQ 0-1.5) days, compared to 0.0 (IQ -0.37-1) days with 
placebo, p= 0.14. Average weekly scores for the severity of bloating (0-3, 
 128 
where 0 is no bloating, 1 is mild bloating, 2 is moderate bloating and 3 is 
severe bloating) were again unchanged from baseline when taking 
Ondansetron by 0.12 (IQ -0.14- 0.5)points, compared to 0.07 (IQ -0.29-0.43) 
points whilst taking placebo, p =0.25. 
 
 
 Ondansetron  Placebo  p 
Decrease in stool 
frequency 
0.86 (IQ 0.24-1.7) 0.44 (IQ 0-1.13) 0.001 
Decrease in 
urgency score (0-3) 
0.62 (95% CI 0.48-
0.77) 
0.34 (95% CI 0.21-
0.47) 
<0.0001 
Decrease in 
days/week with 
urgency 
1.5 ( IQ 0-4) 0.5 (IQ 0-2) <0.0001 
Decrease in 
abdominal pain 
score (0-3) 
0.25 (95% CI 0.12-
0.37) 
0.17 (95% CI 0.06-
0.29) 
0.12 
Decrease in  
days/week with 
pain  
0.25 (IQ 0.0-1.5) 0.0 (IQ 0.0- 1.5) 0.37 
Decrease in 
bloating score (0-3)  
0.25 (IQ 0-1.5) 0.0 (IQ -0.37-1) 0.14 
Decrease 
days/week  with 
bloating 
0.12 (IQ -0.14- 0.5) 0.07 (IQ -0.29-
0.43) 
0.25 
Table 4-5 Secondary endpoints (intention to treat). 
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4.5.3 IBS symptom severity score (IBS SSS)  
There is a significant reduction in the IBS SSS compared to baseline when 
taking Ondansetron of 83 ± 9.8 points compared to 37 ± 9.7 points whilst 
taking placebo, p=0.001. The maximum achievable score is 500. Mild, 
moderate and severe cases are indicated by scores of 75 to 175, 175 to 300 
and > 300 respectively. Healthy controls score below 75 and patients scoring 
in this range can be considered to be in remission[167]. At baseline only 6% of 
patients had mild disease, 36% had moderate disease and 58% had severe 
disease. After taking Ondansetron (n=106) 9% had entered remission with 
26% having mild, 40% having moderate and 25% having severe disease. This is 
compared to with Placebo (n=108) where 4% had entered remission, 15 % had 
mild, 43 % had moderate and 39 % had severe disease, p=0.04 Chi squared. 

4.5.4 Proportion of patients preferring ondansetron versus 
placebo 
When asked at the final study visit which treatment they preferred 
significantly more patients, 74%, preferred Ondansetron with only 17% 
preferring placebo, 9% patients preferred neither treatment with 
Ondansetron or placebo, chi squared p=<0.0001. This is shown in fig 4.7 
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Figure 4-7 Proportion of patients preferring Ondansetron vs. Placebo, 74%, preferred 
Ondansetron with only 17% preferring placebo, 9% patients preferred neither treatment 
with Ondansetron or placebo, chi squared p=<0.0001. 
4.5.5 Proportion wanting to continue with ondansetron versus 
placebo 
After completing the 15 week trial 73% of patients if given the choice would 
have chosen to continue taking Ondansetron compared to 18% who would 
have preferred to continue placebo, chi squared p=<0.001.  9% of patients did 
not wish to continue either Ondansetron or placebo, 1% would have 
continued either Ondansetron or placebo, this is shown in fig 4.8. 
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Figure 4-8 Proportion wanting to continue Ondansetron vs. Placebo where 73% of would 
have chosen to continue taking Ondansetron compared to 18% who would have preferred 
to continue placebo, chi squared p=<0.001. 
4.5.6 Percentage satisfactory relief  
67 % of patients when asked at the end of the study if they had recieved 
satisfactory relief from their symptoms said yes whilst taking Ondansetron,  
compared to 18% who described satisfactory releif after taking placebo, chi 
squared p=<0.0001. 18% of patients did not get satisfactory relief from their 
symptoms whilst taking either placebo or Ondansetron. 3% of  patients got 
satisfactory from their symptoms with both the ondansetron and placebo 
treatment arms, fig 4.9. 
 132 
	

9




	

2 .
$
#$
+$
($
6$
"$$
1	
	
 
Figure 4-9 Percentage satisfactory relief at the end of treatment with Ondansetron was 67 
% compared to 18% with placebo, chi squared p=<0.0001 
4.6 Number needed to treat (NNT) 
The number needed to treat is a measure of the effectiveness of an 
intervention; it is an expression of the average number of patients needed to 
treat for one patient to benefit, the ideal number to treat is 1, where 
everyone improves with treatment and nobody improves with control. In 
order to calculate this for Ondansetron it is necessary to define what a 
response to treatment is. 
There are several potential methods of describing what constitutes a response 
to treatment. Adequate relief, patient preference, and improvement in stool 
form can all be used. the definition of a responder to treatment has been 
contentious and I am helped by recent guidelines for clinical trials in IBS from 
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the US Food and Drug Administration (FDA) [168] which propose that for a 
patient to be a stool form responder to a medication they should have a 
reduction of 50% or greater in the number of days a week they have a stool 
with a BSF >5  this is termed an FDA response. We have seen using the 
baseline diaries that days with stool form >5 correlate with symptom severity, 
quality of life and psychological distress adding weight to this being a clinically 
meaningful measure of improvement with treatment. I will outline the 
number needed to treat in this trial using these 4 different measures of 
response. 
4.6.1 Patient preference  
17% of patients preferred placebo and 83% did not, whilst 74% patients 
preferred Ondansetron and 26% did not giving a NNT of 2 (95% CI 1.5-2.2).  
4.6.2 Adequate relief 
18% of patients had an adequate relief whilst taking placebo, whilst 82% did 
not. Whilst taking Ondansetron 67% patients had adequate relief whilst 33% 
did not giving a NNT of 3 (95% CI 1.7-2.7) 
4.6.3 Improvement in mean stool form  
A clinically significant reduction in mean BSF would be a reduction of 1 whole 
point on the scale. Using this definition of response 31% patients taking 
Ondansetron did not respond to treatment and 69% did, 81% patients did not 
respond to the placebo whereas 19% did giving a number needed to treat of 3 
(95% CI 1.6-2.6). 
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4.6.4 FDA response 
33% of patients had a response according to the FDA criteria to placebo with 
67% not responding, whilst taking Ondansetron 70% responded and 30% did 
not giving a NNT of 3 (95% CI 2-4.2), fig 4.10. 
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Figure 4-10 FDA response, 33% of patients had a response according to the FDA criteria to 
placebo with 67% not responding, whilst taking Ondansetron 70% responded and 30% did 
not giving a NNT of 3 (95% CI 2-4.2) 
4.7 Effect of Ondansetron on measures of 
“unpredictability”, stool form variability and 
EMR 
It is clear that Ondansetron has an effect on mean weekly stool form 
frequency and urgency but in order to investigate the ability of Ondansetron 
to affect day to day symptoms I introduced the concept of stool form 
variability, EMR, and number of days with stool form>5, whilst reviewing the 
results of the baseline diaries.  These alternative measures aim to capture 
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daily events that are responsible for patients distress and symptoms. The 
effect of Ondansetron on number of days per week with stool form >5 has 
been discussed in the preceding section.  
In the patent group Ondansetron does not reduce stool form variability when 
compared to placebo, in fact the median change in stool form variability was 0 
(IQ -1-1.5)with Ondansetron and 0 with placebo (IQ -1-1)p=0.39. Those with 
high stool form variability were not more likely to respond using the FDA 
criteria than those with low stool form variability, Fishers exact test p=0.39.  
There was no reduction in number of days with EMR from baseline whilst 
taking Ondansetron compared to placebo, median reduction 0.0 for 
Ondansetron (IQR 0-1) and 0.0 for placebo (IQR 0-1).  
4.8 Other considerations  
4.8.1 The effect of Ondansetron on stool form in men 
There are more females affected by IBS than men so it is natural to assume 
men will form a smaller proportion of subjects in this study. There were in fact 
28 men in the intention to treat analysis, looking at this small subgroup there 
was still a significant improvement in stool form of 1.3 (IQ 0.6-1.8)points 
compared to 0 (IQ -0.2-0.3)points with placebo.  The mean change in stool 
form for men when taking ondansetron was not significantly different from 
that in women, 1.2 ( 95% CI 0.84-1.50) compared to 1.50 (1.24-1.72)points on 
the BSF scale, p=0.16, suggesting there is not a sex dependent mechanism by 
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4.8.2 Order effect  
In a crossover study such as this it is important to consider whether there is 
an order efect i.e. more chance of experiencing a positive effect depending on 
the treatment period in which the active drug is given. Using a Freidmen test 
with Dunn’s multiple comparisons there was no significant difference in 
decrease in baseline stool form between those receiving ondansetron first 
and those receiving ondansetron second p=<0.05  
4.8.3 Dosing  
The dose of Ondansetron taken in the final 2 weeks of treatment ranged 
between 4mg every 3 days- 8mg tds, the mode dose taken was 4mg every 
other day. The mode dose of placebo taken during the endpoint weeks was 6 
tablets a day with a range between1 tablet alternate days and 6 a day. 
 
 
5 The effects of Ondansetron on measures of whole 
gut function 
5.1 Whole gut transit (WGT) in hours 
Whole gut transit was measured in healthy volunteers and in patients at the 
end of each treatment period, i.e. once after placebo and once after 
Ondansetron as described in section 3.2. 
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5.1.1 WGT in healthy volunteers and patients 
WGT was non-normally distributed (Shapiro-Wilks test). The median whole 
gut transit in healthy volunteers was 46 hours (IQR 12-58) whilst WGT in the 
patients taking placebo had a significantly shorter median transit of 16 hours 
(IQR 7-29) p= 0.004, Mann Whitney test, fig 5.1. 
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Figure 5-1 WGT transit time in healthy volunteers and patients, median WGT  in healthy 
volunteers was 46 hours (IQR 12-58) significantly different from the  16 hours (IQR 7-29) in 
patients whilst taking placebo, p= 0.004. 
Dividing the transit into 3 sections as detailed in section 3.2 gives values for 
segmental transit. Segmental transit was non-normally distributed (Shapiro-
Wilks test). There was a significant shortening in left colonic transit time in 
patients which was 2.5 hours (IQR 0-7) vs. 12 hours (IQR 3-24) in healthy 
volunteers  p=<0.05 similarly the  rectosigmoid transit time was 4 (IQR 1-9) in 
patients vs. 7 (IQR 4-15) in healthy controls, p=<0.05. Segmental transit times in 
patients and healthy volunteers are shown in Table 5.1 
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Transit time 
(hours) HV 
(n=19) 
Transit time 
(hours)Placebo 
(n=106) 
P value (Kruskall-
Wallis) 
Right colon 13 (IQR 5-18) 6 (IQR 2-12) ns 
Left colon 12 (IQR 3-24) 2.5 (IQR 0-7) 0.0001 
Rectosigmoid  7 (IQR 4-15) 4 (IQR 1-9) 0.0001 
 
Table 5-1 Segmental transit in patients (placebo) and Healthy volunteers. 
 
5.1.2 Whole gut transit, stool form and stool frequency 
There was no correlation between weekly average Bristol stool form in patients 
taking placebo (n=102) with whole gut transit r =-0.115 p=0.26 (Spearman) 
and stool form did not correlate with transit in healthy volunteers either r 
=0.25 p= 0.313 (Pearson). 
Stool frequency whilst taking placebo did however weakly correlate with WGT 
in patients r =-0.293 p=0.003 (Spearman) but this was not seen in healthy 
volunteers r= 0.178 p= 0.47 (Spearman) 
 
5.1.3 Whole gut transit, psychological distress and 
somatisation  
It should be noted that this was a comparison of baseline psychological 
distress (anxiety + depression component of the HADS score) and whole gut 
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transit in patients when taking placebo (n=102). This did not demonstrate a 
significant correlation r=-0.185 p=0.065 (Spearman). 
Baseline somatisation in patients as measured by the PHQ-12 score also 
showed no correlation with whole gut transit r=-0.143 p=0.151 (Spearman).  
 
5.1.4 The effect of Ondansetron on whole gut transit 
Ondansetron significantly increased whole gut transit time compared to 
placebo (n= 98) with a median transit time of 25 hours (IQR 13.5-47.5) 
compared to 16 (IQR 7-29), p=<0.0001 (Wilcoxon matched pairs), this remains 
markedly lower (by 21 hours) than the median transit time for healthy 
volunteers, fig 5.2. 
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Figure 5-2 Whole gut transit in patients taking Ondansetron vs. Placebo with a median 
transit time of 25 hours (IQR 13.5-47.5) on Ondansetron compared to 16 (IQR 7-29)  on 
placebo, p=<0.0001 (Wilcoxon Matched pairs). 
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5.1.5 The effect of Ondansetron on segmental transit 
The effect of Ondansetron on colonic transit (n=96) was greatest in the left 
colon and rectosigmoid where the median transit times were 6 and 7 hours 
respectively compared to 2.5 and 4 hours whilst taking placebo, as 
summarised in table 5.2 . 
 Transit time 
(hours)Placebo 
(n=106) 
Transit time 
(hours)Ondansetron 
(n=102) 
P value 
Right colon 6 (IQR 2-12) 7 (3-16) ns 
Left colon 2.5 (IQR 0-7) 6 (0-17.25) <0.05 
Rectosigmoid  4 (IQR 1-9) 7 (2-13) <0.05 
Table 5-2 The effect of Ondansetron on segmental transit. 
5.2 MRI Small bowel water 
The method for calculating fasting SBWC is described in section 3.1.6.1 
5.2.1 Small bowel water content in healthy volunteers 
Fasting SBWC was non-normally distributed in patients and healthy volunteers 
(Shapiro-Wilk test). Fasting SBWC was significantly greater in healthy 
volunteers (n=20) 53.48 ml (IQR 36.22-125.6) compared to 35.55 ml (IQR 
16.75-72.69) in patients (n=51) with IBS-D p=0.0335 (Mann Whitney U), fig 
5.3. This is in keeping with previous findings [148] although it should be noted 
that the difference is smaller than previously described. 
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Figure 5-3 Median fasting SBWC is significantly greater in healthy volunteers, 53.48 ml (IQR 
36.22-125.6) compared to 35.55 ml (IQR  16.75-72.69) in The effect of Ondansetron on small 
bowel water content 
We hypothesised that Ondansetron would increase the amount of fasting 
SBWC by lengthening small bowel transit time. There was a trend towards 
increased fasting SBWC whilst taking Ondansetron 56.52 ml (IQR 24.03-87.17) 
compared to placebo 35.55 ml (IQR 16.75-72.69), p=0.21 (Wilcoxon Matched 
Pairs) (n=50). Although this did not reach significance it is interesting that the 
increase in water content results in values similar to the median SBWC seen in 
our age and sex matched healthy population.  
5.2.2 Small bowel water content and transit  
SBWC has previously been shown to correlate well with small bowel transit 
[148]; 
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But in this study the correlation of SBWC in patients taking placebo (n=56) 
with WGT r=0.261 did not reach statistical significance p=0.067 (Spearman). 
Given that small bowel transit time is usually only a small fraction of WGT, it is 
not surprising that this link is seen to be less significant when making 
comparisons taking into account the transit time within the large bowel as 
well. 
5.2.3 Small bowel water content and BSF diary data 
Combining healthy volunteers and patients taking placebo we were able to 
show a weak but significant association between SBWC and bloating (n=63) 
r=-0.308 p= 0.014. There was however no correlation between SBWC and 
average urgency r=-0.07 p=0.584, average pain r= -0.164 p=0.199, average 
stool consistency r =0.103 p=0.424, average stool frequency r= -0.27 p= 0.106 
(Spearman) 
5.2.4 Small bowel water content psychological distress 
and somatisation  
Again Combining healthy volunteers and patients taking placebo we were able 
to show a weak but significant association between SBWC and somatisation 
(n=68) r =-0.2 p= 0.049 (Spearman), but not between baseline measures of 
psychological distress r=-0.2 p= 0.1 (Spearman).  
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5.3 MRI parameters in the colon 
5.3.1 MRI ascending colon water content (ACWC) 
ACWC was non-normally distributed (Shapiro-Wilks). There was no increase in 
median free water in the ascending colon in patients (n=56) which was 0.5ml 
(IQR 0.0-2.4) compared to healthy volunteers (n=20) 1.0ml (IQR 0.2-3.1), 
difference not statistically significant with p=0.3 It is however clear that the 
variability was much greater in the patient group with a maximum value of 
31.7 compared to 9.5mls in the healthy volunteers. 
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6 Markers of Serotonin function 
6.1 5-hydroxytryptamine transporter linked 
polymorphic region(5-HTTLPR) identification 
in patients with IBS-D  
 
6.1.1 Distribution of 5-HTTLPR polymorphisms 
There was no difference in the distribution of 5-HTTLPR polymorphisms 
between the 122 patients and the 19 healthy volunteers accepting that the 
number of healthy volunteers is small, Chi squared p=0.64. This is summarised 
in Table 6.1. 
5-HTTLPR polymorphism Patients (%) Healthy Controls(%) 
Ll 40(33) 8(42) 
Ls 53(43) 8(42) 
ss 29(24) 3(16) 
Table 6.1 Distribution of 5-hydroxytryptamine transporter linked polymorphic region (5-
HTTLPR)  group in the patient and control groups. 
 
6.1.2 5-HTTLPR polymorphisms and baseline patient and 
volunteer characteristics 
There was no difference in baseline stool form, frequency, pain, urgency, 
bloating, or quality of life, symptom severity and measures of somatisation, 
when grouped by 5-HTTLPR polymorphism as shown in Table 6.2.  
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5-HTTLPR 
polymorphism 
ll ls ss P= 
Baseline stool 
form  (1-7) 
5.2  (95% CI 
4.9-5.4) 
5.1   (95% CI 
4.8-5.3) 
5.0   (95% CI 
4.6-5.4) 
0.52 
Baseline stool 
frequency 
2.6 (IQR 1.3-
4.1) 
2.4 (IQR 1.7-
3.4) 
2.4 (IQR 1.7-
3.0) 
0.77 
Baseline pain 
score  (0-3) 
1.26   (95% CI 
1.01-1.51) 
1.18   (95% CI 
0.95-1.42) 
1.09   (95% CI 
0.78-1.40) 
0.72 
Baseline 
urgency score 
(0-3) 
1.57 (IQR 
1.14-2.14) 
1.50 (IQR 
0.75-2.11) 
1.43 (IQR 1.0-
2.14) 
0.76 
Baseline 
bloating score 
(0-3) 
0.86 (IQR 
0.29-1.71) 
1.14 (IQR 
0.33-2.0) 
1.43( IQR 
0.43-2.0) 
0.3 
Baseline IBSQOL 400.4 (IQR 
342.5-526.7) 
450.0 (IQR 
331.2-593.1) 
485.8 (IQR 
301.9-588.5) 
0.7 
Baseline IBSSSS 311.9 (95%CI 
281.8-341.9) 
307.2 (95%CI 
284.2-330.3) 
299.8 (95%CI 
270.3-329.2) 
0.85 
Baseline  PHQ-
12 
6.8 (95%CI 
5.6-8.0) 
6.6 (95%CI 
5.6-7.5)  
7.9 (95%CI 
6.5-9.3) 
0.27 
Table 6.2 Baseline values for symptoms and psychological scores by of 5-hydroxytryptamine 
transporter linked polymorphic region group. 
 
 There was a trend to an increase in baseline anxiety and depression scores in 
patients and volunteers with the ss polymorphism, though this did not reach 
significance, with a p value of 0.053 for anxiety scores and 0.24 for 
depression. These data are shown in Figure 6.1 and Figure 6.2.  
 146 
*	;	%2=1
;
	
%






  
$

"$
"
#$
#
 
Figure 6-1 Baseline anxiety scores in each of the three 5-hydroxytryptamine transporter 
linked polymorphic region (5-HTTLPR) polymorphism groups. The mean anxiety score in the 
ll group was 8.3(95% CI 7.1-9.5), in the ls group 8.9 (95% CI 7.7-10.0) and in the ss group 
10.8 (95% CI8.9-12.6) p=0.053. 
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Figure 6-2 Baseline depression scores in each of the three 5-hydroxytryptamine transporter 
linked polymorphic region (5-HTTLPR) groups. The median depression score in the ll group 
was 4.0 (IQ 1-6.5), in the ls group 4.0 (IQ 2-9) and in the ss group 6.0 (IQ 2-9) p=0.24. 
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6.1.3 5-HTTLPR polymorphisms and response to Ondansetron 
Using the draft FDA criteria for a stool form responder, (a reduction of 50% or 
more in the number of type 6 and 7 stools in a week), and dividing the 
patients into two groups, those who responded to Ondansetron and not to 
placebo or “true responders” and all others, non responders, there is a trend 
towards fewer responders in the groups with those with the most available 
serotonin. The ll (n=36) group had the greatest number of responders with 
56% responding compared to 44% in the ls group (n=39) and 34% in the ss 
group (n=26), although this does not reach significance p=0.098 (chi-squared 
test for trend).  
5-HTTLPR 
polymorphism 
ll ls ss P= 
Delta stool form  
(1-7) 
1.18 95% (CI 
1.13-1.73) 
1.43 95%(CI 
1.12-2.02) 
1.57 95%(CI 
1.12-2.02) 
0.3 
Delta stool 
frequency 
0.79 IQ (0.21-
1.50)  
0.97 IQ (0.24-
2.22) 
0.69 IQ (0.34-
1.13)  
0.59 
Delta pain score  
(0-3) 
0.30 95%CI 
(0.07-0.52) 
0.32 95%CI 
(0.13-0.50)  
0.10 95%CI (-
0.20-0.40) 
0.36 
Delta urgency 
score (0-3) 
0.67 95% 
CI(0.39-0.94) 
0.58 95% 
CI(0.32-0.84) 
0.63 95% 
CI(0.37-0.90) 
0.88 
Delta bloating 
score (0-3) 
0.15 95% CI(-
0.02-0.32) 
0.12 95% CI   (-
0.11-0.32) 
0.30 95% CI   (-
0.05-0.70) 
0.5 
Delta IBSSSS 62.53 95%CI 
(28.87-96.19) 
93.77 95%CI 
(64.13-123.4) 
92.28 95%CI 
(45.18-139.4) 
0.35 
Table 6.3 Change in mean weekly stool form, stool frequency, pain urgency and bloating 
scores from baseline whilst taking Ondansetron by 5-hydroxytryptamine transporter linked 
polymorphic region (5-HTTLPR) group. 
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5-HTTLPR polymorphisms do not exert a significant effect over mean 
improvement in stool form, frequency, pain, urgency, bloating or IBSSSS 
between groups as shown in table 6.3 above. 
6.1.4 5-HTTLPR polymorphisms and WGT 
Others have shown least improvement in gut transit times with Alosetron in the ls 
group compared to the ll group although in this study the number of participants 
with the ss polymorphism was too small to study [75]. We found no significant 
difference in transit whilst taking placebo or Ondansetron between the groups. These 
results are displayed in Table 6.4. 
5-HTTLPR ll ls ss P= 
WGT (hrs) with 
placebo 
14 IQ (7-31) 14 IQ (6-24) 18 IQ (9-31) 0.25 
WGT (hrs) with 
Ondansetron 
23 IQ (12-35) 24 IQ (13-55) 28 IQ (22-48) 0.38 
Table 6.4 Whole gut transit (WGT) taking placebo and Ondansetron by polymorphism. 
 
6.1.5 5-HTTLPR polymorphisms and other markers of 
serotonin function 
5-HTTLPR polymorphisms did not significantly alter platelet paroxetine 
binding kinetics, and the Bmax, and Kd were not significantly different 
between groups. Baseline plasma 5HIAA levels were also not significantly 
different between the ll, ls and ss groups. These results can be seen in Table 
6.5.  
 
 149 
5-HTTLPR 
polymorphism 
ll ls ss P= 
Bmax (fMol/mg) 478.1 (IQR 
272.0-738.7) 
480.3 (IQR 
237.2-783.3) 
408.2 (IQR 
312.6-564.9) 
0.82 
Kd (nMol/L) 0.9169 (IQR 
0.3274-1.602) 
0.6049 (IQR 
0.3658-
0.9705) 
0.5559 (IQR 
0.2515-1.001) 
0.18 
Plasma 
5HIAA(nMol/L) 
16.0 (IQR 
12.4-20.0) 
16.3 (IQR 
13.0-20.0) 
18.4 IQR 16.4-
21.0) 
0.3 
Table 6.5 Effect of 5-hydroxytryptamine transporter linked polymorphic region (5-HTTLPR) 
polymorphisms on platelet Paroxetine binding kinetics and plasma 5-HIAA. 
 
6.2 Paroxetine binding in patients and healthy 
controls 
There was no difference in the number of SERT receptors on the platelet membranes 
of patients (n=70) compared to healthy volunteers (n=20) (Bmax) in addition the 
strength of binding to these receptors (kd) was also not different between the 2 
groups. 
 Patients  Healthy Contols P= 
Bmax (fMol/mg) 475.1 IQR (270.3-
728.7) 
458.3 IQR (213.0-
683.2) 
0.5 
Kd (nMol/L) 0.61 IQR(0.28-1.24) 0.77 IQR(0.51-1.54) 0.24 
Table 6.6 Paroxetine binding kinetics of patients and healthy controls. 
 
6.2.1 Paroxetine binding and baseline patient and control 
characteristics 
 
There was no correlation between Paroxetine binding bmax or Kd and plasma 
5HIAA.There was also no correlation between bmax and Kd with any of the 
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other baseline measures contained in the stool diaries, HADS, PHQ-15 or IBSSS 
scores.  
 
6.3 Plasma 5-HIAA 
 
6.3.1 Plasma 5HIAA in patients and healthy controls  
Fasting plasma 5-HIAA was non-normally distributed in patients (n=71) and 
normally distributed in healthy controls (n=20) (Shapiro Wilks). Median fasting 
plasma 5HIAA was significantly higher in controls than patients, 20.75 (IQR 
19.64-22.28) vs. 16.23 (IQR 12.22-19.21) nMol/L, p=>0.001 Mann Whitney U 
test as seen in Figure 6.3. 
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Figure 6-3. Fasting plasma 5-HIAA in patients is greater, 20.75 (IQR 19.64-22.28) than in 
controls 16.23 (IQR 12.22-19.21) nMol/L, p=>0.001. 
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6.3.2 Plasma 5-HIAA and baseline patient and control 
characteristics 
71 patients and 20 age and sex matched healthy controls had their fasting 
plasma 5HIAA measured. There no correlation with fasting plasma 5HIAA and 
pain , urgency , bloating, stool form, and stool frequency  There was no 
significant correlation between anxiety depression, PHQ-12, IBSQOL , IBSSS in 
patients. 
 
 
 r= 
Spearman 
P= 
Average Pain  -0.057 0.642 
Average Urgency  0.066 0.593 
Average Bloating  0.003 0.978 
Stool form  -0.085 0.486 
Stool frequency  -0.130 0.284 
Anxiety  -0.068 0.582 
Depression  0.125 0.311 
PHQ-12 0.074 0.540 
IBSQOL -0.003 0.978 
IBSSSS -0.104 0.390 
Table 6.7 Correlation of baseline patient characteristics with plasma 5-HIAA. 
 
 152 
Similarly there was no correlation with plasma 5-HIAA and any of the baseline 
values in healthy volunteers. 
 
6.4 Predicting the responder 

 True responder Non responder P= 
Age  38 (IQR 26-47) 45.0 (IQR 38-51) 0.0078* 
Average pain (0-3) 1.19 (95% CI 0.97-
1.42) 
1.56 (95% CI 1.35-
1.77) 
0.0186* 
Days with pain 5 (IQR 3-7) 6 (IQR 5-7) 0.0246* 
Average urgency (0-3) 1.526 (95% CI 1.32-
1.73) 
1.774 (95% CI 1.59-
1.95) 
0.0675 
Days with urgency 6 (IQR 5-7) 7 (IQR 5-7) 0.1162 
Average Bloating (0-3) 1.0 (IQR 0.43-1.71) 1.43 (IQR 0.68-2.0) 0.1295 
Days with bloating 5 (IQR 3-7) 6 (IQR 3-7) 0.1481 
Stool form (0-7) 5.55 (IQR 4.85 -5.85) 5.46 (IQR 5.0-5.95) 0.5023 
Stool frequency  2.64 (IQR 1.86-3.86) 2.62 (IQR 1.90-3.93) 0.9236 
Anxiety  8.35 (95% CI 7.2-9.5) 10.38 (95% CI 9.2-
11.6) 
0.0158* 
Depression  5 (IQR 3.0-7.25) 6 (3.0-9.0) 0.376 
PHQ-12 6.7 (95% CI 5.8-7.6) 8.1 (95% CI 7.1-9.2) 0.0488* 
IBSQOL 149.1 (95% CI 427.5-
514.0) 
170.5 (95% CI 399.1-
490.4) 
0.4134 
IBSSSS 290.3 (95%CI 265.4-
315.1) 
321.3 (95% CI 298.5-
344.1) 
0.675 
Table 6.8 Difference in baseline characteristics between true responders (those
							 , according to the FDA responder 
criteria) and non responders to Ondansetron(all others).  
Using the FDA stool form responder criteria, a reduction in 50% or more in 
number days a week with stool form >5, patients were dived into 2 groups. 
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Those who responded only to Ondansetron and not to placebo were termed 
true responders, and all others, who for the purpose of this analysis were 
termed non-responders. The difference in baseline characteristics between 
the two groups can be seen in table 6.8 above.
 
All the baseline parameters derived from questionnaires were slightly worse 
in those who did not respond to Ondansetron, with non responders being 
significantly older, having significantly more days with pain, greater average 
pain, anxiety, and somatisation as measured by the PHQ-12. However since 
these parameters were closely linked in a multivariate analysis (backwards 
logistic regression) only days with pain remained a significant independent 
predictor of response.
 
Markers of serotonin function were only analysed in the Nottingham group 
(n=71), there was no significant differences seen between those who 
responded and those who did not this can be seen in Table 6.9.
 Responders Non responders P= 
Bmax (fMol/mg) 487.1(IQR 265.0-
795.0) 
429.3 (IQR 299.3-
645.6) 
0.7136 
Kd (nMol/L) 0.8452 (IQR 0.33-
1.25) 
0.5983 (IQR 0.22-
1.11 
0.3 
5HIAA(nMol/L) 16.97(IQR 13.09- 
19.82) 
15.4 (IQR 12.02-
17.50) 
0.2821 
Table 6.9 Difference in baseline measures of serotonin (taken in patients recruited in 
Nottingham  only) between true responders and non-responders to Ondansetron. 
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7 Characterisation of faecal serine proteases  
The results of a series of pilot experiments are presented first, followed by the 
analysis of faecal serine proteases (FSP) activity in the subjects included in the 
trial: Ondansetron in patients with diarrhoea predominant Irritable bowel 
syndrome “identifying the responder”, the methods are detailed in Chapter 3. 
As noted in the methods section, assay’s in this chapter were performed by Dr 
David Tooth and Dr Gulzar Singh, with the exception of the mast cell tryptase 
estimation which was done by the Queen’s Medical Centre immunology 
department.   
7.1 Study 1:  FSP activity in patients and healthy 
volunteers 
FSP activity was measured in baseline samples from 36 IBS-D and 9 healthy 
controls. FSP showed wide variability and was non-normally distributed in IBS-
D (Shapiro Wilk, r=0.8, p 0.0003) but not in healthy controls. Values were 
significantly elevated in IBS-D with a median (IQR) of 451 units of trypsin/mg 
protein (61-963) versus 147(82-336), p=0.038, Mann-Whitney U test.   
7.2 Study 2: In vitro inhibition of FSP activity in 
patient samples 
The serine protease inhibitor, Aprotinin, was added to Trypsin standards and 
faecal extracts at a range of concentrations and showed a concentration 
dependent inhibition. At the higher dose (100 µg.ml-1) all FSP activity from 7 
IBS-D patients was inhibited. 
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7.3 Study 3: Proteomic techniques 
A test mixture of bovine trypsinogen and equine myoglobin demonstrated 
Benzamidine-sepharose column selectivity (Figure 7.1a) giving a peak not seen 
in control samples (Figure 7.1b). Buffered faecal extracts, when 
chromatographed similarly yielded chromatograms showing non-retained 
components in flow-through followed by a stable baseline and retained 
components were then selectively eluted (Figure 7.1c and 7.1d). 
 
 
Figure 7-1 Chromatograms of Benzamidine affinity chromatographed faecal extracts.The 
top left chromatogram (7.1a) using bovine trypsinogen and horse myoglobin mixture shows 
a clear peak corresponding to trypsinogen which was not seen in the control sample (7.1b). 
7.1c and 7.1d displays 2 IBS-D faecal extracts showing the eluting components peak in the 
same fraction as trypsinogen.  
Micropreparative SDS-PAGE showed the flow-through and eluate fractions to 
be heterogeneous mixtures of components with a broad molecular size range 
(Figure 7.2). Several components were selectively retained and their relative 
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abundance was elevated in a sample pooled from 6 patients compared to a 
pooled sample from 6 healthy controls. Eleven gel bands were excised and 
proteins identified (Table 7.1) using Proteomic procedures. The major 
component bands were human pancreatic enzymes including  trypsin,  alpha-
1 anti-trypsin,  carboxypeptidase B1/A, peptidase S1, PRSS1/2 (tryptases), 
alpha-amylase, pancreatic elastase 3A  as well as IgG light chain (kappa) 
together with various bacterial products including transmembrane protease 
M50, GADH and various  GADPH bacterial membrane receptors. 
 

Figure 7-2 Showing SDS-PAGE profiles of non-retained and retained components from faecal 
extracts of (pools of) IBS-D (Test) and Healthy controls (Control) each at two gel loadings. 
MW shows protein calibrants at a range of molecular weights. Components 1 to 11 were 
excised and putatively identified (Table 7.1). 
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Experimental 
Ref(Band 
No.) 
Components identified Rationale 
1 Porcine Trypsin This is the protease used to ‘digest’ target proteins 
2 Pancreatic amylase  
Human keratin 
Porcine Trypsin 
Not unexpected in gut. Inexplicable interaction with 
affinity ligand. 
Common human derived contaminant and not 
unexpected in human samples 
3 Human N-peptidase 
Pancreatic amylase 
Porcine Trypsin 
Specifically retained low abundance protease 
4 Pancreatic amylase 
Porcine Trypsin 
 
5 Maltase glucoamylase 
Porcine Trypsin 
Probable amylase homologue. Unknown whether 
uniquely identified or data artefact 
6 Human alpha-amylase 
other spp glycosyl hydrolases 
Amylase isoform 
Unknown if uniquely identified or data artefact 
7 Human alpha-1 anti-trypsin 
alpha-amylase 
bacterial GADH 
Kunitz domain Serine-Protease inhibitor, possible 
interaction partner with a target enzyme 
                                                                                                   
Probably an abundant microbial enzyme 
8 Various spp GADPH 
bacterial membrane receptors 
Probably an abundant microbial enzyme 
Probably an abundant microbial surface protein 
9 Human carboxypeptidase B1/A, 
Human Trypsin 
Human peptidase S1                                            
(AKA tryptases; there are various spliced 
25-31kDa homologues [90-98% homology], 
including mast-cell tryptase) 
IgG light chain (kappa) 
Human pancreatic elastase 3A 
Human alpha amylase 
Bacterial transmembrane protease  M50 
Specifically enriched protease 
Not unexpected in gut 
Possible Trypsin homologues 
10 Human Trypsin (various homologues),        
Human mesotrypsin 
bacterial GADPH 
 
11 Human Trypsin 
Human PRSS1/2 (tryptases) 
bacterial transmembrane protease M50 
 
Table 7-1 Putative identity of bands on SDS-PAGE chromatograms in Figure 7.2. 
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7.4 Study 4: Faecal elastase, amylase and mast cell 
tryptase quantification 
Since our proteomic analysis suggested a major serine protease component 
was trypsin we also wanted to look at levels of 2 other commonly produced 
pancreatic enzymes within the stool, pancreatic amylase and elastase. While 
trypsin and amylase are degraded by faecal bacteria and so normally excreted 
in small amounts, elastase is more stable and readily detectable in stool. As 
such it is used widely to detect pancreatic insufficiency in clinical practice. 
Faecal elastase values were normally distributed but not significantly different 
in the IBS-D patients being 2.4 ± 0.2 (mean ± SEM) versus 2.47 ±0.36 units/mg 
of stool in healthy controls, p=0.85, N=36. Pancreatic amylase was also 
identified and quantitated (Figure 7.3). This was non-normally distributed, and 
somewhat higher in IBS with a median (IQR) of 122.4(0.48-325.2) versus 17.0 
(10.3-102.8) units/mg for healthy controls but this did not achieve statistical 
significance owing to wide variability, p=0.07. However faecal amylase did 
correlated with FSP activity, r=0.04, p=0.006, n=45. 
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  Figure 7-3 Faecal levels of amylase in IBS-D versus controls 
Using a specific well validated Phadia Immunocap assay for mast cell tryptase 
we found undetectable levels in stool even though spiking the sample with 
pure human tryptase (Sigma-Aldrich, Warrington,UK) did show that we could 
detect mast-cell tryptase (MCT) when present in stool extract using this 
method.  
7.5 Baseline faecal serine protease activity in 
patients and healthy controls 
FSP activity was measured in 21 healthy controls and 79 patients with IBS-D as 
part of the study Ondansetron in patients with diarrhoea predominant 
Irritable bowel syndrome “identifying the responder”. As with the baseline 
values of the first 36 patients there was wide variability in the larger group 
from the placebo arm and although IBS values, median (IQR) 501(245-1421) 
trypsin units/mg protein were numerically greater than the matched healthy 
controls 302(147-4) trypsin units/mg protein the difference was not 
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significant. If we combine all the healthy controls from part 1 and part 2 the 
control value is 302(147-475) trypsin units/mg protein n=51 and the 
difference from IBS-D is significant, p=0.003 but as Figure 7.4 shows there is a 
wide variation in both groups. 
 
Figure 7-4 Faecal serine protease activity expressed in trypsin units/mg of protein showing 
IBS-D with significantly higher values than controls but with wide variability in both groups. 
Mann Whitney U, p=0.003. 
7.5.1 Baseline faecal serine protease activity, anxiety, 
depression, and symptom severity. 
 
Anxiety scores were normally distributed, whereas depression scores were non-
normally distributed (Shapiro Wilks).There was a positive correlation between both 
anxiety and depression with FSP activity, Pearson r=0.26, p=0.018 and Spearman r 
=0.31, p= 0.0026 respectively. There was a negative correlation with FSP activity and 
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quality of life score, Pearson r=-0.25, p=0.029, but not PHQ12-SS, or IBSSS. The 
results are summarised in Table 7.2 
 r= P= 
Anxiety 0.26 0.018* 
Depression 0.31 0.0026* 
IBSQOL (patients only) -0.25 0.029* 
PHQ-12 0.14 0.15 
IBSSSS (patients only) 0.19 0.11 
 
Table 7-2 Summary of correlation of FSP activity with baseline patient and volunteer 
baseline psychological and symptom severity scores. 
 
These psychological variables are closely correlated and when entered into a 
backwards logistic regression model using the 72 cases with data for all variables only 
depression remained an independent predictor of FSP activity in the model, p=0.012. 
 
7.5.2 Total FSP activity and stool form, frequency, pain, urgency 
and bloating 
Mean weekly pain, urgency and bloating scores were all non-normally distributed 
(Shapiro Wilk) .There was a positive correlation between FSP activity in patients and 
controls and mean weekly pain scores Spearman r =0.16 p= 0.019, mean weekly 
urgency scores Spearman r=0.16, p=0.018, and mean weekly bloating scores 
Spearman r= 0.16, p=0.019. There was no correlation between serine protease 
activity and stool form or frequency. These results are summarised in Table 7.3. 
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 r= P= 
Stool form -0.02 0.71 
Stool frequency 0.04 0.53 
Pain 0.16 0.019* 
Urgency 0.16 0.018* 
Bloating  0.16 0.018* 
 
Table 7-3 Summary of correlation of FSP activity with mean weekly symptom scores. 
 
7.5.3 Alteration in FSP activity with Ondansetron treatment 
compared to placebo 
Change in FSP activity between baseline and Ondansetron and baseline and placebo 
was non-normally distributed (Shapiro Wilk). There was no significant reduction in 
FSP activity from baseline with Ondansetron compared to placebo with a median 
(IQR) fall of 20.61 (-366.8-409.9) vs. 26.74 (-349.6-414.7) units of trypsin/mg protein 
p= 0.9, Mann Whitney U test. 
7.5.4 Faecal serine protease activity and WGT 
WGT transit (hours) in patients taking placebo and controls was non-normally 
distributed (Shapiro-Wilk). WGT in this group was positively correlated with FSP 
activity Spearman r=0.31, p= 0.0047. The addition of data from the Ondansetron arm 
of the study (non-normally distributed data Shapiro Wilk) abolishes this effect 
Spearman r =-1.67, p=0.084. 
In order to understand this variation we correlated transit and FSP activities 
measured on placebo in the IBS-D patients which showed a significant negative 
correlation, Figure 7.5  Spearman -0.32 95%CI (-0.51 -  0.09), p=0.005, n=79, as did 
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the healthy volunteers in whom we had transit measurements, Spearman r=-0.55 
95%CI (-0.81—0.11), p=0.014, n=20. FSP activity also correlated significantly with the 
average urgency in IBS patients, Spearman r=0.2695%CI (0.03-0.47), p=0.02, n=73. 
Ondansetron slowed transit increasing transit time while decreasing FSP with a 
negative correlation between the rise in transit and the increase in FSP, r=-0.40, 
p=0.003, in the 55 patients with complete values for both FSP and transit at both 
time points. 
 
 
Figure 7-5 Inverse correlation between FSP activity and whole gut transit in IBS-D, 
Spearman -0.32, p=0.05 n=79. 
As will be discussed in chapter 8, our interpretation was that increased bacterial 
degradation of endogenous trypsin, facilitated by the slowing of WGT, leads to a 
reduction in downstream stool FSP activity. 
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8 Discussion  
Patients with IBS-D suffer markedly, not only from loose and frequent stools 
but particularly from the associated urgency and fear of incontinence which 
generates panic and anxiety. Relief from these symptoms therefore 
represents an important unmet need. The 5-HT3 receptor antagonist 
Alosetron has been shown to increase stool consistency, decrease urgency 
and reduce abdominal pain leading to a global increase in satisfaction with 
treatment [1]. Its use is restricted following an increased incidence of 
ischaemic colitis and this agent is not available in Europe. The aims of this 
thesis were to assess the efficacy of the commonly prescribed 5-HT3 
antagonist Ondansetron, which has a good safety profile, in patients with IBS-
D and to identify biomarkers that might allow us to predict response defining 
an Ondansetron responsive endophenotype of IBS:  
The following hypotheses were tested: 
5. The 5-HT3 receptor antagonist Ondansetron is an effective and well 
tolerated treatment in patients with IBS-D with a low number of side 
effects. 
6. Ondansetron acts to increase small bowel water and slow colonic 
transit. 
7. Response to Ondansetron will be more effective in those with 
abnormally increased mucosal serotonin availability at baseline. 
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8. Faecal serine protease activity will be reduced by treatment with 
Ondansetron as a result of slower colonic transit. 
This study has shown Ondansetron to be a well tolerated and effective 
treatment in patients with IBS-D, and that it significantly slows whole gut 
transit time, but does not increase small bowel water content. Ondansetron 
has a number needed to treat of only 3 using the FDA stool responder criteria 
and represents a potentially significant breakthrough in the treatment of this 
patient group.  Defining an Ondansetron responsive phenotype in this study 
has been challenging, in part because of a small sample size and also as a 
result of the use of a dose titration model (see below).  The discussion of the 
results obtained for baseline measures of serotonin turnover and the studies 
to identify the origin of faecal serine proteases and the effect of Ondansetron 
on faecal serine protease activity will follow the main discussion of the RCT of 
Ondansetron vs. placebo. 
8.1 Baseline data 
8.1.1 Stool form variability 
As part of this RCT we have learnt much from the information contained in 
the baseline stool diaries. As expected our patients were anxious and 
depressed, they had looser stool and more urgency than healthy volunteers 
but no difference in stool form variability (difference between minimum and 
maximum stool form within one day). Stool form variability was proposed as 
measure of the unpredictability of symptoms in IBS-D, a known major cause of 
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distress in patients. This measure in our patient population appears unhelpful 
and does not mirror the intra-individual variability or unpredictability in 
symptoms described, with no difference between healthy volunteers and 
patients and no correlation with symptoms or symptom severity. This is 
contrary to others who have shown variability to be greater in patients than 
controls in a smaller population (54 patients) but this may reflect the subtypes 
included. IBS-D may be more consistent than IBS-mixed type who probably 
form around half of most IBS series. Stool form variability has been noted to 
be a major predictor of discordancy between reported subtype and actual 
subtype [169] supporting the explanation that there is a tendency for patients 
to “catastrophise” and report the occasional severe symptom as being 
common when in reality it is rare enough in this case not to alter average 
data.  
Stool form variability did not change with Ondansetron. Given that baseline 
was not different from the healthy population this is a reassuring finding, 
large swings from loose stool to constipated as often described by patients 
when for example taking Loperamide would be a potentially unacceptable 
symptom. 
8.1.2 Baseline data: EMR. 
A commonly recognised clinical phenotype and a major source of 
unpredictable symptoms and high stool frequency is that of the “early 
morning rush”. Here the patient complains of multiple and frequent bowel 
motions (BM) soon after waking. In this study I have defined a morning rush 
 167 
as 2 or more BM in less than 1 hour occurring after midnight and before12 
midday. Greatly more patients than volunteers experience this EMR and a 
severe morning rush defined as more than 5 days a week with a morning rush 
represented a group with a greater mean stool frequency, higher IBSSS 
coupled with increased psychological distress and a more impaired quality of 
life. One might hypothesise that this morning frequency leads to difficulties 
with leaving the home and may impact on employment, a major source of 
stress making this an area worthy of further study. It is interesting to note that 
the group with SMR contained 4 of the 12 dropouts in this study, suggesting 
they are a more difficult group to study, either because of increased 
psychological abnormalities or perhaps difficulty attending study visits, many 
of which took place in the morning. 
Ondansetron did not reduce the number of days with EMR, despite an overall 
reduction in loose stool and urgency and whole gut transit.  It is possible that 
this has been influenced by the high number of dropouts in the SMR group, 
but also may be a reflection of increased psychological abnormalities in this 
subgroup of patients that is ongoing despite improvements in some aspects of 
their stool habit. In addition many patients have altered their behaviour over 
time with a need to open their bowels several times before leaving home to 
reduce fear of accidents. It is possible that this particular driver to bowel 
opening may improve over time as confidence in the effect of Ondansetron 
grows and that the 5 week study period was therefore not long enough to 
observe a change in EMR.  
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8.2 Primary end point  
There was a significant change in stool form whilst taking Ondansetron 
compared to placebo. The BSF scale is not ordinal, but as seen in this study, an 
average improvement of more than 1 point on this 7 point scale, represents a 
clinically relevant change in stool form.  A reduction in 1 point leads to 
significantly less loose stool. It is these loose stools which are associated with 
more urgency contributing to incontinence, a major fear and source of 
distress in our patient group. 
The clinical relevance of this is also captured as part of the measure of 
satisfactory relief. This was 68% of patients whilst taking Ondansetron 
compared to 17% on placebo, telling us the improvements in symptoms were 
meaningful to the majority of patients taking part. As we did not find 
significant changes in pain and bloating it is assumed that the major 
contributors to this measure would be the improvement in stool form 
frequency and urgency.  
Satisfactory relief is a subjective measure of treatment efficacy that captures 
the range of symptoms experienced. Debate as to the magnitude of change 
captured by this measure exists. Data from a study examining patients 
receiving standard care found that patients who at baseline had the mildest 
severity reported the highest proportion of satisfactory relief when this 
measure was repeated 6 months later. These findings suggest that 
satisfactory relief is confounded by IBS symptom severity [170] but this effect 
was abolished in a further study where those who reported adequate relief at 
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the start of the study were excluded [171]. Although vital to understand the 
true impact a drug is having on symptoms in a condition plagued with a high 
placebo response rate this measure of satisfactory relief does still capture 
what our patients want: to feel relieved of their symptoms. Therefore in a 
condition where there remains an absence of clinical markers this measure 
remains a useful outcome. 
The mean weekly BSF whilst taking Ondansetron was 3.94, not dissimilar to 
the mean weekly stool form in healthy volunteers of 3.5, caution should be 
exercised however as this is by no means the whole story. It is important to be 
mindful of the multitude of symptoms reported by this patient group, 
including additional disturbances of defecation such as straining, urgency and 
a sensation of incomplete evacuation even when the stool form is normal 
[172], reminding us that factors other than altered stool form contribute to 
the generation of symptoms in IBS.  
Comparison of the magnitude of this effect with other treatments acting on 
stool form is ideally done in a head to head study. Existing studies tell us that 
the other 5-HT3 antagonists have a significant effect on stool form and 
Alosetron for example improves form by 0.6 on a 5 point scale, but 
importantly this reduction is coupled with a high incidence of constipation of 
25% [156]. Loperamide is a commonly prescribed drug in IBS-D and is both 
cheap and readily available. It acts on peripheral opiate receptors to slow 
transit through the small and large bowel. This results in an increased 
capacitance of the gut and a delay in the passage of fluid through the intestine 
[173]. Direct comparison of the order of reduction in form is however difficult, 
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few trials have been done in IBS and there is methodological variation, with 
for example the use of visual analogue scales, and reporting of stool as 
watery, intermediate or shaped[174]. In a very small placebo controlled study 
stools were reported as formed in 72% of 11 patients taking Loperamide and 
7% of 10 patients taking placebo[175].  The use of rescue Loperamide in this 
study was unfortunately not uniformly recorded but would have been an 
insight into understanding the relative effectiveness of these 2 preparations.  
8.3 The effects of Ondansetron on symptoms 
8.3.1 Urgency 
We have seen a significant reduction in urgency whilst taking Ondansetron. 
This finding is important since urgency is one of the strongest predictors of 
reduced quality of life[176] and as others have reported, response to 5-
HT3RAs also correlates with improvement in quality of life [177]. Quality of life 
at baseline was measured as part of this study and follow up measurement 
after treatment with Ondansetron would be an important area for further 
study. 
 
8.3.2 Pain 
We have not been able to demonstrate a reduction in either average pain 
scores or number of days with pain with Ondansetron in this study. This is 
surprising when one considers that 5-HT3 -receptors are present in peripheral 
and central nervous systems[178], and in animal models of visceral pain, the 
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5-HT3 - receptor antagonists Granisetron and Ondansetron  reduce vasoactive 
reflexes induced by gastrointestinal tract distension[179]. Early in vivo studies 
using Ondansetron at a dose of 16mg TDS gave conflicting results when it 
came to improvements in pain. One demonstrated a reduction in daily 
episodes of pain as well as changes in rectal sensitivity and compliance[180] 
whilst in contrast, another study of just 11 patients, Ondansetron showed no 
improvement in abdominal pain [80]. Alosetron and Cilansetron both relieve 
abdominal pain in patients with a pooled relative risk of 1.30: 95% CI, 1.22-
1.39[1]. It is possible that these higher doses of Ondansetron are needed to 
affect pain sensation (the mode dose in patients was just 4mg on alternate 
days) but 68 % of our patients reported adequate relief from their symptoms 
with Ondansetron, compared to 17% with placebo, coupled with a significant 
reduction on overall symptom severity as measured by the IBSSS , so perhaps 
pain is less important than the urgency in this particular patient group.  
 
New partial agonists of the 5-HT3receptor have been proposed to overcome 
the high incidence of constipation seen with Alosetron, a reduction in 
constipation with these agents may lead to higher dosing and perhaps a 
greater effect on pain[181]?  
 
8.3.3 Bloating 
Bloating is a notoriously difficult symptom in IBS and the mechanism of its 
generation disputed. Slowing of transit via 5-HT3antagonism might potentially 
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increase bloating and Tegasarod a 5-HT4 receptor partial agonist and 
promotility agent does reduce bloating in patients with constipation[182] 
Findings that 5-HT3antagonism in the upper GI tract reduces the  sensation of 
post prandial fullness, by perhaps acting on visceral afferent perception[183] 
and  blunting of antral distension evoked increases in colonic 
tone[184]suggest a potential for an impact on bloating using Ondansetron.   
However no alteration in bloating was seen in our study or in other studies 
with the 5-HT3 antagonist Alosetron [156]. Changes in gas handling, gas 
production, visceral sensation and posture have all been implicated in the 
generation of bloating in this patient group and it has been suggested a more 
complex management strategy combining dietary, pharmacological, 
bacteriological and even behavioural approaches may be needed to improve 
this difficult symptom[185].  
 
It is interesting to note that studies of the effect of Loperamide, one of the 
most commonly prescribed drugs in this patient group, have not convincingly  
shown an effect on symptoms other than perhaps a reduction in stool 
frequency[186]. It is our experience that patients use this medication as a 
“rescue” therapy but its use in the long term appears not to be satisfactory, 
one could speculate this lack of demonstrated efficacy in reduction of other 
symptoms such as pain and bloating and even a reported increase in pain at 
night in one study[174] might be contributing to reduced patient satisfaction . 
The absence of a documented increase in pain with the use of Ondansetron 
may make its use more appealing to patients than Loperamide. 
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8.4 Dose and Safety  
Regrettably Alosetron , a 5-HT3 RA for which there is substantial evidence of 
benefit[1] was withdrawn from widespread use because of an unacceptable 
incidence of severe constipation (around 25%) and a much lower incidence 
(0.7 per 1,000 patient-years) [187] of ischemic colitis . Our trial shows that 
Ondansetron can achieve useful results with a low incidence of side effects. 
Constipation occurred in just 9% and rapidly resolved on dose reduction giving 
a discontinuation rate due to constipation of just 2% with no incidents of 
ischemic colitis.  
 The high incidence of constipation with Alosetron appears in retrospect to 
have been due to the use of too high a dose.  Subsequent studies using lower 
doses  suggest that 0.5 of a mg daily is associated with a much reduced 
incidence of constipation which was just 9% in the 0.5 mg group compared 
with 5% in the placebo group.  However these low doses were sufficient to 
produce a response in 50.8% of patients compared with 30.7% in placebo 
[188]. Unfortunately ischemic colitis remains a concern despite careful 
monitoring with an incidence of 2 per 1000 [189]. Ondansetron’s potency in 
blocking the 5-HT3 receptor is between 3-10 times lower than Alosetron [190] 
which may explain the low incidence of side effects in our study.  Ramosetron 
is another 5-HT3 RA, proven to be effective in IBS-D but unfortunately only 
marketed in Japan. It has an affinity for the 5-HT3 receptor 3 times Alosetron 
[191] but  is given at a very low dose of 5ug, with  Constipation rates of 
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7%[71] equivalent to 0.015 mg Alosetron again suggesting that lower doses of 
5-HT3 RAs might well be the best strategy in IBS-D.  
The use of dose titration in this study was key to its success; patients were 
able to select the lowest effective dose, the mode being just 4mg every other 
day, leading to greatly less constipation than has been seen in other related 
preparations. 
The further benefits of Ondansetron, particularly in Europe, where neither 
Alosetron nor Ramosetron are available, are that it is generic drug, available 
worldwide at a low price, with a very long experience of safe usage and, to 
our knowledge, no reports of ischemic colitis.  
8.5 Number needed to treat  
We have demonstrated that Ondansetron in our patient group is effective 
with a low risk of side effects, its effectiveness is summarised by its low NNT 
of just 3. This allows us to place this treatment alongside therapies that are 
currently available and speculate that the use of Ondansetron may lead to 
improved outcomes in this group of patients who are often dissatisfied with 
conventional treatment. 
One of the most frequently used groups of agents are the tricyclic 
antidepressants. These are cheap and readily available, and a single meta-
analysis has reported a number needed to treat of as low as 3 although the 
individual trial quality was variable [192]. In contrast attempts to compare 
tricyclics and a SSRI against placebo did not find either to be superior, 
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although Imipramine had a greater effect on the psychological distress 
experienced by patients [193]. Additionally further meta-analysis of 
antidepressants in IBS by Cochrane concluded that there was no evidence that 
antidepressants were effective in the treatment of IBS, it is notable that many 
larger studies were excluded because of methodological weakness and 
numbers were small [194]. Many of these studies used the global assessment 
of patients response to therapy, this comprises of a variety of dimensions 
each differently weighted by the individual, which despite the negative 
conclusions of the meta-analyses points to potential gains on a patient by 
patient basis. The FDA has attempted to address this deficiency in endpoint 
selection with its new symptom specific criteria which we have adopted in our 
current study. In practice tricyclic agents although frequently initiated have 
the potential to aggravate constipation and their other side effects including 
dry mouth and drowsiness often preclude their use even at low dose, with up 
to 40% discontinuing for these reasons [195].  
The NNT of Ondansetron compares favourably with the other 5-HT"
antagonists. Ramosetron has been shown to achieve global relief from IBS 
symptoms in 47% compared to 27% with placebo giving an NNT of 5, which is 
similar to Alosetron [71]. Cilansetron which was withdrawn at an early stage 
because of 4 cases of ischaemic colitis reduced stool consistency, stool 
frequency and urgency leading to satisfactory relief in 41% compared to 18% 
with placebo giving an NNT of 4.7 [196] and a metanalysis of 14 eligible RCTs 
of Alosetron (n=3024) or Cilansetron (n=1116) vs. placebo resulted in a NNT of 
7.7 for relief of abdominal pain, 4.2 for global relief of symptoms [1]. 
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The low NNT in this study is not likely to be a direct result of enhanced drug 
efficacy, indeed we have described the lower receptor affinity of Ondansetron 
compared to Alosetron [190] and Ramosetron in the preceding section [191], 
but of the dose titration model used. This model reflects clinical practice and 
patients were able to take a daily dose that did not result in constipation. It 
can be seen that individual dosing ranged from 4mg every 3 days, to 24mg 
daily demonstrating a very large variation in individual sensitivity to 5-HT3
antagonism with Ondansetron  
Comparison of Ondansetron with Loperamide is more difficult, studies are 
small and although use is widespread, evidence for efficacy beyond a 
reduction is stool frequency is lacking[186]. 
The place of Ondansetron in the treatment algorithm for patients with IBS-D is 
an area where further study is needed, but its quick onset of action and low 
NNT make it an attractive first choice in a condition where repeated trials of 
treatment are often needed, allowing the patient and clinician to move on 
quickly if it is not found to be efficacious. 
8.6 Mechanisms of action  
8.6.1 Transit  
We have demonstrated a significant slowing of colonic transit in patients 
taking Ondansetron compared to placebo with the greatest effect seen in the 
left colon.This is a well documented effect of this class of medication and our 
findings compare favourably with earlier work.  The first of these studies using 
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radio opaque markers in healthy volunteers and Ondansetron at high dose 
(16mg TDS) resulting in a mean total colonic transit time on placebo of 27.8 h, 
vs 39.1 h whilst taking Ondansetron. Transit times through the left colon and 
rectosigmoid were prolonged by the drug, but right colonic transit was not 
significantly altered leading the authors to postulate that the left colon may 
have the highest density of 5-HT3receptors in the large bowel[79]. In a second 
study of 11 patients taking 16mg tds of Ondansetron, colonic transit tended to 
be longer during drug therapy than during the placebo trial, but this 
difference was not significant. Small intestinal transit and orocecal transit 
were unchanged by the drug[80].  It is striking that these earlier studies used a 
much greater dose than in our patient group yet we are able to demonstrate a 
significant alteration in transit.  
The effect of Alosetron on transit appears to be  similar with no overall effect 
on the orocaecal transit time using the radiopaque marker technique, but an 
increase the whole gut transit time as a result of an increase in the left colonic 
transit time [197]. Both Alosetron and Ondansetron have a direct, selective 
inhibitory effect on the frequency of spontaneous MMC in isolated small and 
large intestine in C57BL/6 mice [198], but also may influence transit by 
changing rectal sensitivity. These changes in sensitivity have been 
demonstrated with the use of iv Granisetron [199] and also with Alosetron , 
this change in sensitivity may underlie slowing of left sided transit seen in our 
patients.  Although rectal sensitivity was not measured here it could be 
inferred that the significant reduction in urgency may be in part secondary to 
changes in sensitivity.  
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Changes in receptor density and rectal sensitivity may important but in a 
patient group with fast transit caution should be exercised in interpreting the 
findings of a measurement taken at day 3. It may be that this cheap and 
patient acceptable method of measuring transit is not in fact sensitive enough 
and may miss subtle differences in right sided transit at 72 hour post marker 
ingestion. This may be a factor underlying the surprising finding that stool 
form in this study does not correlate with transit as has been shown by 
others[200].  
8.6.2 Small bowel water 
As in other work from Nottingham [148] we have again shown a reduction in 
SBWC in patients compared to healthy volunteers, the size of the effect is 
smaller, and we speculate this is a reflection of the heterogeneity of the 
measure.  
We hypothesised that Ondansetron would slow small bowel transit and 
reduce MMC frequency leading to increased small bowel water in patients 
taking Ondansetron compared to placebo. This was not seen, with no 
difference in SWBC whilst taking placebo compared to taking Ondansetron. 
This might initially seem surprising given that we have shown a reduction in 
SBWC and the antroduodenal Motility Index with Ondansetron in healthy 
volunteers. The dosing in these subjects was however much higher with 
volunteers taking 8mg of Ondansetron 3 times a day on the day preceding 
scanning and 16mg of Ondansetron 1 hour preceding the scan[153]. This is 
consistent with other studies in which 5-HT administration increased the 
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frequency of the MMC[201, 202], and 5-HT3 antagonism reduces MMC 
frequency[198] .In  our study the SBWC measurements were taken in the final 
week of treatment when because of the use of dose titration, some patients 
had been taking doses as low as 4mg every other day. 
In contrast to changes in transit in the small bowel in volunteers receiving 
high doses of Ondansetron, it is interesting to note that 2 studies using 16mg 
of Ondansetron in patients showed a significant prolongation in whole gut 
transit but did not change mouth to caecum time[80, 203] Selective5-
hydroxytryptamine receptor antagonism with Alosetron also exerts its effect 
on whole gut transit in the colon, not the small bowel when assessed by the 
radio opaque marker method used in conjunction with the breath hydrogen 
test to quantify small bowel transit time[197].  
 
Despite the overall lack of effect of Ondansetron on SBWC we were able to 
show a weak but significant association between SBWC and bloating, and also 
between SBWC and somatisation. In the original work knowing both the total 
SBwC and the rate of transit an average Flow Index was calculated. This 
suggested that the faster transit seen was mostly due to a smaller intestinal 
diameter, or “spaghetti bowel,” which may reflect increased circular muscle 
tone [148]. This increased tone was hypothesised to be related to anxiety and 
result in pain and bloating. The finding of a link with both bloating, and a 
measure of psychological abnormality in the form of somatisation in this study 
fits with this hypothesis and points to a small effect of Ondansetron on the 
small bowel. 
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MRI of the bowel is a new technique; as yet many of the other drugs that alter 
gut transit have not been evaluated using this novel method, so a comparison 
of the effect on SBWC with other agents is not possible. It is interesting to 
note that Loperamide which we know acts to slow gut transit times has been 
evaluated in volunteers and does reduce SBWC [151] but its effect on this 
measure in patients is not yet known. 
8.6.3 Colon water analysis 
Colon water analysis took place in the ascending colon. It is not surprising that 
there was no effect downstream given that we were unable to demonstrate a 
change in SBWC. Additionally characterising the water content of the colon 
using MRI is fraught with difficulty. The T1 and T2 of colonic contents are very 
short and the reasons for this are not clear. Hypotheses include the presence 
of iron or the low free water fraction. Within the department (unpublished 
work, by Elisa Placidi) ex vivo MRI of stool that was subsequently freeze dried 
and then rehydrated revealed a very low free water content. The persistence 
of a short T1 and T2 after water addition may imply quenching of the signal is 
due to ferrous ions or bacterial products present in the faecal matter.  
 
8.7 Markers of serotonin turnover 
5-HT3 antagonists are logical treatment in patients with IBS-D given the 
abnormalities of serotonin metabolism which have been demonstrated in this 
patient group.  Post infective IBS, a subtype of IBS-D with very similar clinical 
features [204] has been shown to be associated with increased 5-HT-
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containing enteroendocrine cells [35] and also increased post prandial 5-HT 
release [110] We examined 3 measures of serotonin function in this group; 
1. The 5-HTTPLR polymorphism. 
2. Platelet serotonin binding kinetics.  
3.  Plasma 5HIAA. 
8.7.1 8=1Polymorphism 
Serotonergic action is terminated through reuptake from the synaptic cleft by 
the serotonin transporter protein (SERT-P). There is a 44 bp insertion ⁄ 
deletion in the 5’-flanking promoter region (5-HTTLPR), which creates a short 
and a long allele. The presence of the short allele is associated with lower 
transcriptional activity and, as a consequence, lowers levels of SERT-P 
expression and reduced reuptake of serotonin [205] 
 
We found no difference in 5-HTTPLR distribution between healthy volunteers 
and patients.  Drawing a conclusion from this finding alone would be 
inappropriate given the small numbers involved but it is notable that there is 
considerable debate as to what the role of this polymorphism is in IBS. In a 
total of 1034 patients with the irritable bowel syndrome, and 1377 healthy 
controls, the presence of the short allele was not associated with an increased 
risk for the irritable bowel syndrome: OR 1.0; 95% CI: 0.7–1.4 for homozygous 
subjects, and OR 1.0; 95% CI: 0.8–1.2 for homozygous subjects and 
heterozygotes together[206](
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In our study there was a trend to an increase in baseline anxiety and 
depression scores in patients and volunteers with the ss polymorphism, this 
did not reach significance but is in keeping with the finding that the 5-HTTPLR 
polymorphism accounts for 3 to 4 percent of total variation and 7 to 9 percent 
of inherited variance in anxiety-related personality traits [205]. There was 
however no difference in any of the other baseline parameters between 
groups despite the suggestion that 5-HTTPLR status might affect the severity 
of symptoms in patients with IBS. It has been hypothesised that S allele 
impairs the efficiency of 5-HT reuptake with a consequent prolonged and 
enhanced activation of serotonergic pathways mediating abdominal pain 
sensation. Camilleri et al found that the LS/SS genotypes are associated with 
increased pain sensation at rectal distension [207]  and more recently    LS and 
SS genotypes have been shown to be significantly correlated with IBS 
symptom severity across all IBS subtypes[208]. The same polymorphism 
predisposes to developing depression in response to life stressors [209]. Our 
patients had a high degree of satisfaction with Ondansetron treatment 
despite no significant difference from placebo on pain severity. As previously 
mentioned this group, all of whom had diarrhoea >25% of the time are often 
much troubled by the sensation of urgency, and may rate pain as a less 
troublesome symptom. 
There is a suggestion from our data that there is a difference in response to 
Ondansetron between the 3 5HTTPLR polymorphisms with those in the ll 
group most likely to respond, numbers are too small to draw conclusions but 
comparison with others shows a variation in response according to 
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polymorphism has been demonstrated. Camilleri’s group have shown an 
improvement in gut transit times with Alosetron in the ls group compared to 
the ll group, although in this study the number of participants with the ss 
polymorphism was too small to study. Here the hypothesis is that the drug 
can act more effectively in an environment with a lower synaptic 
concentration of 5-HT that needs to be competitively inhibited by the 
antagonist. In our population the greatest prolongation of transit with 
Ondansetron was also seen in the ls group. This was not significant even 
though we had 4 times the number of subjects and again this may reflect the 
far greater potency of Alosetron versus Ondansetron at the doses used. 

5-HTTPLR polymorphism status did not significantly alter platelet paroxetine 
binding kinetics, or baseline plasma 5HIAA levels. Other work has shown 
platelet 5-HT uptake to be significantly higher in LL homozygotes compared 
with S carriers among a group of healthy individuals, but no significant 
difference was observed in transporter densities as measured by paroxetine 
binding between groups [210]. In alcoholic subjects Bmax did not differ in a 
statistically significant manner among LL, LS, and SS genotypes in, but they did 
find differences in platelet serotonin uptake [211]. The lack of difference in 
these measures of serotonin binding and breakdown may simply be a result of 
small numbers, or may suggest a lack of functional significance in this patient 
group.  
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8.7.2 Platelet paroxetine binding 
The endogenous activity of 5-HT is controlled by the specific 5-HT transporter 
(SERT), which facilitates the intracellular reuptake of 5-HT and can be 
specifically blocked by selective 5-HT reuptake inhibitors (SSRIs), such as 
paroxetine and fluoxetine. SERT is widely expressed in intestinal epithelial 
cells, central or peripheral serotonergic neurons, and platelets, where it 
shares common molecular and physiological features [212]. It has therefore 
been hypothesized that changes in intestinal SERT function might also be 
present in SERT in platelets, which circulate systemically and are exposed to 
the same intestinal environment. Indeed previous work from our department 
has demonstrated binding of paroxetine to membranes of platelets from 
patients with IBS-D to be significantly greater than that from HVs and that this 
measure correlated inversely with platelet uptake of 5-HT and with mucosal 
SERT mRNA [121]. This inverse relationship between platelet 5-HT uptake and 
paroxetine binding led us to use paroxetine binding, an assay which can be 
performed on frozen samples, as a surrogate marker of impaired SERT in our 
patients with IBS-D. 
In this study there was no difference in the number of SERT receptors on the 
platelet membranes of patients compared to healthy volunteers (Bmax) in 
addition the strength of binding to these receptors (kd) was also not different 
between the 2 groups.  
The values obtained for Bmax and Kd in this study, performed in the same 
department, by the same operator, using the same methods and equipment, 
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are higher than in the study by Foley et al (Bmax = 475.1 IQR (270.3-728.7) vs. 
226 IQR [92– 405] fmol/mg protein in patients and 458.3 IQR (213.0-683.2) vs. 
109 IQR [69 –175] fmol/mg protein in healthy volunteers)[121]. A review of 
the literature suggests there is variability in this measure with mean values for 
Bmax in patients with IBS-d reported as 523 +/- 40 fmol/mg and healthy 
volunteers 1152 +/- 187 fmol/mg, in the only other study of this assay in an 
IBS population [120]. 
It is notable that in this piece of work that the healthy volunteers were age 
and sex matched and that the numbers were greater, 71 patients and 20 
volunteers, compared to 12 subjects in each arm in the earlier Alosetron [120]  
work and 29 and 20 patients and healthy volunteers respectively  in the 
previous study from this department[121]. 
There is evidence in fibromyalgia that Bmax correlates negatively with 
symptom severity but not Kd values [213], and after treatment with 
Alosetron, symptom severity score decreased significantly whereas B(max) 
and K(d) values did not change [120]. We did not however find an association 
with paroxetine binding and symptoms in our patients, and it may be that this 
convenient surrogate marker of SERT function is subject to too greater a 
degree of variability in this already heterogeneous population (in whom only 
some may have altered serotonin handling as a disease mechanism) to 
accurately reflect underlying changes gut mucosal serotonin handling. 
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8.7.3 Plasma 5 HIAA 
5HIAA in platelet poor plasma is another surrogate marker of 5HT turnover, 
representing the relative activity of the enzyme monoamine oxidase not only 
in the platelets but also in other tissues such as the liver and lungs. Studies in 
IBS patients have found reduced fasting 5HIAA in patients with constipation, 
and normal 5HIAA in patients with diarrhoea but with an altered 5HIAA:5HT 
ratio after feeding, pointing to a reduced capacity for serotonin breakdown in 
this patient group [109].  
Median fasting plasma 5HIAA was significantly higher in controls, which would 
fit with a reduced capacity for serotonin breakdown via impaired SERT 
function in patients as shown by others [121], however despite this there was  
no correlation with plasma 5HIAA levels  and any of the baseline values in 
healthy volunteers or patients, including stool form and frequency suggesting 
this difference may not have a detectable functional consequence in this small 
number of subjects. 
 
8.8 Predictors of response  
Patients were selected to meet the Rome III criteria and so were necessarily 
similar at baseline( Only days with pain remained a significant independent 
predictor of response after multivariate analysis, but all the baseline 
parameters derived from questionnaires were slightly worse in those who did 
not respond to Ondansetron, with non responders being significantly older, 
having significantly more days with pain, greater average pain, anxiety, and 
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somatisation as measured by the PHQ-12. We found that those most severely 
affected were also more likely to dropout, indicating that the efficacy for 
treating severe diarrhoea with Ondansetron is limited, and perhaps the 
greater anxiety displayed is reflection of a different mechanism of diarrhoea 
unresponsive to 5-HT3 modulation. The best response to Ondansetron is 
therefore likely to be in those with mild to moderate symptoms.  However 
given its safety, low side effect profile and rapid onset of effect within 1 week 
in most cases, a trial of treatment would seem reasonable in most cases of 
IBS-D. 
One of the stated aims of this thesis was to identify an Ondansetron 
responsive phenotype. The variable dosing regime mirrored clinical practice 
and gives a better idea of how the drug will perform in clinical practice. It 
undoubtedly improved response rate and had we chosen a fixed dose many 
patients would have developed constipation and probably dropped out or had 
worsening symptoms. It does however present a problem for analysis since 
only the stool diaries in the last 2 weeks are truly informative of the response 
meaning that we cannot input data to allow for incomplete diaries which 
would be normal practice. This led to a reduction in an already small sample 
(powered to detect a change in stool consistency) and this small number is 
likely to be a significant factor in preventing this aim from being achieved. 
Despite this the reduced response at the more severe end of the spectrum 
presents an interesting clue for further study. 
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8.9 Serine proteases  
This thesis cofirms previous reports [94] that FSP activity is elevated in some 
patients with IBS-D but also shown that there is considerable overlap with 
normal subjects without IBS. Characterisation of the proteins responsible for 
the serine protease activity shows that most of this activity is likely due to 
human pancreatic enzymes. 
 
While the pancreas is the putative source of this trypsin-like activity, 
enterocytes also contain trypsin mRNA and trypsin-like immunoreactivity 
[214], though the amounts are small relative to expression in the pancreas. 
Trypsin levels in colonic biopsies have been shown to be increased in IBS-D 
[143] so we cannot be certain how much of the observed increase in FSP is 
from enterocytes and how much pancreatic. Furthermore human epithelial 
cell lines secrete trypsinogen IV [215]  the mRNA of which has also been found 
to be 1.5 fold increased in human small intestinal biopsies from IBS-D patients 
[216]. 
Trypsinogen IV is known to activate PAR2 receptors [215] and so may be 
important in activating afferent nerves, generating inflammatory changes and 
increasing permeability; all of which could contribute to IBS symptoms. 
 
Using a Benzamindine affinity resin we extracted faecal serine proteases and 
characterised them by mass-spectrometric analysis of proteolysed 
components in gel electrophoresis. We identified several human enzymes 
including amylase, elastase, carboxypeptidase and trypsin. However it should 
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be noted that of these enzymes, only trypsin I is known to activate the PAR2 
receptor and hence would be predicted to influence visceral sensitivity, gut 
barrier function and immune function. Surprisingly, using a highly specific 
immunoassay we found endogenous mast cell tryptase was undetectable in 
faecal extracts. Several papers have examined release of trypsin-like 
mediators from supernatants of IBS biopsies and most [143, 217, 218] but not 
all [219] have found increased release. Others have suggested that faecal 
serine proteases might be of bacterial origin but we found major components 
in purified faecal extract to be human derived. Earlier studies argued that 
because high levels of FSP activity were not seen in bacterial gastroenteritis 
this meant that fast transit was not important[94].However work not shown 
in this thesis done in our department using Moviprep to purge the colon of 
healthy volunteers shows a significant increase in FSP activity after 
accelerated transit. Most patients with gastroenteritis become anorexic which 
would be expected to reduce pancreatic enzyme secretion while our subjects 
in this purging study ate a 400 kcal low residue diet the night before the study 
which would be expected to adequately stimulate pancreatic secretion. 
Since our data suggested a probable pancreatic origin for the serine protease 
activity we then examined other pancreatic enzymes in stool. Faecal amylase 
was assessed using a specific immunoassay to identify human pancreatic 
amylase and showed a similar trend to serine proteases with increased values 
which correlated with FSP activity. The amylase levels suggested two groups 
of patients and we found that IBS-D patients with higher faecal amylase had 
significantly higher FSP activity and greater anxiety scores and a tendency to 
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faster transit than those with lower values, suggesting to us that these 
increases might both be due to accelerated transit. Previous studies of faecal 
trypsin indicate that the very substantial amounts of pancreatic trypsin 
secreted each day are mostly degraded during transit through the colon since 
the 24 hour faecal output is approximately 1mg compared to an ileostomy 
output of 50-200mg [220]. Antibiotic therapy which inhibits bacterial 
degradation increases faecal trypsin and elastase in both rats [221] and 
humans [222]. The pancreas is the major source of human faecal elastase 
since very little is excreted in the faeces of patients with pancreatic 
insufficiency as assessed by intubated pancreatic function testing [223]. 
Elastase appears to be inherently more resistant to bacterial degradation. 
Thus after reducing the faecal bacterial content in humans by oral antibiotics, 
trypsin levels rose 100 fold while elastase levels rose only 2-3 fold[220] This 
may explain why elastase is not increased in IBS-D as little degradation occurs 
so faecal levels reflect pancreatic secretion which is not expected to be 
different in IBS-D compared to controls. 
Slowing transit by any means would be predicted to reduce faecal tryptic 
activity and benefit symptoms. Although faecal serine protease activity whilst 
taking Ondansetron was not different compared to placebo there was a  
negative correlation between the rise in transit on Ondansetron and the 
increase in FP (r=−0.40, p=0.003) in the 55 patients with complete values for 
both FP and transit at both time points. .  We have shown that pancreatic 
proteases are entering the colon as a function of rapid small bowel transit and 
this small bowel transit time may not be altered. This is supported by the 
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finding that SBWC is not altered leading us to believe that the changes in 
whole gut transit seen with Ondansetron are related to slowing of colonic 
transit. Higher doses of Ondansetron are likely to be needed to affect the 
small bowel but the effects on colonic transit are so potent that higher doses 
are precluded. Targeting the small bowel transit or directly influencing faecal 
serine protease activity may be the important in influencing difficult 
symptoms such as pain and bloating, whilst stool form and urgency can be 
successfully treated with Ondansetron.  Direct targeting of FSP activity due to 
undegraded pancreatic enzymes may well be important since trypsin is a 
potent activator of PAR2 receptors. This activation can increase gut 
permeability [94] , which in some human studies is very clearly linked to 
abdominal pain and visceral hypersensitivity [224] Furthermore, sensitising 
the distal gut may aggravate diarrhoea and urgency. 
8.10Limitations and further work 
 
8.10.1 Ondansetron in patients with IBS-D 
“identifying the responder” 
There are 4 broad areas of limitation that should be taken into account when 
interpreting the findings of this study. The principal of these is the failure to 
define an Ondansetron responsive phenotype. This was a particularly 
important target as without a way to identify patients who might respond to a 
particular therapy physicians can contribute to patient dissatisfaction with 
treatment with multiple trials of ineffective therapy, with the additional risk of 
a patient experiencing side effects to a drug that has no impact on their 
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condition. As discussed this is most likely the result of a small sample size and 
also as a consequence of the use of a dose titration model.  
 Secondly although patients were selected both form primary and secondary 
care and as such are likely to be a representative sample it is recognised that 
participants in a study scenario often gain benefit from the extra care and 
attention they receive whilst taking part in research, this factor may falsely 
enhance the efficacy of Ondansetron in this group. 
Thirdly the duration of this study is short (6 weeks of treatment only), and is 
therefore not able to provide data on the longevity of effect, or incidence of 
side effects such as constipation over time. As we know patients symptoms 
naturally wax and wane and constipation might be expected to occur with 
longer term use. 
Finally a number of treatments exist for patients with IBS-D, including dietary, 
psychological and pharmacological. The most commonly used drug therapies 
are Loperamide and the tricyclic antidepressants. This study is not able to 
demonstrate enhanced efficacy or tolerability of Ondansetron when 
compared to these readily available treatments. 
Taking these factors into account it is clear that a further larger study is 
warranted.  Given the low number needed to treat, the definition of a 
phenotype responsive to Ondansetron although still an important question 
might not be the best focus for a subsequent study. Additionally, 
acknowledging the small sample size, I would suggest the markers of 
serotonin system have not shown promise in this study. There are however 
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clinical clues which suggest that those with the most severe symptoms and 
greatest pain are least likely to respond. In my own practise this has led me to 
treating those who are more “biological” i.e. those with less anxiety and 
depression, less somatisation, better coping skills and perhaps a post 
infectious onset of their symptoms,  with Ondansetron and those who are 
more “psychological” i.e. more anxious with more somatisation and less good 
coping skills  with a TCA first line.   
I would therefore suggest a study in which the place of Ondansetron in our 
current treatment algorithm was assessed whilst also garnering data in a 
larger number of patients over a longer follow up period. This should be a trial 
of Ondansetron vs. Amitryptiline, again using a dose titration method, with 
particular focus on collecting data on anxiety, depression, somatisation and 
coping skills as predictors of response. 
A large study such as this is I believe a vital next step, but its execution will be 
costly and time consuming. A smaller study could explore the use of other 
biomarkers that may have promise. The changes seen in urgency in our 
patients led us to speculate that as well as changes in transit there may be 
changes in rectal sensitivity. Changes in rectal sensitivity as measured by 
barostat bag distension are well documented in patients with IBS and 
measurement pre and post the administration of Ondansetron has been 
demonstrated [225]. The presence of rectal hypersensitivity at baseline may 
predict response to treatment, and this could be explored in a smaller, 
mechanistic study. Work with in the department using MRI has demonstrated 
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a reduced capacity for the ascending colon to accommodate a postprandial 
inflow in patients with IBS-D as a potential driver to fast transit [226]. A test 
meal administered to patients on and off Ondansetron, would yield 
information not only on the effects of Ondansetron in the colon, but has the 
promise of a dynamic test that might be used to predict response to the drug.  
Other smaller scale and no less valuable work could also increase our 
understanding of the effect of Ondansetron in patients. Baseline quality of life 
data was collected from all participants and a follow up study with an 
assessment of quality of life whilst taking Ondansetron would be of great 
interest. This would also collate data on the duration of efficacy, and medium 
to long-term tolerability of Ondansetron. It would be particularly exciting to 
see if there is ongoing resolution of symptoms and perhaps an improvement 
in pain over a greater study period as longer term changes transit may result 
in changes in gut flora and thus sensitivity. 
As is often the case when such a large volume of information is collected as 
well as ideas for future work, there remains much potential for use of already 
collected data.  Further analysis of the wealth of data contained in the stool 
diaries at baseline might identify other clinical biomarkers.  For example it 
would be interesting to compare those who were ever constipated vs. never 
constipated as a predictor of response.  Further diary work is also suggested 
following the identification of an early morning rush. Although the data is not 
recorded here, future diaries could contain the timing of meals to identify a 
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post-prandial rush, a very commonly reported symptom in patients. This 
would link well with a future study looking at colonic volumes post feeding. 
  
8.10.2 Faecal serine proteases 
We have identified the pancreas as the putative source of increased serine 
protease activity in patients with IBS-D, and suggest this increased activity is 
related to changes in transit.  Ondansetron did not have a significant effect on 
small bowel transit in this study and it is clear that further work looking at 
small bowel transit time and FSP activity is needed. Other measures of small 
bowel transit, either using scintigraphy or the hydrogen breath test in patients 
and healthy volunteers would be appropriate, although we have already 
shown that rapid transit during purging leads to a large increase in FSP 
activity[227].  
The correlation of FSP activity with urgency also suggests that new therapies 
targeting faecal serine protease could be useful in the treatment of this most 
debilitating symptom of IBS-D. Finally, if these changes in FSP are due to 
changes in gut microbiota it opens the possibility that modifying the 
microbiota by diet or probiotics might benefit IBS symptoms by degrading 
FSPs.   
 
8.11 Conclusion 
Reviewing the original aims of this thesis, I have been able to demonstrate 
that: 
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a. The 5-HT3 receptor antagonist Ondansetron is an effective and well 
tolerated treatment in patients with IBS-D with a low number of side 
effects. 
b. Ondansetron slows whole gut transit, but without a demonstrable 
difference in small bowel water content. 
9. Markers of mucosal serotonin activity were not in this study predictors 
of response to Ondansetron. 
10.Faecal serine protease activity was reduced by treatment with 
Ondansetron in proportion to the change in colonic transit. 
In addition other important findings include: 
Confirmation of previous reports that FSP activity is elevated in some patients 
with IBS-D but also that there is considerable overlap with normal subjects 
without IBS. We have increased our understanding of this phenomenon by 
characterising the proteins responsible for the serine protease activity, 
showing that most of this activity is likely due to human pancreatic enzymes. 
 
Our study suggests that clinical rather than biochemical indicators predicted 
responsiveness to Ondansetron best. Patients with less severe symptoms are 
more likely to respond well to Ondansetron which should prove a useful 
addition to the current rather limited therapies available for this important 
group of patients.  

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9  Appendices 
Appendix I 

HAD questionnaire
 
 
Please complete each of the following questions, checking the one 
response that comes closest to how you have been feeling in the 
past week. 



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